

## RE: Today's vaccine number

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Shahpar, Cyrus G. EOP/WHO" (b)(6) "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>  
**Date:** Sun, 08 Aug 2021 14:24:13 -0400

---

Hi Cyrus,  
Thanks for the chat this morning.

(b)(5)

Much appreciated,  
Rochelle

---

**From:** Shahpar, Cyrus G. EOP/WHO (b)(6)  
**Sent:** Sunday, August 8, 2021 11:11 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** FW: Today's vaccine number

FYI, (b)(5)

(b)(5)

Thanks again,  
Cyrus  
-----

(b)(5)









## FW: Daily update: Data, 5/13

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Thu, 13 May 2021 11:22:20 -0400

---

What is (b)(5) in the last bullet? (b)(5)

---

**From:** Shahpar, Cyrus EOP/WHO  
**Sent:** Wednesday, May 12, 2021 11:26 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Po, Rosa EOP/WHO (b)(6)  
Hussain, Farhana P. EOP/WHO (b)(6) Kwak, Grace EOP/WHO  
(b)(6) Mirza, Asma Y. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO  
(b)(6) Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Siegel, Becca G. EOP/OMB (b)(6) Jarman-Miller, Hannah L. EOP/WHO  
(b)(6)  
**Subject:** Daily update: Data, 5/13

(b)(5)



# RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Choucair, Bechara N. EOP/WHO" (b)(6) "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" (b)(6) "Munoz, Kevin A. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" <marcella.nunez-smith@hhs.gov>  
**Date:** Fri, 02 Jul 2021 16:19:27 -0400

Got it. (b)(5)

(b)(5)

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Friday, July 2, 2021 4:12 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Wakana, Benjamin L. EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara N. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Munoz, Kevin A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Friday, July 2, 2021 1:03 PM  
**To:** Wakana, Benjamin (who.eop.gov) (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara N. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) <Marcella.Nunez-Smith@hhs.gov>  
**Subject:** Re: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)  
Vivek

--  
**Vivek Murthy**  
U.S. Surgeon General  
Vice Admiral, U.S. Public Health Service

The information in this e-mail and its attachments are confidential, pre-decisional and deliberative. Contents may include sensitive information and are for official use only. If you are not the original intended recipient, please delete the content and notify the sender.

**From:** Wakana, Benjamin L. EOP/WHO (b)(6)  
**Sent:** Friday, July 2, 2021 12:53 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara N. EOP/WHO



(b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
Cc: Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) <Marcella.Nunez-Smith@hhs.gov>  
Subject: RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

Got it. Thank you all.

From: Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
Sent: Friday, July 2, 2021 12:53 PM  
To: Choucair, Bechara N. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
Cc: Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
Subject: RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

(b)(5)

Thanks,  
R

From: Choucair, Bechara N. EOP/WHO (b)(6)  
Sent: Friday, July 2, 2021 12:37 PM  
To: Wakana, Benjamin L. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
Cc: Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Munoz, Kevin A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
Subject: RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5) Thanks.

Bechara  
Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

From: Wakana, Benjamin L. EOP/WHO  
Sent: Friday, July 2, 2021 12:34 PM  
To: Choucair, Bechara N. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
Cc: Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Munoz, Kevin A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
Subject: RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

(b)(5)

(b)(5)

(b)(5)

**From:** Choucair, Bechara N. EOP/WHO

**Sent:** Friday, July 2, 2021 12:28 PM

**To:** Wakana, Benjamin L. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO

(b)(6) Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>;

Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Munoz, Kevin

A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Nunez-

Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Friday, July 2, 2021 9:35 AM

**To:** Zients, Jeffrey D. EOP/WHO (b)(6) Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>;

Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Munoz, Kevin

A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Choucair,

Bechara N. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) <[Marcella.Nunez-Smith@hhs.gov](mailto:Marcella.Nunez-Smith@hhs.gov)>

**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5) ?

(b)(5)

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Thursday, July 1, 2021 9:11 PM  
**To:** Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6); Sams, Ian (HHS/ASPA) <[lan.Sams@hhs.gov](mailto:lan.Sams@hhs.gov)>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Wakana,  
Benjamin L. EOP/WHO (b)(6); Munoz, Kevin A. EOP/WHO (b)(6)  
Quillian, Natalie H. EOP/WHO (b)(6); Choucair, Bechara N. EOP/WHO  
(b)(6); Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** Re: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

On Jul 1, 2021, at 9:01 PM, Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)> wrote:

Thanks for sending Ian - (b)(5)

(b)(5)

Vivek

--

**Vivek Murthy**  
U.S. Surgeon General  
Vice Admiral, U.S. Public Health Service

The information in this e-mail and its attachments are confidential, pre-decisional and deliberative. Contents may include sensitive information and are for official use only. If you are not the original intended recipient, please delete the content and notify the sender.

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Thursday, July 1, 2021 8:54 PM  
**To:** Sams, Ian (HHS/ASPA) <[lan.Sams@hhs.gov](mailto:lan.Sams@hhs.gov)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6);  
Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Wakana,  
Benjamin (who.eop.gov) (b)(6); Kevin.Munoz (b)(6);  
natalie.h.quillian (eop.gov) (b)(6); Zients, Jeffrey D. EOP/WHO  
(b)(6); Choucair, Bechara N. EOP/WHO (b)(6); Nunez-  
Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

++

---

**From:** Sams, Ian (HHS/ASPA) <[lan.Sams@hhs.gov](mailto:lan.Sams@hhs.gov)>  
**Sent:** Thursday, July 1, 2021 8:46 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy,  
Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Rowe, Courtney M. EOP/WHO (b)(6);  
Wakana, Benjamin L. EOP/WHO (b)(6); Munoz, Kevin A. EOP/WHO  
(b)(6)  
**Subject:** J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

>>>><https://www.bloomberg.com/news/articles/2021-07-02/j-j-covid-shot-neutralizes-delta-variant-is-durable-over-time><<<<;;

# J&J Covid Shot Neutralizes Delta Variant, Company Says

[Riley Griffin](#) July 1, 2021, 8:01 PM EDT

[Johnson & Johnson](#) said that its single-shot coronavirus vaccine neutralizes the fast-spreading delta variant and provides durable protection against infection more broadly.

The company said in a statement Thursday that recipients of its vaccine produced strong neutralizing antibodies over the course of at least eight months against all variants including delta, which was first seen in India and has been spreading around the globe.

Delta is expected to become the dominant strain in the U.S. in the coming weeks, according to the Centers for Disease Control and Prevention. The J&J shot provides less protection initially than messenger RNA vaccines from [Pfizer Inc.](#) and [Moderna Inc.](#), and experts have been discussing whether some people may need booster shots to keep the virus at bay long-term.

“We’re extremely happy, actually, and confident there’s no need for the booster at the moment and we’re protected against different strains,” said Johan Van Hoof, J&J’s global head of infectious diseases and vaccines, in an interview.

The shot neutralized the delta variant within 29 days of a first dose, and protection matured and improved over time, the company said.

With the latest data in hand, Van Hoof said J&J doesn’t believe people who have been given its vaccine should need a booster within a year of having gotten it. “And if a boost is needed,” he said, “we don’t think we’ll need to change the formulation.”

Scientists and some vaccine manufacturers have been crafting updated versions of their shots to directly target the emerging variants, which have proved to be significantly more transmissible than the original virus that first emerged in Wuhan, China, in late 2019.

The continued evolution of the pathogen, however, is creating an ever-moving target, leading some to evaluate whether additional doses of existing immunizations may provide more protection.

[Read More: Astra Shot Response Higher With Longer Gap, Third Dose](#)

The findings J&J disclosed Thursday were from two studies.

The company evaluated the blood samples of eight participants in its late-stage clinical trial of the vaccine to assess neutralizing antibodies produced against the delta variant. Dan Barouch of Beth Israel Deaconess Medical Center evaluated the durability of the immune response in 20 participants of an early-stage vaccine study.

More robust results will be published in bioRxiv, an online research depository, the company said.

## **Two-Shot Regimen**

Data released by the company showed antibody counts, known as titres, were substantially higher in response to the delta variant than the beta variant first detected in South Africa.

J&J said a second dose of its vaccine is known to increase a person's antibody count. The company plans to report efficacy data from a late-stage trial of a two-shot regimen at the end of August, Van Hoof said.

The company is also studying its vaccine's ability to create T cells, another gauge of its protective power. The shot produced increasing T cell immunity against the virus and its variants over eight months, according to Van Hoof.

J&J's shot has struggled to get broad traction amid production problems and after a brief pause in use as regulators investigated reports that some people suffered dangerous blood clots after receiving it. The pause was lifted after 10 days on April 23.

Sent from my iPhone

## RE: Some Who Were Hesitant to Get a Vaccine Changed Their Mind Because of Family, Friends and Doctors

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Choucair, Bechara N. EOP/WHO" <(b)(6)>, Drew Altman <drewa@kff.org>, Vivek Murthy <(b)(6)>, "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" <marcella.nunez-smith@hhs.gov>, <(b)(6)> @nih.hhs.gov  
**Date:** Tue, 13 Jul 2021 17:37:48 -0400

---

Indeed, Drew – echoing the data and the gratitude here.  
So appreciated!  
Rochelle

---

**From:** Choucair, Bechara N. EOP/WHO <(b)(6)>  
**Sent:** Tuesday, July 13, 2021 4:52 PM  
**To:** Drew Altman <DrewA@kff.org>, <(b)(6)>, <(b)(6)>, Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) <Marcella.Nunez-Smith@hhs.gov>, <(b)(6)> @nih.hhs.gov  
**Subject:** RE: Some Who Were Hesitant to Get a Vaccine Changed Their Mind Because of Family, Friends and Doctors

Thanks for sharing Drew. This is very helpful. Please keep them coming!

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

<(b)(6)>

---

**From:** Drew Altman <DrewA@kff.org>  
**Sent:** Tuesday, July 13, 2021 1:10 PM  
**To:** <(b)(6)>, Choucair, Bechara N. EOP/WHO <(b)(6)>, Slavitt, Andrew M. EOP/WHO <(b)(6)>, <(b)(6)>, Rochelle Walensky, MD, MPH (aux7@cdc.gov) <aux7@cdc.gov>; Smith <(b)(6)>, <(b)(6)> @nih.hhs.gov  
**Subject:** [EXTERNAL] Some who were Hesitant to Get a Vaccine Changed Their Mind Because of Family, Friends and Doctors

Sorry folks I forgot to send this one, so here it is a little late (from a flight to NYC). Hope you are all well!

If there is something you think we should be doing (that we are not doing) just let me know.

Best,

Drew

[View in browser](#)

The report features a second round of interviews with a nationally representative sample of adults six months after they first shared their vaccine intentions in January, early in the nation's vaccine distribution effort. The new survey assesses whether or not they got a COVID-19 vaccine, the reasons behind their choice, and how they feel about their decision.

Half initially told us that they planned on getting vaccinated as soon as possible or had already received at least one dose. Now two-thirds say have been vaccinated, including the vast majority (92%) of those who had planned to get vaccinated "as soon as possible" in January, along with slightly more than half (54%) of those who wanted to "wait and see." At the same time, three quarters (76%) of those who previously said they would get vaccinated "only if required" or would "definitely not" get a COVID-19 vaccine remain unvaccinated.

---

Importantly, one in five (21%) of all adults are now vaccinated after expressing some level of hesitation in January, saying then that they planned on waiting to get vaccinated, would only get it if required, or would definitely not get vaccinated. Many in this group cite friends, family members, and their personal doctors as influencing their decision to get a vaccine. This includes seeing friends and family members get vaccinated without serious side effects (25%), pressure from friends and family (8%), being able to safely visit family members (3%), and conversations with their personal doctors (11%). Another one in ten (9%) say that easing of restrictions for vaccinated people was a factor.

## In their own words: What did you learn or hear that persuaded you to get vaccinated?

"Not many side effects and others have been vaccinated" – 21 year old, male, white, independent, Georgia ("wait and see" in January)

"That it was clearly safe. No one was dying." – 32 year old, male, white, Republican, South Carolina ("wait and see" in January)

"Five generations of our family are getting together in one week from now" – 68 year old, male, white, Democrat, California ("wait and see" in January)

"My Ob/Gyn advised it was safe to take while pregnant and/or trying to conceive and there are studies showing women who get pregnant that caught COVID had more hematological problems during and after birth" – 32 year old, female, white, independent, Alabama ("wait and see" in January)

In fact, some vaccinated adults cite protecting or being able to see their friends and family members as **the main reason** why they decided to get vaccinated. And two-thirds (65%) say they have personally tried to persuade friends and family members to get a shot.

One-third of all adults remain unvaccinated, including 16% of adults who had previously said they planned on getting vaccinated "as soon as possible" or wanted to "wait and see" see before getting a vaccine. When asked why they changed their minds, many cite the side effects of the vaccine as a key reason.

## In their own words: What changed your mind?

"What's changed my mind is people telling me how sick they got after they received the vaccination. I really don't want to be sick from a vaccination so I kind of lost interest" – 54 year old, male, white, Republican, California ("ASAP" in January)

"I have allergies considering the possible risks. The risks in my opinion are not a chance I'm willing to take." – 18 year old, male, Hispanic, Democrat, Florida ("ASAP" in January)

"My husband got the vaccine and he experienced a lot of side effects. I usually end of having some [or] all the listed side effects" – 42 year old, female, Hispanic, independent, California ("wait and see" in January)

[Read the Report](#)

Available through the Monitor's [online dashboard](#), the new report also quotes the open-ended responses given by many of those surveyed reflecting the diversity of their views and experiences related to their views and decision around vaccination.



The [KFF COVID-19 Vaccine Monitor](#) is an ongoing research project tracking the public's attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfold, including vaccine confidence and hesitancy, trusted messengers and messages, as well as the public's experiences with vaccination.

**CONTACT:**

Craig Palosky | (202) 654-1369 | [cpalosky@kff.org](mailto:cpalosky@kff.org)

*Filling the need for trusted information on national health issues,*  
KFF is a nonprofit organization based in San Francisco, California.

[kff.org](http://kff.org) | [khn.org](http://khn.org)



Did someone forward this to you? [Click here to sign up for emails from KFF.](#)

This email was sent to [drewa@kff.org](mailto:drewa@kff.org). [Update your email preferences](#) to choose the types of emails you receive. Or, [permanently unsubscribe from all future emails.](#)

If you need help or have questions, please send an email to [subscriptions@kff.org](mailto:subscriptions@kff.org).  
Please do not reply to this email as this address is not monitored.

KFF  
185 Berry Street Suite 2000  
San Francisco, CA 94107

# RE: COVID Data Tracker Daily Site Update Information

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>  
**Cc:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Christie, Athalia (CDC/DDPHSIS/CGH/OD)" <akc9@cdc.gov>  
**Date:** Thu, 03 Jun 2021 13:38:43 -0400

Thank you, and also thanks to your teams (b)(5)

(b)(5)

Cyrus

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>  
**Sent:** Thursday, June 3, 2021 10:36 AM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, June 2, 2021 12:46 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 1, 2021 4:25 PM  
**To:** 'Shahpar, Cyrus EOP/WHO' (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 1, 2021 1:29 PM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Monday, May 31, 2021 2:43 PM  
**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

Thank you for the update and hope you can enjoy today.  
Cyrus

Sent from my iPhone

On May 31, 2021, at 11:40 AM, Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)> wrote:

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Sunday, May 30, 2021 1:41 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Saturday, May 29, 2021 1:53 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Friday, May 28, 2021 1:31 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>; Christie, Athalia

(CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Thursday, May 27, 2021 1:58 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Wednesday, May 26, 2021 1:28 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Tuesday, May 25, 2021 1:44 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J.

(CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Monday, May 24, 2021 1:23 PM

**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Sunday, May 23, 2021 1:29 PM

**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Saturday, May 22, 2021 4:47:30 PM

**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Saturday, May 22, 2021 2:57:02 PM

**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Thanks

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>

**Sent:** Saturday, May 22, 2021 2:51 PM

**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

R

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Saturday, May 22, 2021 2:03 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Shahpar, Cyrus EOP/WHO (b)(6)

**Sent:** Saturday, May 22, 2021 1:13 PM

**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Understand and thank you for letting us know. I received the updated vaccine data this morning so appreciate that.  
Cyrus

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Saturday, May 22, 2021 9:56 AM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

All.

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Friday, May 21, 2021 10:11 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Friday, May 21, 2021 7:44:54 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

(b)(5)

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Friday, May 21, 2021 7:35 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information



Hi Michael,

(b)(5)

Much appreciated,  
Cyrus

Sent from my iPhone

On May 21, 2021, at 4:33 PM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)> wrote:

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)

**Sent:** Friday, May 21, 2021 6:38 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)

**Sent:** Friday, May 21, 2021 6:14 PM

**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Thanks!  
Cyrus

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Friday, May 21, 2021 2:52 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>;

Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus--

(b)(5)

(b)(5)

Michael

(b)(5)

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Friday, May 21, 2021 1:46 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Thursday, May 20, 2021 1:19 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Wednesday, May 19, 2021 1:20 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

[REDACTED] (b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Tuesday, May 18, 2021 1:25 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

[REDACTED] (b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

## RE: Some Who Were Hesitant to Get a Vaccine Changed Their Mind Because of Family, Friends and Doctors

---

**From:** "Choucair, Bechara N. EOP/WHO" (b)(6)  
**To:** Drew Altman <drewa@kff.org>, Vivek Murthy (b)(6), david kessler (b)(6), "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" (b)(6), (b)(6)@nih.hhs.gov  
**Date:** Tue, 13 Jul 2021 16:51:46 -0400

---

Thanks for sharing Drew. This is very helpful. Please keep them coming!

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

---

**From:** Drew Altman <DrewA@kff.org>  
**Sent:** Tuesday, July 13, 2021 1:10 PM  
**To:** Vivek Murthy (b)(6), Choucair, Bechara N. EOP/WHO (b)(6), Slavitt, Andrew M. EOP/WHO (b)(6), david kessler (b)(6), Rochelle Walensky, MD, MPH (aux7@cdc.gov) <aux7@cdc.gov>; Smith, Marcella (b)(6) <(b)(6)>; (b)(6)@nih.hhs.gov  
**Subject:** [EXTERNAL] Some Who Were Hesitant to Get a Vaccine Changed Their Mind Because of Family, Friends and Doctors

Sorry folks I forgot to send this one, so here it is a little late (from a flight to NYC). Hope you are all well!

If there is something you think we should be doing (that we are not doing) just let me know.

Best,

Drew


[View in browser](#)

## **Some Who Were Hesitant to Get a Vaccine in January Say They Changed Their Mind Because of Family, Friends and Their Personal Doctors**

A new [KFF COVID-19 Vaccine Monitor report](#) finds that people who were initially hesitant to get a vaccine in January but ultimately did so often say that family, friends and their personal doctors helped change their minds.

The report features a second round of interviews with a nationally representative sample of adults six months after they first shared their vaccine intentions in January, early in the nation's vaccine distribution effort. The new survey assesses whether or not they got a COVID-19 vaccine, the reasons behind their choice, and how they feel about their decision.

Half initially told us that they planned on getting vaccinated as soon as possible or had already received at least one dose. Now two-thirds say have been vaccinated, including the vast majority (92%) of those who had planned to get vaccinated "as soon as possible" in January, along with slightly more than half (54%) of those who wanted to "wait and see." At the same time, three quarters (76%) of those who previously said they would get vaccinated "only if required" or would "definitely not" get a COVID-19 vaccine remain unvaccinated.



Importantly, one in five (21%) of all adults are now vaccinated after expressing some level of hesitation in January, saying then that they planned on waiting to get vaccinated, would only get it if required, or would definitely not get vaccinated. Many in this group cite friends, family members, and their personal doctors as influencing their decision to get a vaccine. This includes seeing friends and family members get vaccinated without serious side effects (25%), pressure from friends and family (8%), being able to safely visit family members (3%), and conversations with their personal doctors (11%). Another one in ten (9%) say that easing of restrictions for vaccinated people was a factor.

## In their own words: What did you learn or hear that persuaded you to get vaccinated?

"Not many side effects and others have been vaccinated" – 21 year old, male, white, independent, Georgia ("wait and see" in January)

"That it was clearly safe. No one was dying." – 32 year old, male, white, Republican, South Carolina ("wait and see" in January)

"Five generations of our family are getting together in one week from now" – 68 year old, male, white, Democrat, California ("wait and see" in January)

"My Ob/Gyn advised it was safe to take while pregnant and/or trying to conceive and there are studies showing women who get pregnant that caught COVID had more hematological problems during and after birth" – 32 year old, female, white, independent, Alabama ("wait and see" in January)

In fact, some vaccinated adults cite protecting or being able to see their friends and family members as **the main reason** why they decided to get vaccinated. And two-thirds (65%) say they have personally tried to persuade friends and family members to get a shot.

One-third of all adults remain unvaccinated, including 16% of adults who had previously said they planned on getting vaccinated "as soon as possible" or wanted to "wait and see" see before getting a vaccine. When asked why they changed their minds, many cite the side effects of the vaccine as a key reason.

## In their own words: What changed your mind?

"What's changed my mind is people telling me how sick they got after they received the vaccination. I really don't want to be sick from a vaccination so I kind of lost interest" – 54 year old, male, white, Republican, California ("ASAP" in January)

"I have allergies considering the possible risks. The risks in my opinion are not a chance I'm willing to take." – 18 year old, male, Hispanic, Democrat, Florida ("ASAP" in January)

"My husband got the vaccine and he experienced a lot of side effects. I usually end of having some [or] all the listed side effects" – 42 year old, female, Hispanic, independent, California ("wait and see" in January)

[Read the Report](#)

Available through the Monitor's [online dashboard](#), the new report also quotes the open-ended responses given by many of those surveyed reflecting the diversity of their views and experiences related to their views and decision around vaccination.

The [KFF COVID-19 Vaccine Monitor](#) is an ongoing research project tracking the public's attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfold, including vaccine confidence and hesitancy, trusted messengers and messages, as well as the public's experiences with vaccination.

**CONTACT:**

Craig Palosky | (202) 654-1369 | [cpalosky@kff.org](mailto:cpalosky@kff.org)

*Filling the need for trusted information on national health issues,*  
KFF is a nonprofit organization based in San Francisco, California.

[kff.org](http://kff.org) | [khn.org](http://khn.org)



Did someone forward this to you? [Click here to sign up for emails from KFF.](#)

This email was sent to [drewa@kff.org](mailto:drewa@kff.org). [Update your email preferences](#) to choose the types of emails you receive. Or, [permanently unsubscribe from all future emails.](#)

If you need help or have questions, please send an email to [subscriptions@kff.org](mailto:subscriptions@kff.org).  
Please do not reply to this email as this address is not monitored.

KFF  
185 Berry Street Suite 2000  
San Francisco, CA 94107



## Re: COVID data tracker

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>, "Shahpar, Cyrus (CDC who.eop.gov)" (b)(6)  
**Cc:** "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>, "Christie, Athalia (CDC/DDPHSIS/CGH/OD)" <akc9@cdc.gov>  
**Date:** Fri, 18 Jun 2021 15:39:52 -0400

---

Please let me second that. Grateful to this incredible team for their holiday work...  
R

Get [Outlook for iOS](#)

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Friday, June 18, 2021 1:46:30 PM  
**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Many thanks to the team (b)(5)  
Cyrus

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>  
**Sent:** Friday, June 18, 2021 10:38 AM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Thursday, June 17, 2021 1:19 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, June 16, 2021 1:15 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 15, 2021 1:35 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Monday, June 14, 2021 1:18 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Sunday, June 13, 2021 1:38 PM

**To:** 'Shahpar, Cyrus EOP/WHO' (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Saturday, June 12, 2021 6:40 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Saturday, June 12, 2021 5:55 PM  
**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** Re: COVID data tracker

Thank you for the update!

Sent from my iPhone

On Jun 12, 2021, at 1:51 PM, Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)> wrote:

Cyrus,

(b)(5)

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Saturday, June 12, 2021 1:57 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Friday, June 11, 2021 1:35 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>;

Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Thursday, June 10, 2021 4:29 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)

**Sent:** Thursday, June 10, 2021 2:51 PM

**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Thank you for the update! (b)(5)

(b)(5)

(b)(5)

Much appreciated,  
Cyrus

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Sent:** Thursday, June 10, 2021 11:44 AM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Thursday, June 10, 2021 1:32 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, June 9, 2021 3:26 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, June 9, 2021 1:49 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 8, 2021 4:41 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 8, 2021 3:02 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 8, 2021 1:49 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Monday, June 7, 2021 3:21 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Monday, June 7, 2021 1:26 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Sent:** Sunday, June 6, 2021 2:25 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** Re: COVID data tracker

The data pull has begun- ETA for the update is between 3:45 and 4:15 pm.

Get [Outlook for iOS](#)

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Sunday, June 6, 2021 1:47:52 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C.



(CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** COVID data tracker

(b)(5)

Get [Outlook for iOS](#)

# RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Munoz, Kevin A. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Choucair, Bechara N. EOP/WHO" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" <marcella.nunez-smith@hhs.gov>  
**Date:** Fri, 02 Jul 2021 09:35:04 -0400

(b)(5)

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Thursday, July 1, 2021 9:11 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Wakana, Benjamin L. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Choucair, Bechara N. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** Re: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

**The Delta variant is not driving a surge in hospitalization rates in England, health data shows.** The Delta variant, which is now responsible for most coronavirus infections in England, is not driving a surge in the rate of hospitalizations there, according to [data released by Public Health England](#) on Thursday. Although the number of coronavirus infections has risen sharply in recent weeks, hospitalization rates remain low. Between June 21 and June 27, the weekly hospitalization rate was 1.9 per 100,000 people, the same as it was the previous week. The hospitalization rate has increased slightly over the past month, rising from 1.1 admissions per 100,000 people in early June, according to the agency's data. But it remains considerably lower than during England's surge last winter, when the hospitalization rate peaked at more than 35 admissions per 100,000 people. The data suggest that countries with high vaccination rates are unlikely to see major surges in hospitalization rates from Delta. Nearly 75 percent of adults in England — including 95 percent of those who are 80 or older — have had at least one shot, according to the agency's numbers.

On Jul 1, 2021, at 9:01 PM, Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov> wrote:

Thanks for sending Ian (b)(5)

(b)(5)

Vivek

--

**Vivek Murthy**

U.S. Surgeon General  
Vice Admiral, U.S. Public Health Service

The information in this e-mail and its attachments are confidential, pre-decisional and deliberative. Contents may include sensitive information and are for official use only. If you are not the original intended recipient, please delete the content and notify the sender.

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Thursday, July 1, 2021 8:54 PM  
**To:** Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Wakana,  
Benjamin (who.eop.gov) (b)(6) Kevin.Munoz (b)(6)  
natalie.h.quilliam (eop.gov) (b)(6) Zients, Jeffrey D. EOP/WHO  
(b)(6) Choucair, Bechara N. EOP/WHO (b)(6) Nunez-  
Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

++

---

**From:** Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>  
**Sent:** Thursday, July 1, 2021 8:46 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy,  
Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Rowe, Courtney M. EOP/WHO (b)(6)  
Wakana, Benjamin L. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO  
(b)(6)  
**Subject:** J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

>><https://www.bloomberg.com/news/articles/2021-07-02/j-j-covid-shot-neutralizes-delta-variant-is-durable-over-time><<

## J&J Covid Shot Neutralizes Delta Variant, Company Says

[Riley Griffin](#) July 1, 2021, 8:01 PM EDT

[Johnson & Johnson](#) said that its single-shot coronavirus vaccine neutralizes the fast-spreading delta variant and provides durable protection against infection more broadly.

The company said in a statement Thursday that recipients of its vaccine produced strong neutralizing antibodies over the course of at least eight months against all variants including delta, which was first seen in India and has been spreading around the globe.

Delta is expected to become the dominant strain in the U.S. in the coming weeks, according to the Centers for Disease Control and Prevention. The J&J shot provides less protection initially than messenger RNA vaccines from [Pfizer Inc.](#) and [Moderna Inc.](#), and experts have been discussing whether some people may need booster shots to keep the virus at bay long-term.

“We’re extremely happy, actually, and confident there’s no need for the booster at the moment and we’re protected against different strains,” said Johan Van Hoof, J&J’s global head of infectious diseases and vaccines, in an interview.

The shot neutralized the delta variant within 29 days of a first dose, and protection matured and improved over time, the company said.

With the latest data in hand, Van Hoof said J&J doesn’t believe people who have been given its vaccine should need a booster within a year of having gotten it. “And if a boost is needed,” he said, “we don’t think we’ll need to change the formulation.”

Scientists and some vaccine manufacturers have been crafting updated versions of their shots to directly target the emerging variants, which have proved to be significantly more transmissible than the original virus that first emerged in Wuhan, China, in late 2019.

The continued evolution of the pathogen, however, is creating an ever-moving target, leading some to evaluate whether additional doses of existing immunizations may provide more protection.

[Read More: Astra Shot Response Higher With Longer Gap, Third Dose](#)

The findings J&J disclosed Thursday were from two studies.

The company evaluated the blood samples of eight participants in its late-stage clinical trial of the vaccine to assess neutralizing antibodies produced against the delta variant. Dan Barouch of Beth Israel Deaconess Medical Center evaluated the durability of the immune response in 20 participants of an early-stage vaccine study.

More robust results will be published in bioRxiv, an online research depository, the company said.

## **Two-Shot Regimen**

Data released by the company showed antibody counts, known as titres, were substantially higher in response to the delta variant than the beta variant first detected in South Africa.

J&J said a second dose of its vaccine is known to increase a person’s antibody count. The company plans to report efficacy data from a late-stage trial of a two-shot regimen at the end of August, Van Hoof said.

The company is also studying its vaccine’s ability to create T cells, another gauge of its protective power. The shot produced increasing T cell immunity against the virus and its variants over eight months, according to Van Hoof.

J&J’s shot has struggled to get broad traction amid production problems and after a brief pause in use as regulators investigated reports that some people suffered dangerous blood clots after receiving it. The pause was lifted after 10 days on April 23.

Sent from my iPhone

## RE: COVID Data Tracker Daily Site Update Information

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Beach, Michael J. (CDC/DDID/NCEZID/DFWED)" <mjb3@cdc.gov>  
**Cc:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>  
**Date:** Mon, 17 May 2021 18:20:28 -0400

---

Ok thank you (b)(5)  
Cyrus

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Monday, May 17, 2021 3:19 PM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Monday, May 17, 2021 4:04 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Saturday, May 15, 2021 1:37 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Wednesday, May 12, 2021 1:48 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Tuesday, May 11, 2021 1:23 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Monday, May 10, 2021 1:26 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Sunday, May 9, 2021 1:27 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>

**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)

**Sent:** Friday, May 7, 2021 1:31:12 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Sent:** Thursday, May 6, 2021 4:24 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

Pulling data for CDT now. Posting estimated to be between 5:15 to 5:45

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention



1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Thursday, May 6, 2021 1:21 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)

**Sent:** Wednesday, May 5, 2021 1:24 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)

**Sent:** Tuesday, May 4, 2021 3:30 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Tuesday, May 4, 2021 1:56 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)  
**Sent:** Monday, May 3, 2021 1:45 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Sunday, May 2, 2021 6:29:29 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Sunday, May 2, 2021 3:03:35 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Sunday, May 2, 2021 1:46:19 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) <(b)(6)>  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Saturday, May 1, 2021 3:42:17 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) <(b)(6)>  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Shahpar, Cyrus EOP/WHO <(b)(6)>  
**Sent:** Saturday, May 1, 2021 1:51 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

Copy, thank you for the update  
Cyrus

Sent from my iPhone

On May 1, 2021, at 10:29 AM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)> wrote:

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018

404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Friday, April 30, 2021 1:21 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

[REDACTED] (b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Tuesday, April 27, 2021 1:25 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

[REDACTED] (b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Monday, April 26, 2021 1:33 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** COVID Data Tracker Daily Site Update Information

Cyrus,

[REDACTED] (b)(5)

Thanks  
Michael

(b)(5)

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Sunday, April 25, 2021 1:37 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) <[shahpar@cdc.gov](mailto:shahpar@cdc.gov)> (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** Fwd: COVID Data Tracker Daily Site Update Information

Cyrus

(b)(5)

# RE: COVID Tough QA

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Cheema, Subhan N. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Sanchez-Velasco, Marissa EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6) "Bernier, Kate K. EOP/WHO" (b)(6)  
"Munoz, Kevin A. EOP/WHO" (b)(6) "Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>  
**Date:** Tue, 19 Oct 2021 22:42:17 -0400  
**Attachments:** Tough QA 10.19.21 9PM.docx (49.03 kB)

Hi, attached please find the latest Tough QA on COVID. Looking forward to the bright and early briefing tomorrow.

-Ben

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Monday, October 18, 2021 2:16 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO (b)(6) 'Sams, Ian (HHS/ASPA)' <ian.sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Saez, Mariel S. EOP/WHO' (b)(6) Bernier, Kate K. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido, Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi, (b)(5)

(b)(5)

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Tuesday, October 12, 2021 11:05 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO (b)(6) 'Sams, Ian (HHS/ASPA)' <ian.sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO <Marissa.Sanchez-Velasco@who.eop.gov>; Saez, Mariel S. EOP/WHO (b)(6) Bernier, Kate K. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido, Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>

(CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi All, attached please find the latest tough QA on COVID.

Thank you,  
Ben

---

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Wednesday, October 6, 2021 1:48 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO (b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO <Marissa.Sanchez-Velasco@who.eop.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido, Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi all, updated QA attached based on this morning's prep. (b)(6)

(b)(5)

---

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Tuesday, October 5, 2021 10:59 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C. EOP/WHO (b)(6) (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith' (b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]'  
(b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)'  
<Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)'  
<Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry,  
Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K.  
EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido,  
Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi, attached please find an updated tough QA.

Thank you,  
Ben

---

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Friday, October 1, 2021 3:09 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy,  
Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C.  
EOP/WHO (b)(6) (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'  
(b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO  
(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]'  
(b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)'  
<Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)'  
<Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry,  
Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K.  
EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido,  
Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi, attached please find an updated version based on prep this morning. New topics from last night include:

(b)(5)

Thanks as always.  
-Ben

---

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Thursday, September 30, 2021 10:31 PM  
**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy,  
Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C.  
EOP/WHO (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'  
(b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO  
(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]'  
(b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)'  
<Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)'  
<Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry,  
Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K.  
EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6) 'Salcido,  
Dorinda (Dori) (CDC/OD)' <spe9@cdc.gov>  
**Subject:** RE: COVID Tough QA

Hi, attached please find the latest Tough QA on COVID.

(b)(5)

Talk soon,  
Ben



**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Tuesday, September 28, 2021 8:18 AM

**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C. EOP/WHO (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)' <Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry, Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO (b)(6)

**Subject:** RE: COVID Tough QA

Hi, attached please find the latest Tough QA on COVID.

(b)(5)  
Ben

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Friday, September 17, 2021 9:58 PM

**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C. EOP/WHO (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)' <Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry, Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K. EOP/WHO (b)(6)

**Subject:** RE: COVID Tough QA

Hi, attached (b)(5)

(b)(5)  
(b)(5)

Ben

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Friday, September 17, 2021 1:00 PM

**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C. EOP/WHO (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)' <Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry, Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K. EOP/WHO (b)(6)

**Subject:** RE: COVID Tough QA

(b)(5)

(b)(6)

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Thursday, September 16, 2021 10:32 PM

**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; 'Rachel.Levine@hhs.gov' <Rachel.Levine@hhs.gov>; Webb, Cameron C. EOP/WHO (b)(6) (b)(6) (b)(6) (b)(6) 'Marcella Nunez-Smith'

(b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Broido, Tara (HHS/OASH)' <Tara.Broido@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; Sanchez-Velasco, Marissa EOP/WHO (b)(6) 'Perry, Sherice (OS/IEA)' <Sherice.Perry@hhs.gov>; Saez, Mariel S. EOP/WHO (b)(6) Berner, Kate K. EOP/WHO (b)(6)

**Subject:** COVID Tough QA

Attached please find the latest Tough QA on COVID. A huge thanks to Courtney.

Hope this helps,  
Ben

**RE: NY Yankees**

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Thu, 13 May 2021 11:23:49 -0400

(b)(5) – thank you –

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Thursday, May 13, 2021 11:19 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>  
**Subject:** FW: NY Yankees

(b)(5)

---

**From:** Shahpar, Cyrus EOP/WHO  
**Sent:** Thursday, May 13, 2021 10:36 AM  
**To:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO (b)(6)  
Cisneros, Eduardo EOP/WHO (b)(5) Quillian, Natalie H. EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(5)  
**Subject:** NY Yankees

(b)(5)

---

Cyrus Shahpar  
COVID Data Director  
(b)(6)

# RE: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" (b)(6) "Kessler, David (HHS/IOS)" <david.kessler@hhs.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Date:** Tue, 21 Sep 2021 11:03:21 -0400

---

(b)(5)

R

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Tuesday, September 21, 2021 10:38 AM  
**To:** Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6) (b)(6)  
Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Subject:** FW: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

(b)(5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)

National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b)(6) / (b)(6)  
FAX: (b)(6)  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Folkers, Greg (NIH/NIAID) [E] (b)(6)  
**Sent:** Tuesday, September 21, 2021 8:24 AM  
**Subject:** Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

**Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.**

- **Additional data show a booster increases protection**
- **94 percent protection in the U.S. with booster given at two months**
- **Four-fold increase in antibodies when given at two months**
- **12-fold increase in antibodies when booster given at six months**

**NEW BRUNSWICK, N.J., September 21, 2021** – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster.

“Our large real-world evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations. Additionally, our Phase 3 trial data further confirm protection against COVID-19-related death,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”

“It is critical to prioritize protecting as many people as possible against hospitalization and death given the continued spread of COVID-19. A single-shot COVID-19 vaccine that is easy to use, distribute and administer, and that provides strong and long-lasting protection is crucial to vaccinating the global population,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “At the same time, we now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly.”

The Company has provided available data to the U.S. Food and Drug Administration (FDA) and plans to submit the data to other regulators, the World Health Organization (WHO) and National Immunization Technical Advisory Groups (NITAGs) worldwide to inform decision-making on local vaccine administration strategies, as needed.

The data are summarized below:

#### **Johnson & Johnson single-shot vaccine showed strong and long-lasting protection in the real world**

The largest [real-world evidence study](#) for a COVID-19 vaccine reported to date in the U.S. demonstrated stable vaccine effectiveness of 79 percent (CI, 77%-80%) for COVID-19-related infections and 81 percent (CI, 79%-84%) for COVID-19-related hospitalizations. There was no evidence of reduced effectiveness over the study duration, including when the Delta variant became dominant in the U.S. Sequencing data were not available for analysis. The study included 390,000 people who received the Johnson & Johnson COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity conducted from March to late July 2021.

These data were consistent with the Phase 3 ENSEMBLE trial, where strong protection against severe/critical disease and death was observed at least 28 days post-final vaccination:

- 75 percent overall efficacy (CI, 65%-82%) against severe/critical COVID-19, across all age cohorts and all countries included in the study.
- 74 percent efficacy in the U.S. against severe/critical COVID-19 (CI, 39%-91%); 89 percent against hospitalization (CI, 24%-100%); 83 percent against COVID-19-related death (CI, 41%-97%).

#### **Booster shot at two months provided 94 percent protection against COVID-19 in the U.S.**

The Phase 3 ENSEMBLE 2 study showed that another shot of the Johnson & Johnson COVID-19 vaccine given 56 days after the first provided:

- 100 percent protection (CI, 33%-100%) against severe/critical COVID-19 – at least 14 days post-final vaccination.
- 75 percent protection against symptomatic (moderate to severe/critical) COVID-19 globally (CI, 55%-87%).
- 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%).

When a booster of the Johnson & Johnson COVID-19 vaccine was given two months after the first shot, antibody levels rose to four to six times higher than observed after the single shot.

#### **Booster shot at six months provided 12-fold increase in antibodies**

When a booster of the Johnson & Johnson COVID-19 vaccine was given six months after the single shot, antibody levels increased nine-fold one week after the booster and continued to climb to 12-fold higher four weeks after the booster. All rises were irrespective of age.

The Johnson & Johnson single-shot COVID-19 vaccine, developed by its Janssen Pharmaceutical Companies of Johnson & Johnson, received an [Emergency Use Authorization \(EUA\) in the United States](#) on February 27, 2021 and [Conditional Marketing Authorization \(CMA\)](#) by the European Commission on March 11. The World Health Organization (WHO) issued [Emergency Use Listing](#) on March 12, and the Company received an [interim recommendation](#) by the Strategic Advisory Group of Experts (SAGE) on Immunization for the WHO on March 17. Many more authorizations have been granted in countries worldwide, and regulatory submissions are ongoing.

#### **- Additional Notes -**

##### **Real-World Evidence Study**

In the largest [real-world evidence](#) Vaccine Effectiveness (VE) study of participants receiving the Johnson & Johnson single-shot COVID-19 vaccine in the U.S. to date, the Janssen R&D Data Science team, Harvard University and Aetion

utilized the HealthVerity database, which consisted of longitudinal de-identified patient-level information representative of the U.S. population. This study compared approximately 390,000 people who received the Company's single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.

This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety, effectiveness, and value of medical technologies. All transformations of the raw data are preserved for full reproducibility and audit trails are available, including a quality check of the data ingestion process.

In the real-world U.S. [data](#), the Johnson & Johnson single-shot COVID-19 vaccine showed VE of 81 percent (CI, 79%-84%) for COVID-19-related hospitalizations and effectiveness of 79 percent (CI, 77%-80%) for COVID-19-related infections (VE was corrected to compensate for vaccination status misclassification due to under-recording of true vaccination status in health care claims data). Uncorrected VE was 69 percent (CI, 67%-71%) for COVID-19-related infections; VE of 73 percent (CI, 69%-76%) for COVID-19 hospitalizations.

The Johnson & Johnson single-shot COVID-19 vaccine showed VE against COVID-19-related hospitalizations at 86 percent (CI, 83%-89%) for participants younger than 60 years, and 78 percent (CI, 74%-81%) for those 60 years and older. VE against COVID-19 infections was 81 percent (CI, 79%-82%) for people younger than 60 years, and 75 percent (CI, 73%-78%) for those 60 years and older. These results are consistent with what was observed in the ENSEMBLE study.

### **ENSEMBLE 1 Study**

The Phase 3 ENSEMBLE study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a single-dose vaccine versus placebo in adults 18 years old and older.

The ENSEMBLE study was designed to evaluate the safety and efficacy of the Johnson & Johnson vaccine candidate in protecting against moderate to severe/critical COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints.

In the Phase 3 ENSEMBLE study, a single dose of the Johnson & Johnson COVID-19 vaccine offered strong and durable overall efficacy (75%; CI, 65%-82%; n=46 cases vaccine arm, n=176 cases placebo arm) against severe/critical COVID-19, across all age cohorts and all countries included in the study, after at least 28 days post-vaccination. While efficacy against severe/critical COVID-19 caused by the initial circulating SARS-COV-2 reference strain (Wuhan) remained high (93%; CI, 54%-99%; n=1 case vaccine arm, n=14 cases placebo arm), there was somewhat lower vaccine efficacy (72%; CI, 56%-82%; n=27 cases vaccine arm, n=93 cases placebo arm) against severe/critical disease caused by variants.

The single-dose regimen had 53 percent (CI, 47%-58%; n=433 cases vaccine arm, n=883 cases placebo arm) efficacy against moderate to severe/critical infection with 58 percent (CI, 35%-74%; n=30 cases vaccine arm, n=69 cases placebo arm) efficacy against the reference strain. Efficacy against hospitalizations related to COVID-19 in the ENSEMBLE trial was 76 percent (CI, 54%-88%; n=16 cases vaccine arm, n=64 cases placebo arm), and efficacy against COVID-19-related deaths was 83 percent (CI, 41%-97%; n=3 cases vaccine arm, n=17 cases placebo arm).

In the U.S., the ENSEMBLE trial demonstrated vaccine efficacy against moderate to severe/critical COVID-19 infection of 70 percent 28-days post-vaccination (CI, 61%-77%; n=77 cases vaccine arm, n=239 cases placebo arm), 74 percent against severe/critical infection (CI, 39%-91%; n=7 cases vaccine arm, n=26 cases placebo arm) and 89 percent against hospitalization (CI, 24%-100%; n=1 case vaccine arm, n=9 cases placebo arm).

Median follow-up time in the ENSEMBLE study was four months, with 23 percent of the participants with follow-up of greater than six months.

The vaccine was generally well-tolerated by all participants, with fewer local and systemic reactions as compared with Phase 1/2 data.

ENSEMBLE was initiated in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) under Other Transaction Agreement HHSO100201700018C, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at HHS.

Full data will be submitted for publication in the coming months.

### **ENSEMBLE 2 Study**

The Phase 3 ENSEMBLE 2 study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of a two-dose vaccine regimen, given at a 56-day interval, versus placebo in adults 18 years old and older with and without comorbidities associated with an increased risk for severe COVID-19.

The study was designed to assess efficacy of the investigational vaccine after both the first and second dose to evaluate protection against the virus and potential incremental benefits for duration of protection with a second dose. In the ENSEMBLE 2 Phase 3 study solicited and unsolicited adverse events following this second dose are similar to those seen in single-dose studies.

Compared to the single-dose results, ENSEMBLE 2 also demonstrated increased efficacy of a two-dose schedule against moderate to severe/critical COVID-19 of 75 percent (CI, 55%-87%; n=14 cases vaccine arm, n=52 cases placebo arm) and severe/critical COVID-19 of 100 percent (CI, 33%-100%; n=0 cases vaccine arm, n=8 cases placebo arm) at least 14

days following the second vaccination prior to unblinding. In the U.S., efficacy against moderate to severe/critical COVID-19 was 94 percent (CI, 58%-100%; n=1 case vaccine arm, n=14 cases placebo arm).

Median follow-up time in the ENSEMBLE 2 study was 36 days since second vaccination, with 29 percent of participants having at least two months of follow-up after receipt of their second dose.

The vaccine, when given as a second dose or booster, remained generally well-tolerated.

Full data will be submitted for publication in the coming months.

For more information on the Company's multi-pronged approach to helping combat the pandemic, visit: [www.jnj.com/covid-19](http://www.jnj.com/covid-19).

###

### **Authorized Use**

The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

### **IMPORTANT SAFETY INFORMATION**

#### **WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE JANSSEN COVID-19 VACCINE?**

Tell the vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine
- have ever fainted in association with an injection

#### **WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE?**

You should not get the Janssen COVID-19 Vaccine if you:

- had a severe allergic reaction to any ingredient of this vaccine.

#### **HOW IS THE JANSSEN COVID-19 VACCINE GIVEN?**

The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle. The Janssen COVID-19 Vaccine vaccination schedule is a **single dose**.

#### **WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE?**

Side effects that have been reported with the Janssen COVID-19 Vaccine include:

- Injection site reactions: pain, redness of the skin, and swelling.
- General side effects: headache, feeling very tired, muscle aches, nausea, fever.
- Swollen lymph nodes.
- Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling or sensitivity, especially in the skin (hypoesthesia).
- Persistent ringing in the ears (tinnitus).
- Diarrhea, vomiting.

#### **Severe Allergic Reactions**

There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

#### **Blood Clots with Low Levels of Platelets**

Blood clots involving blood vessels in the brain, lungs, abdomen, and legs along with low levels of platelets (blood cells that help your body stop bleeding), have occurred in some people who have received the Janssen COVID-19 Vaccine. In people who developed these blood clots and low levels of platelets, symptoms began approximately one to two-weeks following vaccination. Reporting of these blood clots and low levels of platelets has been highest in females ages 18

through 49 years. The chance of having this occur is remote. You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

- Shortness of breath,
- Chest pain,
- Leg swelling,
- Persistent abdominal pain,
- Severe or persistent headaches or blurred vision,
- Easy bruising or tiny blood spots under the skin beyond the site of the injection.

These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical trials.

#### Guillain Barré Syndrome

Guillain Barré syndrome (a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who have received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within 42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is very low. You should seek medical attention right away if you develop any of the following symptoms after receiving the Janssen COVID-19 Vaccine:

- Weakness or tingling sensations, especially in the legs or arms, that's worsening and spreading to other parts of the body
- Difficulty walking
- Difficulty with facial movements, including speaking, chewing, or swallowing
- Double vision or inability to move eyes
- Difficulty with bladder control or bowel function

#### **WHAT SHOULD I DO ABOUT SIDE EFFECTS?**

If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Report vaccine side effects to **FDA/CDC Vaccine Adverse Event Reporting System (VAERS)**. The VAERS toll-free number is 1-800-822-7967 or report online to <https://vaers.hhs.gov/reportevent.html>. Please include "Janssen COVID-19 Vaccine EUA" in the first line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech Inc. at 1-800-565-4008.

Please read Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including full EUA Prescribing Information available at [www.JanssenCOVID19Vaccine.com/EUA-factsheet](http://www.JanssenCOVID19Vaccine.com/EUA-factsheet)

#### **About Johnson & Johnson**

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at [www.jnj.com](http://www.jnj.com). Follow us at @JNJNews.

#### **About the Janssen Pharmaceutical Companies of Johnson & Johnson**

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at [www.janssen.com](http://www.janssen.com). Follow us at @JanssenGlobal.

#### **Cautions Concerning Forward-Looking Statements**

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.



###

- **Media Contacts:**

Jake Sargent  
+1 732-524-1090  
[JSargen3@its.jnj.com](mailto:JSargen3@its.jnj.com)

Seema Kumar  
+1 908-405-1144  
[SKumar10@its.jnj.com](mailto:SKumar10@its.jnj.com)

Katie Buckley  
+44 7900-655-261  
[KBuckle8@its.jnj.com](mailto:KBuckle8@its.jnj.com)

- **Investor Relations:**

Jennifer McIntyre  
+1 732-524-3922

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

# FW: FACT SHEET: President Biden to Announce All Americans to be Eligible for Vaccinations by May 1, Puts Nation on Path to Get Closer to Normal by July 4

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Hussain, Farhana P. EOP/WHO" (b)(6)  
**Date:** Thu, 11 Mar 2021 18:51:02 -0500

---

---

**From:** Munoz, Kevin EOP/WHO  
**Sent:** Thursday, March 11, 2021 6:50 PM  
**To:** Cisneros, Eduardo EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)  
**Subject:** FW: FACT SHEET: President Biden to Announce All Americans to be Eligible for Vaccinations by May 1, Puts Nation on Path to Get Closer to Normal by July 4

---

**From:** White House Press Office <info@mail.whitehouse.gov>  
**Sent:** Thursday, March 11, 2021 6:49 PM  
**To:** Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** FACT SHEET: President Biden to Announce All Americans to be Eligible for Vaccinations by May 1, Puts Nation on Path to Get Closer to Normal by July 4

[Redacted signature block]

**FOR IMMEDIATE RELEASE**

March 11, 2021

**FACT SHEET:**

**President Biden to Announce All Americans to be Eligible for Vaccinations by May 1, Puts the Nation on a Path to Get Closer to Normal by July 4th**

*President Biden Implements Next Phase of National Strategy to Put the Pandemic Behind Us; Will Direct States, Tribes, and Territories to Make All Adults Eligible for Vaccine by May 1*

Today, in his first prime time address, President Biden will announce the next phase of our war-time effort to vaccinate the U.S. population, with the goal of getting the nation closer to normal by July 4th, Independence Day.

The President launched a new, comprehensive strategy to beat this pandemic on January 21, 2021. In the subsequent 7 weeks, we've delivered over 81 million vaccinations to Americans -- today, more people are once again able to visit their loved ones. There is more work to do and today, the President is outlining the next phase of his whole of government strategy to put the pandemic behind us.

Today, the President will announce that in the coming weeks, the Administration will:

**Make every adult in the U.S. eligible for vaccination no later than May 1.** Today, in the next phase of our vaccination effort, the President will announce that he will direct states, Tribes, and territories to make all adults eligible for the COVID-19 vaccine no later than May 1st. The White House COVID-19 Response Team has concluded that our accelerated vaccination efforts will enable prioritized vaccinations to be far enough along by end of April that all eligibility restrictions for vaccinations can be lifted by May 1st.

Once all Americans are eligible to be vaccinated, the Administration will ensure that every adult is actually able to get the vaccine by:

Increasing the number of places Americans can get vaccinated. With the resources available through President Biden's *American Rescue Plan*, the Administration will ramp up efforts to create more places for people to get vaccinated, reaching the hardest-hit and hardest to reach populations.

*Community Health Centers:* Today, the Administration announced that over the next six weeks the Administration will deliver vaccines directly to up to an **additional** 700 community health centers that reach underserved communities, increasing the total number of participating community health centers across the country to 950. These health centers serve low income and minority patients, provide services to rural communities and Tribal communities, and many will utilize mobile vans to deliver services.

*Pharmacies:* The Administration will **double** the number of pharmacies participating in the federal pharmacy program, making the vaccine available at more than 20,000 pharmacies in locations convenient to all Americans. The Administration is directing pharmacies to expand mobile operations into the hardest hit communities to reach more people.

*Community Vaccination Centers:* The Administration will more than **double** the number of federally-run mass vaccination centers, run by FEMA, the U.S. military, and other federal agencies in partnership with states, to ensure that we reach the hardest-hit communities in this historic effort. Many of these sites will be the home base for mobile units that will travel into local communities to provide vaccines directly in underserved populations. With these mobile clinics, we'll work with states to make up to one-third of each site's daily vaccinations available directly in the hardest-hit neighborhoods. Thanks to the American Rescue Plan, the Administration will also increase support for state and local-run community vaccination centers. As a result of these added investments community vaccination centers will be capable of administering hundreds of thousands of shots a day, building on the nearly 600 centers across the country already operating with federal support.

*Increasing the number of people providing and supporting vaccinations.* Today, President Biden will announce the deployment of more than 4,000 active duty troops to support vaccination efforts, bringing the total to over 6,000 in all. Tomorrow, the Administration will expand the pool of qualified professionals able to administer shots to include: Dentists, advanced and intermediate Emergency Medical Technicians, Midwives, Optometrists, Paramedics, Physician Assistants, Podiatrists, Respiratory Therapists, and Veterinarians, as well as medical students, nursing students, and other healthcare students in the previously listed professions under the Public Readiness and Emergency Preparedness Act. The U.S. Department of Health & Human Services will launch a new website to help individuals determine whether they are eligible to sign up to volunteer to administer shots.

**Providing tools to make it easier for individuals to find a vaccine.** The President will announce steps to make it easier for individuals to find a vaccine near them and address some of the barriers to getting vaccinated.

*Find a Vaccination Website:* By May 1<sup>st</sup>, as vaccines are available in more places, the Administration will launch a federally-supported website that will show the locations near them that have vaccines.

*1-800 Number:* To offer a tool for those who may lack Internet access, we will launch a call center by May 1<sup>st</sup> to provide guidance and assistance with finding a vaccine.

*Technical Support to Improve Existing State Websites:* Since many Americans use their state websites to schedule appointments, the Administration will also deploy technology teams to states who need assistance to improve their websites.

UB Our COVID-19 efforts will always be guided by science and the step-by-step approaches to get Americans back to the important people and activities in their lives that they have been missing. Today, the President announced that the Centers for Disease Control and Prevention (CDC) will continue to issue clear guidance for individuals on what they can do after being fully vaccinated.

*Additional CDC Guidance on Activities for the Vaccinated:* As we approach July 4<sup>th</sup>, based on the best available science and the pace of vaccinations, the CDC will provide public health guidance for people as they travel, participate in small gatherings, and go to work and houses of worship.

*Benefits of Vaccination:* CDC guidance and other CDC messaging will make the benefits of vaccination clear to encourage more Americans to get vaccinated.

**Take New Steps to Reopen the Nation's Schools.** Reopening schools safely is critical to getting closer to normal. Tonight, President Biden laid out new steps in the school reopening effort.

*Ensure schools have the resources they need:* Now that the American Rescue Plan has passed, the nearly \$130 billion to safely reopen schools for in-person instruction will begin to be distributed this month by the Department of Education. These dollars will help schools pay for the critical supplies to implement the Centers for Disease Control and Prevention's (CDC) recommended mitigation strategies, hire more staff – and avoid laying off current staff – to accommodate the need for smaller class sizes due to physical distancing, and support children's academic, social and emotional needs after a challenging year.

*Expand screening testing in schools:* We will immediately take steps to help schools implement regular screening testing to assist them in safely reopening classrooms, including through tests and test supplies as well as implementation assistance to make it easier for schools to adopt a testing program. This month, HHS will award \$650 million in an initial investment in expanding K-8 school testing and testing in underserved congregate settings through new regional coordinating centers that will identify existing testing capacity, match it up to an area of need and support testing. This effort will begin to bring more testing to teachers, staff, and students and serve as a bridge to the comprehensive testing investment in the American Rescue Plan that is critical to get the pandemic under control.

*Provide guidance and support:* The Department of Education (ED) will host a national Safe School Reopening Summit this month that will bring together students, teachers, families, community organizations, and state, local, or school leadership to provide assistance in implementing the [CDC K-12 operational strategy](#) for in-person instruction and supporting the academic, social, and emotional well-being of students. ED also is launching the "Safer Schools and Campuses Best Practices Clearinghouse" called for in President Biden's Executive Order. The Clearinghouse will highlight lessons learned and best practices that can help schools and districts identify opportunities to best utilize American Rescue Plan funds to meet their individual needs. Next month, ED will release Volume 2 of its K-12 COVID-19 Handbook for districts, schools, and educators with strategies to address the impact of COVID-19 on students, educators, and staff, especially for historically underserved students and communities that have been hit hardest by the pandemic.

*Help educators get vaccinated:* Throughout March, the Administration will advance our efforts to support educators, school staff and childcare workers getting vaccinated. Last week, the President announced that he is using the Administration's authority to direct states to make Pre-K-12 school staff and child care workers eligible for vaccinations and that the Administration will prioritize educators in the federal pharmacy program. The President challenged all 50 states to get Pre-K-12 school staff and child care workers their first shot by the end of this month. To help meet that goal, the Administration is working with education leaders, advocates, child care providers, community leaders, states and others to help reach educators and to disseminate toolkits and other resources to help amplify the importance of getting vaccinated.

**Continue Effort to Combat Variants and Spread of COVID-19:** As we work to get more people vaccinated, we will continue to take steps to combat the spread of variants including expanding testing and genomic sequencing.

*Expand testing to help stop the spread of COVID-19.* While testing to date has been primarily focused on individuals with symptoms and potential exposures – and this testing remains critical – we will expand testing to ensure that we are identifying asymptomatic infection early to stop the spread. With the nearly \$50 billion in testing funding in the American Rescue Plan, the Administration will invest in screening testing to help schools reopen safely, expand testing in congregate settings like shelters for individuals experiencing homelessness, prisons, and other settings where individuals live in close quarters. This funding also will help to close supply gaps and address critical raw material shortages that have plagued the testing supply chain. And, with new investments in our manufacturing base, we will be able to increase easier to use and more affordable point-of-care and at-home testing.

*Identify variants by expanding genomic sequencing.* Thanks to the American Rescue Plan’s \$1.75 billion investment, we will dramatically expand our ability to sequence samples to identify, track, and mitigate emerging variants. This will build on the nearly \$200 million that the Administration announced last month to grow the number of samples sequenced from 7,000 to approximately 25,000. Growing sample sizes will improve our ability to detect emerging variants and work to mitigate their spread.

###

[Privacy Policy](#) | [Unsubscribe](#) | [press@who.eop.gov](mailto:press@who.eop.gov)

**RE:**

---

**From:** "Quillian, Natalie H. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Wed, 29 Sep 2021 13:51:52 -0400

Got it. Thanks!

---

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Wednesday, September 29, 2021 1:18 PM  
**To:** Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** RE:

(b)(5)

Thanks for the heads up.  
R

---

**From:** Quillian, Natalie H. EOP/WHO (b)(6)  
**Sent:** Wednesday, September 29, 2021 1:04 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:**

(b)(5)





# RE: Urgent COVID Brazil

**From:** "Hussain, Farhana P. EOP/WHO" (b)(6)  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Choucair, Bechara EOP/WHO" (b)(6), "Smith, Marcella N. EOP/OSTP" (b)(6), "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Slavitt, Andrew M. EOP/WHO" (b)(6), "Quillian, Natalie H. EOP/WHO" (b)(6)  
**Date:** Sun, 28 Mar 2021 21:49:19 -0400

All (b)(5)  
(b)(5)

(b)(5)

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Sunday, March 28, 2021 9:45 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara EOP/WHO (b)(6); Smith, Marcella N. EOP/OSTP (b)(6); Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Slavitt, Andrew M. EOP/WHO (b)(6); Quillian, Natalie H. EOP/WHO (b)(6); Hussain, Farhana P. EOP/WHO (b)(6)  
**Subject:** Re: Urgent COVID Brazil

(b)(5) Thanks team.  
JZ

On Mar 28, 2021, at 8:35 AM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

Jeff:

(b)(5)

Thanks,  
Tony

---

**From:** Lenardo, Michael (NIH/NIAID) [E] (b)(6)  
**Sent:** Saturday, March 27, 2021 10:28 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Subject:** FW: Urgent COVID Brazil

Dear Tony,

I am sending you this note from Dr. Lopes, a former NIAID visiting fellow in the Laboratory of Immunology, on the status of the pandemic in Brazil. I don't know what you can do, but I promised Dr. Lopes I would forward this in case this issue were to arise in your deliberations with the Biden administration.

Hope you are doing well!

Best, Mike

---

**From:** "Marcela de F. Lopes" <[marcelal@biof.ufrj.br](mailto:marcelal@biof.ufrj.br)>  
**Date:** Saturday, March 27, 2021 at 6:04 PM  
**To:** "Immunology Fundamental; User: Mlenardo" (b)(6) "Immunology Fundamental; User: Mlenardo"  
(b)(6)  
**Subject:** Urgent COVID Brazil

Dear Mike,

You may be aware that the Brazilian health system has collapsed in 25 out of 27 states according to the last FIOCRUZ report. Even young people are dying without ICU assistance because of the dangerous new P1 variant. There are more than 6000 people waiting for ICU and we may experience soon shortage of sedation drugs and oxygen in some units.

Because of the decisions of the Minister for foreign matters, it seems unlikely he will try to ask the USA to help Brazil out of this crisis.

I heard that the USA has a stock of 30 millions doses of Astrazeneca-Oxford vaccine, which has not been approved by FDA so far. It would make a huge difference here if USA could send right now these Astrazeneca vaccines to Brazil. Perhaps the USA could make an agreement with the Brazilian government to return the same numbers and type of vaccines from our local production in FIOCRUZ at the second semester. The Brazilian health system can immunize more than a million people a day, but we do not have enough vaccine for the next 5-6 months.

The generation of new dangerous variants owing to uncontrolled SARS-CoV-2 transmission in Brazil is a threat to USA and the whole world. We know that new mutations accumulated in the P1 variant, which now predominant in Sao Paulo. These and other new variants may escape vaccine protection in the future.

It would be very important if you could please contact Dr Anthony Fauci to explain to him this situation and advise the Biden government in this direction for the sake of all. Sorry for the long message, but I am desperate to try something to mitigate a catastrophe here that might spread to other countries, including the USA.

Thank you so much,  
Marcela

# FACT SHEET: Biden Announces Major Milestone in Global Vaccination Efforts: More Than 100 Million US COVID-19 Vaccine Doses Donated and Shipped Abroad

---

**From:** "Kwak, Grace J. EOP/WHO" (b)(6)  
**To:** "Kwak, Grace J. EOP/WHO" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Date:** Tue, 03 Aug 2021 10:01:23 -0400

---

Good morning everyone,

Please find below the fact sheet released this morning on the 100M doses.

Thank you!  
Grace

---

**From:** White House Press Office <info@mail.whitehouse.gov>  
**Sent:** Tuesday, August 3, 2021 7:02 AM  
**To:** Kwak, Grace J. EOP/WHO (b)(6)  
**Subject:** FACT SHEET: Biden Announces Major Milestone in Global Vaccination Efforts: More Than 100 Million US COVID-19 Vaccine Doses Donated and Shipped Abroad



The White House Logo

**FOR IMMEDIATE RELEASE**

August 3, 2021

## FACT SHEET:

### President Biden Announces Major Milestone in Administration's Global Vaccination Efforts: More Than 100 Million U.S. COVID-19 Vaccine Doses Donated and Shipped Abroad

Building off of last week's announcement of [additional actions](#) that we are taking to stop the spread of the Delta variant and get more people vaccinated in the United States, President Biden will give an update on another critical piece of his strategy to end the COVID-19 pandemic: stopping the spread of the virus abroad. As one part of our strategy to do that, the President has promised that the United States will be an arsenal of vaccines for the world and is acting with the same urgency to combat the virus abroad as here at home. Today, the President will announce that the U.S. has now donated and shipped more than 110 million doses of its COVID-19 vaccines to more than 60 countries – a major milestone that cements the United States as the global leader in COVID-19 vaccine donations. According to the United Nations, this is more than the donations of all other countries combined and reflects the generosity of the American spirit.

In June, the President committed to donate at least 80 million vaccines from the U.S. supply to countries throughout the world, and he promised to continue to share as we are able. Today's announcement is a fulfillment of his promise and a significant down payment on hundreds of millions of more doses that the U.S. will deliver in the coming weeks. The United States has been able to share these doses because of the aggressive action the President took when he came into office to secure enough vaccines for all Americans. The majority of these vaccines – made in the United States – were shipped through COVAX. The United States has also worked in close partnership with key regional partners, including the African Union and the Caribbean Community (CARICOM).

These more than 110 million doses – that are already saving lives around the world – are just the beginning of the Administration's efforts to provide vaccines to the world. Starting at the end of this month, the Administration will begin shipping a half a billion Pfizer doses that the United States has pledged to purchase and donate to 100 low- income countries in need.

**Biden Administration's Approach to Sharing U.S. Vaccines:** Our goals are to increase global COVID-19 vaccination coverage, prepare for surges and prioritize healthcare workers and other vulnerable populations based on public health data and acknowledged best practice, and help our neighbors and other countries in need. Importantly, the United States has not and will not use its vaccines to secure favors from other countries. Our aim is to save lives.

The Administration looks at a variety of factors, including COVID-19 case rates, death rates, and hospitalizations; current vaccination rates; responses to surges; and a country's ability to receive vaccines and put shots into arms.

We will continue to work with COVAX, regional partners such as the African Union and CARICOM, and other partners to ensure these vaccines are delivered in a way that is equitable and follows the science and public health data. This is a unique moment in history, and it requires American leadership, science and ingenuity, perseverance, and we are demonstrating that we can deliver results for people around the world.

#### To date, the U.S. has donated COVID-19 vaccines as follows:

Afghanistan	3,300,000	Malaysia	1,000,000
Argentina	3,500,000	Mali	151,000
Bangladesh	5,500,000	Mauritania	302,000
Benin	302,000	Mexico	4,049,000
Bhutan	500,000	Moldova	301,000
Bolivia	1,008,000	Morocco	302,000
Brazil	3,000,000	Mozambique	302,000
Burkina Faso	302,000	Nepal	1,534,000
Cambodia	1,058,000	Niger	316,000

Cameroon	303,000	Nigeria	4,000,000
Canada	2,500,000	Pakistan	5,500,000
CAR	302,000	Panama	503,000
Colombia	6,000,000	Paraguay	2,000,000
Costa Rica	500,000	Peru	2,000,000
Djibouti	151,000	Philippines	6,239,000
Ecuador	2,000,000	PNG	302,000
El Salvador	3,000,000	ROK	1,012,000
Eswatini	302,000	Senegal	302,000
Ethiopia	1,664,000	Somalia	302,000
Fiji	150,000	South Africa	5,660,000
Gambia	302,000	Sri Lanka	1,500,000
Georgia	503,000	Sudan	604,000
Guatemala	4,500,000	Taiwan	2,500,000
Guinea Bissau	302,000	Tajikistan	1,500,000
Haiti	500,000	Tanzania	1,058,000
Honduras	3,000,000	Thailand	1,500,000
Indonesia	8,000,000	Tunisia	1,000,000
Jordan	503,000	Ukraine	2,000,000
Laos	1,000,000	Uruguay	500,000
Lesotho	302,000	Uzbekistan	3,000,000
Liberia	302,000	Vietnam	5,000,000
Madagascar	302,000	Zambia	302,000
Malawi	302,000	<b>Total</b>	<b><u>111,701,000</u></b>

###

[Privacy Policy](#) | [Unsubscribe](#) | [press@who.eop.gov](mailto:press@who.eop.gov)

# RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Rowe, Courtney (who.eop.gov)" (b)(6) "Sams, Ian (HHS/ASP)" <ian.sams@hhs.gov>, "Wakana, Benjamin (who.eop.gov)" (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) "Zients, Jeffrey D. EOP/WHO" (b)(6) "Choucair, Bechara N. EOP/WHO" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" <marcella.nunez-smith@hhs.gov>  
**Date:** Fri, 02 Jul 2021 16:23:23 -0400

(b)(5)

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Friday, July 2, 2021 4:13 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASP) <ian.Sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Wakana, Benjamin (who.eop.gov) (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Choucair, Bechara N. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

(b)(5)

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Thursday, July 1, 2021 9:02 PM  
**To:** Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASP) <ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Wakana, Benjamin (who.eop.gov) (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Choucair, Bechara N. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** Re: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

Thanks (b)(5)

(b)(5)

Vivek

**Vivek Murthy**  
U.S. Surgeon General  
Vice Admiral, U.S. Public Health Service

The information in this e-mail and its attachments are confidential, pre-decisional and deliberative. Contents may include sensitive information and are for official use only. If you are not the original intended recipient, please delete the content and notify the sender.

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Thursday, July 1, 2021 8:54 PM  
**To:** Sams, Ian (HHS/ASP) <ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Wakana, Benjamin (who.eop.gov) (b)(6) Kevin.Munoz (b)(6) natalie.h.quillian (eop.gov) (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Choucair, Bechara N. EOP/WHO (b)(6) Nunez-Smith, Marcella (OS/ASPR/IO) (CTR) (b)(6)  
**Subject:** RE: J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

++

**From:** Sams, Ian (HHS/ASPA) <[ian.Sams@hhs.gov](mailto:ian.Sams@hhs.gov)>

**Sent:** Thursday, July 1, 2021 8:46 PM

**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Rowe, Courtney M. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Munoz, Kevin A. EOP/WHO

(b)(6)

**Subject:** J&J Covid Shot Neutralizes Delta Variant, Company Says - Bloomberg

><https://www.bloomberg.com/news/articles/2021-07-02/j-j-covid-shot-neutralizes-delta-variant-is-durable-over-time><

# J&J Covid Shot Neutralizes Delta Variant, Company Says

[Riley Griffin](#) July 1, 2021, 8:01 PM EDT

[Johnson & Johnson](#) said that its single-shot coronavirus vaccine neutralizes the fast-spreading delta variant and provides durable protection against infection more broadly.

The company said in a statement Thursday that recipients of its vaccine produced strong neutralizing antibodies over the course of at least eight months against all variants including delta, which was first seen in India and has been spreading around the globe.

Delta is expected to become the dominant strain in the U.S. in the coming weeks, according to the Centers for Disease Control and Prevention. The J&J shot provides less protection initially than messenger RNA vaccines from [Pfizer Inc.](#) and [Moderna Inc.](#), and experts have been discussing whether some people may need booster shots to keep the virus at bay long-term.

“We’re extremely happy, actually, and confident there’s no need for the booster at the moment and we’re protected against different strains,” said Johan Van Hoof, J&J’s global head of infectious diseases and vaccines, in an interview.

The shot neutralized the delta variant within 29 days of a first dose, and protection matured and improved over time, the company said.

With the latest data in hand, Van Hoof said J&J doesn’t believe people who have been given its vaccine should need a booster within a year of having gotten it. “And if a boost is needed,” he said, “we don’t think we’ll need to change the formulation.”

Scientists and some vaccine manufacturers have been crafting updated versions of their shots to directly target the emerging variants, which have proved to be significantly more transmissible than the original virus that first emerged in Wuhan, China, in late 2019.

The continued evolution of the pathogen, however, is creating an ever-moving target, leading some to evaluate whether additional doses of existing immunizations may provide more protection.

[Read More: Astra Shot Response Higher With Longer Gap, Third Dose](#)

The findings J&J disclosed Thursday were from two studies.

The company evaluated the blood samples of eight participants in its late-stage clinical trial of the vaccine to assess neutralizing antibodies produced against the delta variant. Dan Barouch of Beth Israel Deaconess Medical Center evaluated the durability of the immune response in 20 participants of an early-stage vaccine study.

More robust results will be published in bioRxiv, an online research depository, the company said.

## **Two-Shot Regimen**

Data released by the company showed antibody counts, known as titres, were substantially higher in response to the delta variant than the beta variant first detected in South Africa.

J&J said a second dose of its vaccine is known to increase a person's antibody count. The company plans to report efficacy data from a late-stage trial of a two-shot regimen at the end of August, Van Hoof said.

The company is also studying its vaccine's ability to create T cells, another gauge of its protective power. The shot produced increasing T cell immunity against the virus and its variants over eight months, according to Van Hoof.

J&J's shot has struggled to get broad traction amid production problems and after a brief pause in use as regulators investigated reports that some people suffered dangerous blood clots after receiving it. The pause was lifted after 10 days on April 23.

Sent from my iPhone



## RE: COVID Data Tracker Daily Site Update Information

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Beach, Michael J. (CDC/DDID/NCEZID/DFWED)" <mjb3@cdc.gov>  
**Cc:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>, "Christie, Athalia (CDC/DDPHSIS/CGH/OD)" <akc9@cdc.gov>  
**Date:** Fri, 28 May 2021 13:45:26 -0400

---

Thank you Michael for all your work and hope you have a great holiday weekend.  
Look forward to working you Peggy!  
Cyrus

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Friday, May 28, 2021 10:31 AM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Thursday, May 27, 2021 1:58 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Wednesday, May 26, 2021 1:28 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J.

(CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Tuesday, May 25, 2021 1:44 PM

**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Monday, May 24, 2021 1:23 PM

**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Sunday, May 23, 2021 1:29 PM

**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael  
Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Saturday, May 22, 2021 4:47:30 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)  
(b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Saturday, May 22, 2021 2:57:02 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)  
(b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Thanks

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>  
**Sent:** Saturday, May 22, 2021 2:51 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>; Shahpar, Cyrus (CDC who.eop.gov)  
(b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

R

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Sent:** Saturday, May 22, 2021 2:03 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager

CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Saturday, May 22, 2021 1:13 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)  
Cyrus

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Saturday, May 22, 2021 9:56 AM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

All,  
(b)(5)  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Friday, May 21, 2021 10:11 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

(b)(5)  
Michael  
Get [Outlook for iOS](#)

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Friday, May 21, 2021 7:44:54 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)  
Michael  
(b)(5)

(b)(5)

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Friday, May 21, 2021 7:35 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>  
**Subject:** Re: COVID Data Tracker Daily Site Update Information

Hi Michael,

(b)(5)

Much appreciated,  
Cyrus

Sent from my iPhone

On May 21, 2021, at 4:33 PM, Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov> wrote:

Cyrus

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED)  
**Sent:** Friday, May 21, 2021 6:38 PM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention

1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Friday, May 21, 2021 6:14 PM  
**To:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

(b)(5)

Thanks!  
Cyrus

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Friday, May 21, 2021 2:52 PM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus- (b)(5)  
(b)(5)  
Michael

(b)(5)

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Friday, May 21, 2021 1:46 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <mjb3@cdc.gov>  
**Sent:** Thursday, May 20, 2021 1:19 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky,

Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Wednesday, May 19, 2021 1:20 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Thanks  
Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

---

**From:** Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Sent:** Tuesday, May 18, 2021 1:25 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Beach, Michael J. (CDC/DDID/NCEZID/DFWED) <[mjb3@cdc.gov](mailto:mjb3@cdc.gov)>

**Subject:** RE: COVID Data Tracker Daily Site Update Information

Cyrus,

(b)(5)

Michael

Michael J. Beach, PhD  
Principal Deputy Incident Manager  
CDC COVID-19 Emergency Response  
Centers for Disease Control and Prevention  
1600 Clifton Road  
Atlanta, GA 30329-4018  
404-667-0718

# Re: Messaging guidance on J&J unpause

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Cc:** "Wakana, Benjamin (who.eop.gov)" <(b)(6)> "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>  
**Date:** Sat, 24 Apr 2021 13:04:24 -0400

(b)(5) Thank you, Anne.

Get [Outlook for iOS](#)

**From:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>  
**Sent:** Saturday, April 24, 2021 11:57:17 AM  
**To:** Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>  
**Cc:** Wakana, Benjamin (who.eop.gov) <(b)(6)> Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** RE: Messaging guidance on J&J unpause

(b)(5)

**From:** Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>  
**Sent:** Saturday, April 24, 2021 11:52 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>  
**Cc:** Wakana, Benjamin (who.eop.gov) <(b)(6)> Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** RE: Messaging guidance on J&J unpause

(b)(5)

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Saturday, April 24, 2021 11:19 AM  
**To:** Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>  
**Cc:** Wakana, Benjamin (who.eop.gov) <(b)(6)> Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** RE: Messaging guidance on J&J unpause

(b)(5)

R

**From:** Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>  
**Sent:** Saturday, April 24, 2021 11:14 AM  
**To:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>  
**Cc:** Wakana, Benjamin (who.eop.gov) <(b)(6)> Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** RE: Messaging guidance on J&J unpause

Thanks (b)(5)

(b)(5)



(b)(5)

**From:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <[aws8@cdc.gov](mailto:aws8@cdc.gov)>

**Sent:** Saturday, April 24, 2021 11:06 AM

**To:** Sams, Ian (HHS/ASPA) <[ian.Sams@hhs.gov](mailto:ian.Sams@hhs.gov)>

**Cc:** Wakana, Benjamin (who.eop.gov) <[ben.wakana@hhs.gov](mailto:ben.wakana@hhs.gov)> (b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>

**Subject:** RE: Messaging guidance on J&J unpauses

Ian,

(b)(5)

(b)(5)

Regards,

Abbigail

Abbigail Tumpey, MPH CHES  
Acting Associate Director for Communication  
Centers for Disease Control and Prevention  
1600 Clifton Rd. NE  
Atlanta, GA  
Phone: 404-639-1125  
Cell: 404-259-7064  
Email: [atumpey@cdc.gov](mailto:atumpey@cdc.gov)

---

**From:** Sams, Ian (HHS/ASPA) <[ian.sams@hhs.gov](mailto:ian.sams@hhs.gov)>

**Sent:** Saturday, April 24, 2021 10:57 AM

**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>

**Cc:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <[aws8@cdc.gov](mailto:aws8@cdc.gov)>; Wakana, Benjamin (who.eop.gov)

(b)(6)

**Subject:** Messaging guidance on J&J unpause

Hey Drs. Walensky and Schuchat –

(b)(5)

Thank you

Ian

<< File: JJ TPs.docx >>

--

**Ian Sams**

Deputy Assistant Secretary for Public Affairs (COVID Response)

Office of the Assistant Secretary for Public Affairs

U.S. Department of Health and Human Services

(202) 740-7169

[ian.sams@hhs.gov](mailto:ian.sams@hhs.gov)

## RE: Some positive coverage on boosters

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Date:** Thu, 19 Aug 2021 11:10:00 -0400

(b)(5)  
Rochelle

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Thursday, August 19, 2021 11:06 AM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** FW: Some positive coverage on boosters

**From:** Rowe, Courtney M. EOP/WHO  
**Sent:** Thursday, August 19, 2021 11:05 AM  
**To:** DL EOP COVID All Staff (b)(6)  
**Subject:** Some positive coverage on boosters

Hi all (b)(5)



**Leana Wen, M.D.**

@DrLeanaWen

.

13h

On

@AC360

]

@NIHDirector

Dr. Francis Collins makes a compelling case for why the Biden administration is announcing a booster plan. You don't wait until your car is totally out of gas before you make a plan. If the gauge is running low, you want to know--& get prepared to refuel.

<https://twitter.com/DrLeanaWen/status/1428154332827033602?s=20>



**Leana Wen, M.D.**

@DrLeanaWen

.  
15h  
Coming up on  
[@CNNSitRoom](#)  
: The Biden admin made the right decision on boosters. We must be proactive when there are warnings that immunity against symptomatic [#covid19](#) is waning. It would be irresponsible to wait until vaccinated people start dying before recommending boosters.  
<https://twitter.com/DrLeanaWen/status/1428121804007219205?s=20>

**Leana Wen, M.D.**  
[@DrLeanaWen](#)

.  
16h  
"The Biden administration plan for booster shots should be seen as a necessary tune-up with the same goal as the first shots: survival and resilience." Agree  
[@PostOpinions](#)  
<https://twitter.com/DrLeanaWen/status/1428111985997123592?s=20>



**Leana Wen, M.D.**  
[@DrLeanaWen](#)

.  
20h  
What about those who say, why give boosters to the US when other countries don't have first doses? This cannot be an either or. We have an obligation the world, and to vulnerable Americans too. The Biden team can and should do both.  
[@AnaCabrera](#)  
[@WHCOVIDResponse](#)  
<https://twitter.com/DrLeanaWen/status/1428052129319620609?s=20>



**Leana Wen, M.D.**  
[@DrLeanaWen](#)

.  
20h  
The Biden team made the right call today to announce a plan for [#covid19](#) booster shots. It's their responsibility to give Americans data as they emerge. There are signals that vaccine effectiveness is declining—though remains strong against severe disease.  
[@WHCOVIDResponse](#)  
<https://twitter.com/DrLeanaWen/status/1428050845795590147?s=20>

**Leana Wen, M.D.**

@DrLeanaWen

.  
22h

Good move by Biden admin to announce boosters, following Israel, UK, etc. We are in a stage of the pandemic where there aren't easy answers. Patients should be able to choose whether they want a booster. What's clear is that EVERYONE eligible should get their first 2 doses.  
<https://twitter.com/DrLeanaWen/status/1428019353270816771?s=20>

Squawk Box

@SquawkCNBC

.  
2h

"The first two were administered so close together they really qualify as two primes, and this is the booster that is hopefully going to induce a longer term immunity," says

[@ScottGottliebMD](https://twitter.com/ScottGottliebMD)

on vaccines.  
<https://twitter.com/SquawkCNBC/status/1428335564718215176?s=20>

**Washington Post Editorial Board Headline: "Opinion: The Covid-19 Boosters Have The Same Goals As The First Shots: Survival And Resilience"** [Washington Post, [8/18/21](https://www.washingtonpost.com/health/covid-19-boosters-have-the-same-goals-as-the-first-shots/2021/08/18/)]

- **Washington Post: "The Biden Administration Plan For Booster Shots Should Be Seen As A Necessary Tune-Up With The Same Goal As The First Shots: Survival And Resilience."** "Nothing lasts forever — not even the benefits of the amazingly effective vaccines that have saved millions of lives during the pandemic. Data disclosed Wednesday suggests that robust protection the vaccines provided against infection at the outset is starting to wane, although they still work well against hospitalization and death. The Biden administration plan for booster shots should be seen as a necessary tune-up with the same goal as the first shots: survival and resilience." [Washington Post, [8/18/21](https://www.washingtonpost.com/health/covid-19-boosters-have-the-same-goals-as-the-first-shots/2021/08/18/)]
- **Washington Post: "The Administration's Announcement Wednesday Of Boosters Starting In September Is A Laudable Attempt To Get Ahead Of The Curve, Even If The Precise Reasons And Pace Of Waning Immunity Are Not Yet Fully Understood."** "The administration's announcement Wednesday of boosters starting in September is a laudable attempt to get ahead of the curve, even if the precise reasons and pace of waning immunity are not yet fully understood." [Washington Post, [8/18/21](https://www.washingtonpost.com/health/covid-19-boosters-have-the-same-goals-as-the-first-shots/2021/08/18/)]
- **Washington Post: "We Disagree With Those Who See This As An Either-Or Decision. Boosters In The United States And More Vaccines For The World Are Both Possible. The United States Has Pledged To Export Hundreds Of Millions Of Doses To Other Countries, And Has Begun Doing So."** "Vaccine distribution around the globe has been terribly lopsided. Poorer nations are starved for vaccines, while wealthy ones are awash. But we disagree with those who see this as an either-or decision. Boosters in the United States and more vaccines for the world are both possible. The United States has pledged to export hundreds of millions of doses to other countries, and has begun doing so." [Washington Post, [8/18/21](https://www.washingtonpost.com/health/covid-19-boosters-have-the-same-goals-as-the-first-shots/2021/08/18/)]

**WSJ Editorial Board Headline: "Three Cheers For Vaccine Boosters"** [WSJ, [8/19/21](https://www.wsj.com/articles/covid-19-boosters-are-a-good-idea-11631984000)]

- **WSJ: "Give The Biden Administration Credit For Endorsing Covid Booster Shots In Defiance Of The World Health Organization Scolds Who Have Been Wrong On Nearly Every Major Public Health Issue During The Pandemic."** "Give the Biden Administration credit for endorsing Covid booster shots in defiance of the World Health Organization scolds who have been wrong on nearly every major public health issue during the pandemic." [WSJ, [8/19/21](https://www.wsj.com/articles/covid-19-boosters-are-a-good-idea-11631984000)]

**AP: "Dr. Mark Mulligan Of NYU's Langone Health Center Welcomed The Announcement As A "Proactive" Response To Signs That Vaccine Strength Is Eroding As The Highly Contagious Delta Variant Spreads."** "Dr. Mark Mulligan of NYU's Langone Health center welcomed the announcement as a "proactive" response to signs that vaccine strength is eroding as the highly contagious delta variant spreads." [AP, [8/18/21](https://www.foxnews.com/health/covid-19-boosters-are-a-good-idea-11631984000)]

- **Dr. Mulligan: "Part Of Leadership Is Being Able To See Around The Corner And Make Hard Decisions Without Having All The Data. It Seems To Me That's What They're Doing Here."** "Part of leadership is being able to see around the corner and make hard decisions without having all the data. It seems to me that's what they're doing here," he said." [AP, [8/18/21](https://www.foxnews.com/health/covid-19-boosters-are-a-good-idea-11631984000)]

**On The Today Show, Dr. Richard Besser, Former Acting Director Of The CDC "If We Want To Get The Delta Variant Under Control [...] A Booster Shot Could Help With This."** [Today, [8/18/21](https://www.foxnews.com/health/covid-19-boosters-are-a-good-idea-11631984000)]

- **Besser Adds: “If We’re Starting To See People Who Are Fully Vaccinated Be Hospitalized, A Booster Shot Could Help.”** [Today, [8/18/21](#)]

**Dr. Robert Frenck, A Researcher With Cincinnati Children’s Hospital Who Has Led Several Vaccine Studies, Including One About To Be Published In The New England Journal Of Medicine On Boosters Said Boosters Can Make A Significant Difference.** “Dr. Robert Frenck is a researcher with Cincinnati Children’s hospital. He’s led several vaccine studies, including one about to be published in the New England Journal of Medicine on boosters. Frenck said boosters can make a significant difference.” [WLWT, [8/18/21](#)]

**Frenck Said: “Giving People That Had No Underlying Conditions A Third Dose, As A Booster, We Were Testing Booster To See If The Vaccine Would Boost. We Increased Their Antibody Levels Over 10 Times.”** ““Giving people that had no underlying conditions a third dose, as a booster, we were testing booster to see if the vaccine would boost. We increased their antibody levels over 10 times,” Frenck said.” [WLWT, [8/18/21](#)]

**UPMC Infectious Disease Specialist Dr. John D. Goldman Said The Health Community Was Always Expecting That A Booster Shot Could Be Necessary.** “UPMC Infectious Disease Specialist Dr. John D. Goldman says the health community was always expecting that a booster shot could be necessary. “The reason you need a booster is the vaccines work, and we want to keep them working,” Goldman said.” [ABC 27, [8/18/21](#)]

- **Goldman: “The Reason You Need A Booster Is The Vaccines Work, And We Want To Keep Them Working.”** “UPMC Infectious Disease Specialist Dr. John D. Goldman says the health community was always expecting that a booster shot could be necessary. “The reason you need a booster is the vaccines work, and we want to keep them working,” Goldman said.” [ABC 27, [8/18/21](#)]

**Dr. Anuh Vohra, The Medical Director Of Emergency Services At Charlotte Hungerford Hospital Said A Booster Will Help Boost People’s Antibodies, But Without It, The Effectiveness Of The Initial Vaccines Will Wear Down Over Time.** “Dr. Vohra went on to say that people, both vaccinated and unvaccinated, are being treated for COVID-19 at Charlotte Hungerford Hospital, but the unvaccinated are sicker and require longer stays. Dr. Vohra said a booster will help boost people’s antibodies, but without it, the effectiveness of the initial vaccines will wear down over time. With the fast-spreading delta variant and the possibility of more variants down the road, Dr. Vohra said he would encourage everyone to get the booster shot when it becomes available.” [NBC Connecticut, [8/18/21](#)]

# RE: A conundrum for boosters

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Fauci, Anthony (NIH/NIAID) [E]"  
**Date:** Mon, 06 Dec 2021 12:11:10 -0500

Hi Both,

(b)(5)

(b)(5)

Best,  
Rochelle

**From:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Sent:** Monday, December 6, 2021 10:59 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Re: A conundrum for boosters

(b)(5) JZ

On Dec 6, 2021, at 10:25 AM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

(b)(5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b)(6)  
FAX: (b)(6)  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Dalal, Yamini (NIH/NCI) [E] (b)(6)  
**Sent:** Monday, December 6, 2021 10:19 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Subject:** A conundrum for boosters

Dear Tony,

(b)(5)

Best regards,  
Yamini

**Yamini Dalal**

Senior Investigator, LRBGE/CCR/NCI

Senior Advisor, Faculty Development, OSP/CCR/NCI

Web: [Yamini Dalal, Ph.D. | Center for Cancer Research - National Cancer Institute](#)

><https://www.biophysics.org/profiles/yamini-dalal><

<image001.png>



# RE: WaPo-Omicron covid variant three times more likely to cause reinfection than delta, S. Africa study says

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Fri, 03 Dec 2021 10:06:44 -0500

(b)(5)

R

**From:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Sent:** Friday, December 3, 2021 10:06 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** WaPo-Omicron covid variant three times more likely to cause reinfection than delta, S. Africa study says

## Omicron covid variant three times more likely to cause reinfection than delta, S. Africa study says

Today at 2:33 a.m. EST

Scientists in South Africa say omicron is at least three times more likely to cause reinfection than previous variants such as beta and delta, according to a preliminary study published Thursday. Statistical analysis of some 2.8 million positive coronavirus samples in South Africa, 35,670 of which were suspected to be reinfections, led researchers to conclude that the omicron mutation has a "substantial ability to evade immunity from prior infection."

Scientists say reinfection provides a partial explanation for how the new variant has been spreading. The elevated risk of being reinfected is "temporally consistent" with the emergence of the omicron variant in South Africa, the researchers found.

The team's paper was uploaded to a preprint server and has not been peer-reviewed. Questions about the level of protection vaccines provide against the new variant remain unanswered, as the scientists did not have access to immunization data. But Juliet Pulliam, a South Africa-based epidemiologist and one of the study's authors, said vaccines are likely to still offer the most effective protection against severe disease and death.

Advertisement

Knowing that omicron may lead to more reinfection is important, Pulliam [wrote](#) on Twitter. Acquired immunity from previous infection has been key in helping countries such as South Africa and Botswana, which have relatively low vaccination rates, manage the pandemic.

"Our most urgent priority now is to quantify the extent of Omicron's immune escape for both natural and vaccine-derived immunity, as well as its transmissibility relative to other variants and impact on disease severity," said Harry Moultrie, an infectious-disease expert who co-wrote the study, in a statement.

[Coronavirus cases in South Africa nearly triple in three days as fears over omicron grow](#)

Other variants have been known to cause reinfection: Several patients reinfected with the beta variant [were identified in Israel](#) earlier this year. But the latest study suggests the relative risk of getting infected again remained stable in other variants, underscoring the significance of the findings on omicron.

Advertisement

"Contrary to our expectations and experience with the previous variants, we are now experiencing an increase in the risk of reinfection that exceeds our prior experience," Pulliam said in Thursday's statement.

South Africa's National Institute for Communicable Diseases [said](#) Wednesday that omicron overtook other virus variants in November, accounting for 74 percent of the genomes sequenced last month. Delta had previously been dominant. Overall case numbers have also risen rapidly over the past three days.

"Omicron is probably the fastest-spreading variant that South Africa has ever seen," [said](#) Tulio de Oliveira, a public health professor at South Africa's Stellenbosch University.

Only [6 percent](#) of Africa's population has been fully vaccinated. In South Africa, just under 30 percent of people have been fully immunized, according to Our World in Data, but the country's public health officials [warned](#) that misinformation on social-media sites is hindering the rollout, especially among young adults.

**Read more:**

[First known patient reinfected with South Africa coronavirus variant is in critical condition](#)

[What you need to know about the coronavirus variants](#)

[Mutated virus may re infect people already stricken once with covid-19, sparking debate and concerns](#)

## Re: COVID data tracker

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>  
**Cc:** "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>, "Christie, Athalia (CDC/DDPHSIS/CGH/OD)" <akc9@cdc.gov>  
**Date:** Thu, 17 Jun 2021 14:58:58 -0400

---

Thank you!

Sent from my iPhone

On Jun 17, 2021, at 11:30 AM, Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov> wrote:

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, June 16, 2021 1:15 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Tuesday, June 15, 2021 1:35 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Monday, June 14, 2021 1:18 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Sunday, June 13, 2021 1:38 PM

**To:** 'Shahpar, Cyrus EOP/WHO'

(b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Saturday, June 12, 2021 6:40 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)

**Sent:** Saturday, June 12, 2021 5:55 PM

**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** Re: COVID data tracker

Thank you for the update!

Sent from my iPhone

On Jun 12, 2021, at 1:51 PM, Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)> wrote:

Cyrus,

(b)(5)

Apologies for the delay.

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Saturday, June 12, 2021 1:57 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Friday, June 11, 2021 1:35 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Thursday, June 10, 2021 4:29 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Shahpar, Cyrus EOP/WHO (b)(6)

**Sent:** Thursday, June 10, 2021 2:51 PM

**To:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Thank you for the update [REDACTED] (b)(5)

[REDACTED] (b)(5)

Much appreciated,

Cyrus

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Sent:** Thursday, June 10, 2021 11:44 AM

**To:** Shahpar, Cyrus EOP/WHO [REDACTED] (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

[REDACTED] (b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Thursday, June 10, 2021 1:32 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED] (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,



(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Wednesday, June 9, 2021 3:26 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Wednesday, June 9, 2021 1:49 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C.

(CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Tuesday, June 8, 2021 4:41 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov)

(b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Tuesday, June 8, 2021 3:02 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Tuesday, June 8, 2021 1:49 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Monday, June 7, 2021 3:21 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Monday, June 7, 2021 1:26 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,

Peggy

**Margaret (Peggy) Honein, PhD, MPH**

Principal Deputy Incident Manager

COVID-19 Emergency Response

U.S. Centers for Disease Control and Prevention

[mrh7@cdc.gov](mailto:mrh7@cdc.gov)

<image001.jpg>

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>

**Sent:** Sunday, June 6, 2021 2:25 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED]

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** Re: COVID data tracker

[REDACTED]  
(b)(5)

Get [Outlook for iOS](#)

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Sunday, June 6, 2021 1:47:52 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) [REDACTED]

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** COVID data tracker

[REDACTED]  
(b)(5)

Get [Outlook for iOS](#)



## RE: Vaccine Monitor: A Third of Parents of Children Ages 5-11 Say Their Child Will Get Vaccinated “Right Away” Once Eligible

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** Drew Altman <drewa@kff.org>, david kessler <(b)(6)>, Vivek Murthy <(b)(6)>, "Smith, Marcella" <(b)(6)>, "Bechara Choucair" <(b)(6)>  
**Date:** Thu, 30 Sep 2021 15:07:51 -0400

---

Super, helpful, Drew.  
Thank you so much for sharing!  
Hope you are well,  
Rochelle

---

**From:** Drew Altman <DrewA@kff.org>  
**Sent:** Thursday, September 30, 2021 1:57 PM  
**To:** david kessler <(b)(6)>, Vivek Murthy <(b)(6)>, Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Smith, Marcella <(b)(6)>, Bechara Choucair <(b)(6)> @nih.hhs.gov  
**Subject:** Vaccine Monitor: A Third of Parents of Children Ages 5-11 Say Their Child Will Get Vaccinated “Right Away” Once Eligible

Sorry busy in my board meeting and I forgot to send this one ahead of time.

 COVID-19 Monitor Header\_1

## Nearly Half of Parents of Adolescents Ages 12-17 Say Their Child Got a COVID-19 Vaccine Already; a Third of Parents of Children Ages 5-11 Say Their Child Will Get Vaccinated “Right Away” Once Eligible

### Almost 1 in 4 Parents with Children Attending In-Person School Say a Child Had to Quarantine Since the School Year Began Due to Possible COVID-19 Exposure

Nearly half (48%) of parents of vaccine-eligible children ages 12-17 now say their child has received at least one dose of a COVID-19 vaccine, a [new KFF Vaccine Monitor report](#) shows.

Another 15% of those parents now say they want to “wait and see” how the vaccine works for others before their adolescent gets it, while 4% say they would get vaccinated “only if required” for school or other activities. About one in five (21%) say their adolescent child would “definitely not” get a vaccine.

Largely fielded before Pfizer’s Sept. 20 announcement about favorable results from its clinical trials for children ages 5-11, the new report shows a third (34%) of parents of children in that age group want their child to get vaccinated “right away” once eligible. A similar share (32%) wants to “wait and see,” while a quarter (24%) say their children will “definitely not” get a COVID-19 vaccine.



The report also highlights the toll that the COVID-19 pandemic is taking on students attending in-person classes this fall. Nearly a quarter (23%) of parents say that they have a child who has had to quarantine at home due to a possible COVID-19 exposure since the school year began. The includes 26% of parents with children ages 5-11 and 20% of parents with children ages 12-17.



Most parents (58%) say K-12 schools should require students and staff to wear masks, regardless of their vaccination status, while more than a third (35%) say schools should have no mask requirements. Mothers are much more likely than fathers to favor a mask requirement for all students and staff (70% vs. 42%).

Among parents with a child attending in-person school, nearly seven in ten (69%) say their school is requiring all students and staff to wear masks, just one percent say masks are required only for unvaccinated individuals, and 28% say their school has no mask requirement. Most parents (73%) who say their child's school requires all students and staff to wear masks favor that policy.

Few parents of children attending in-person schools say their school offers routine testing for children who are not vaccinated (6%), and one in five (20%) say that it is offering optional testing.

Two-thirds (66%) of parents with a child attending in-person school say their school overall is doing about the right amount to limit the spread of COVID-19. Parents are somewhat more likely to say that their school is not doing enough (21%) than that their school is doing too much (11%).

Designed and analyzed by public opinion researchers at KFF, the KFF Vaccine Monitor survey was conducted from September 13-22 among a nationally representative random digit dial telephone sample of 1,519 adults, including oversamples of adults who are Black (306) or Hispanic (339). 414 parents were surveyed with a margin of error of plus or minus 6 percentage points. Interviews were conducted in English and Spanish by landline (171) and cell phone (1,348). The margin of sampling error is plus or minus 3 percentage points for the full sample. For results based on subgroups, the margin of sampling error may be higher.

*[The KFF COVID-19 Vaccine Monitor](#) is an ongoing research project tracking the public's attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfold, including vaccine confidence and acceptance, information needs, trusted messengers and messages, as well as the public's experiences with vaccination.*



Read the Report

**CONTACT:**

Craig Palosky | (202) 654-1369 | [cpalosky@kff.org](mailto:cpalosky@kff.org).

*Filling the need for trusted information on national health issues,*  
KFF is a nonprofit organization based in San Francisco, California.

[kff.org](http://kff.org) | [khn.org](http://khn.org)



Did someone forward this to you? [Click here to sign up for emails from KFF.](#)

This email was sent to [drewa@kff.org](mailto:drewa@kff.org). [Update your email preferences](#) to choose the types of emails you receive.  
Or, [permanently unsubscribe from all future emails.](#)

If you need help or have questions, please send an email to [subscriptions@kff.org](mailto:subscriptions@kff.org).  
Please do not reply to this email as this address is not monitored.

KFF  
185 Berry Street Suite 2000  
San Francisco, CA 94107



# Re: CDC Health Alert Network (HAN) Health Advisory: New SARS-CoV-2 Variant of Concern Identified: Omicron (B.1.1.529) Variant

---

**From:** "Quillian, Natalie H. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Thu, 02 Dec 2021 21:08:24 -0500

---

Thanks

Sent from my iPhone

On Dec 2, 2021, at 7:01 AM, Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> wrote:

FYSA – This went live last night.

R

---

**From:** Health Alert Network Priority List <CDC-HAN-PRIORITY-LIST@LISTSERV.CDC.GOV> **On Behalf Of** Health Alert Network (CDC)  
**Sent:** Wednesday, December 1, 2021 11:04 PM  
**To:** CDC-HAN-PRIORITY-LIST@LISTSERV.CDC.GOV  
**Subject:** CDC Health Alert Network (HAN) Health Advisory: New SARS-CoV-2 Variant of Concern Identified: Omicron (B.1.1.529) Variant

View this CDC HAN Health Advisory as a [PDF](#)

## This is an official **CDC HEALTH ADVISORY**

Distributed via the CDC Health Alert Network

December 1, 2021, 11:00 PM ET

CDCHAN-00459

### **New SARS-CoV-2 Variant of Concern Identified: Omicron (B.1.1.529) Variant**

#### **Summary**

Omicron, a new SARS-CoV-2 variant, has been identified in many countries and categorized as a [Variant of Concern](#) by the U.S. government and the World Health Organization (WHO). Because little is known about Omicron currently, it is important for the public health and medical communities as well as the general public to remain vigilant to reduce

potential exposure. This Health Alert Network (HAN) Health Advisory summarizes current knowledge about Omicron and provides recommendations on how to detect the Omicron variant within the United States as soon as possible to mitigate its spread.

## Background

A new SARS-CoV-2 variant, lineage B.1.1.529, was first detected in Botswana on November 11, 2021, and South Africa on November 14, 2021. This new variant has a large number of mutations in portions of the genome that can potentially increase infectivity and transmissibility, confer resistance to certain therapeutics, and reduce neutralization by convalescent and vaccinee sera<sup>1</sup>. For these reasons, on November 26, 2021, WHO classified B.1.1.529 as a variant of concern and named it Omicron<sup>2</sup>. By December 1, the Omicron variant had been detected in at least 20 countries in addition to those in Southern Africa, including the United States, Israel, Hong Kong, Nigeria, Saudi Arabia, South Korea, Australia, Canada, the United Kingdom, and several European countries. In some countries, such as Germany and Portugal, there is evidence of community transmission of Omicron. On November 30, 2021, the U.S. SARS-CoV-2 Interagency Group (SIG), which includes the Centers for Disease Control and Prevention (CDC), the National Institutes of Health, the Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and the Departments of Defense, Agriculture, and Health and Human Services, classified the Omicron variant as a Variant of Concern.

Currently, it is unknown how efficiently the Omicron variant can spread from person to person. It is unknown whether Omicron is more transmissible than other variants, but preliminary data from South Africa suggest that the mutations to the receptor binding protein of the variant virus will confer increased infectivity. Currently, there is limited information about the clinical manifestations of infection due to the Omicron variant and given the small number of identified cases attributed to the Omicron variant to date, current assessment of disease severity and response to vaccines and therapeutics is difficult. Preliminary information from South Africa indicates that there are no unusual symptoms associated with Omicron variant infection, and as with other variants, some patients are asymptomatic<sup>3</sup>. Symptoms may be milder in persons who have been vaccinated or previously infected with SARS CoV-2.

Some SARS-CoV-2 variants, including the Omicron variant, have  $\Delta$ 69-70 deletion in the spike (S) gene. This particular mutation leads to failure of one of the polymerase chain reaction (PCR) targets (sometimes called S-gene target failure (SGTF)) when the virus is tested with assays that include an S gene target, including the Thermo Fisher Scientific TaqPath™ COVID-19 Combo Kit diagnostic assay<sup>4</sup>. TaqPath™ tests for three proteins of SARS-CoV-2 so will still detect the virus but will fail to detect the S gene protein specifically. Such assays can be used as a screen to presumptively identify SARS-CoV-2 variants that have the  $\Delta$ 69-70 deletion, including the Omicron variant. Delta, currently the predominant variant in the United States, does not have this  $\Delta$ 69-70 deletion; therefore, infections due to Delta variant would not produce a SGTF profile.

## Recommendations for Public Health Departments and Public Health Jurisdictions

### *Case identification and reporting*

Public health departments should follow existing state guidelines for case investigations. Case investigation and contact tracing can help ensure compliance with mitigation measures, such as isolation for people who test positive, and identify close contacts for public health follow-up including testing, masking, and quarantine based on vaccination status and history of prior infection. Jurisdictions that are interested in partnering with CDC to conduct enhanced case investigation to identify and characterize initial Omicron cases in the United States should contact their CDC health department liaison officer (HD LNOs). Case investigation will enable better understanding of the characteristics of the initial cases identified in the United States and will provide data on early symptoms, vaccination status, and travel history of these infected persons. In the initial weeks, collecting data on travel history, including any international locations where the infected person was present during the 14 days before illness onset (or date of positive test if asymptomatic), will help monitor importation versus domestic community transmission. All cases should be reported to CDC through existing systems, such as Epi-Info surveys and case surveillance, and using established communication channels, such as HD LNOs.

CDC is collaborating with Xprescheck and Gingko Bioworks on a SARS-CoV-2 surveillance program that involves voluntary testing of arriving international travelers at select U.S. airports. Arriving air travelers are offered both pooled sample collection in the airport and take-home kits for saliva sampling done 3-5 days after arrival; all samples are returned to the laboratory for PCR testing. All positive samples are sequenced, enabling detection of novel COVID-19 variant strains among travelers entering the United States. On November 28, 2021, the program began expanding to test air travelers entering the United States from Southern Africa, including passengers making connections through Europe.

## Recommendations for Laboratories

## Surveillance

Laboratory testing is a critical component of public health response to and surveillance of emerging variants, including the Omicron variant. The presence of the SGTF profile can signal the need for sequencing to characterize the variant in that specimen. Consideration of epidemiological factors, including recent travel history, for patients who test positive for SARS-CoV-2 can also indicate that a specimen should be prioritized and sent to CDC for sequencing.

In partnership with U.S. public health laboratories and the Association of Public Health Laboratories, CDC has implemented enhanced surveillance for specimens with SGTFs and specimens with sequencing data available that indicate a mutation profile resembling Omicron. CDC requests that public health laboratories send SGTF specimens or specimens that are possible Omicron variant by sequencing to CDC through [National SARS-CoV-2 Strain Surveillance \(NS3\)](#) ES21-01 (SGTF) and ES21-03 (specimens with sequence data available) as quickly as possible for rapid confirmation of presumptive Omicron cases and subsequent virological characterization.

Delta variant specimens do not yield an SGTF result using the TaqPath COVID-19 Combo Kit. Given that nearly 100% of viruses circulating in the United States are the Delta variant, specimens with an SGTF using this diagnostic test may be presumptive Omicron variants and should be prioritized for sequencing confirmation. There are other lineages that may contain the  $\Delta 69-70$  deletion and give the SGTF profile, such as the Alpha variant which is uncommon currently but was predominant in the United States earlier this year.

## Recommendations for Healthcare Providers

### *Clinical diagnosis and treatment*

Early reports are that the clinical signs and symptoms of COVID-19 from infection with the Omicron variant are similar to those of other variants and may also be absent (asymptomatic). As CDC and public health officials work to identify cases of COVID-19 with the Omicron variant, it is important to take a travel history for all suspected or confirmed COVID-19 cases. If the case is confirmed and there is a history of international travel within 14 days before symptom onset or positive test (if asymptomatic), the local health department should be notified about the travel history. Health departments should also be notified about household contacts or close contacts of individuals who are confirmed to have the Omicron variant. The utility of travel history to identify Omicron cases will likely decline as domestic community transmission becomes more prevalent. With low levels of domestic community transmission, travel history may be a good screening tool to identify cases of possible Omicron.

There are no data yet available about the effectiveness of monoclonal antibodies and antiviral therapies (e.g., molnupiravir) against the Omicron variant. Whether severity of disease due to Omicron will differ from that of disease caused by other variants is currently unknown. At this time, CDC recommends providers continue to closely follow [NIH treatment guidelines](#) for COVID-19.

## Recommendations for the Public

### *Mitigation*

Layered prevention strategies should be used to reduce the transmission of SARS-CoV-2, including variants such as Delta and Omicron. These strategies include vaccination, masking, improving ventilation, distancing, handwashing, and testing to slow SARS-CoV-2 transmission. CDC recommends that **everyone** ages 2 years or older wear masks in public indoor places in areas of [substantial or high transmission](#). Unvaccinated people should wear masks regardless of community transmission level. [Masks are required](#) in indoor areas of public transportation conveyances and U.S. transportation hubs independent of vaccination status. Persons who have a [close contact](#) with someone who has COVID-19, you should get tested 5-7 days after exposure (even if they are asymptomatic) and wear a mask indoors in public for 14 days following exposure or until their test result is negative. Persons who develop symptoms of COVID-19 should get [tested](#) and [stay home](#) until their test result is negative; persons who have a positive test result should isolate at home for 10 days.

### *Vaccination*

Vaccination remains vital to COVID-19 pandemic control. The COVID-19 vaccines approved or authorized in the United States are highly effective at preventing severe disease and death from the Delta variant, which is currently the dominant variant circulating in the U.S. CDC recommends that everyone ages 5 and older should be fully vaccinated against COVID-19 as soon as possible. In addition, CDC recommends all persons age 18 years and older receive a booster dose [at the recommended interval](#). CDC will provide updates as soon as more information is available about vaccine effectiveness against the Omicron variant.

## For More Information

- [National SARS-CoV-2 Strain Surveillance](#)
- For questions or concerns about specimen shipment or sequencing, please email: [eocevent506@cdc.gov](mailto:eocevent506@cdc.gov).
- For more information about SARS-CoV-2 surveillance program at select airports, please email: [eocevent221@cdc.gov](mailto:eocevent221@cdc.gov)

## References

1. SARS-CoV-2 Interagency Group, Situation Report for B.1.1.529 - November 28, 2021.
2. [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern)
3. [Frequently asked questions for the B.1.1.529 mutated SARS-CoV-2 lineage in South Africa - NICD](#)
4. <https://www.thermofisher.com/us/en/home/clinical/clinical-genomics/pathogen-detection-solutions/covid-19-sars-cov-2/multiplex.html>

*The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.*

---

### Categories of Health Alert Network messages:

<b>Health Alert</b>	Requires immediate action or attention; highest level of importance
<b>Health Advisory</b>	May not require immediate action; provides important information for a specific incident or situation
<b>Health Update</b>	Unlikely to require immediate action; provides updated information regarding an incident or situation
<b>HAN Info Service</b>	Does not require immediate action; provides general public health information

##This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, HAN coordinators, and clinician organizations#

If you would like to unsubscribe from this ListServ LIST, please send an email to [LIST@cdc.gov](mailto:LIST@cdc.gov), enter CDC in the email Subject, and include the following "one" line in the Body of the email: signoff CDC-HAN-PRIORITY-LIST

## RE: Notes ahead of Briefing

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
"Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Berner, Kate EOP/WHO"  
(b)(6) "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Munoz, Kevin  
EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Jones,  
Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Humphrey, Clarke EOP/WHO"  
(b)(6) "Sanchez-Velasco, Marissa EOP/WHO" (b)(6)  
(b)(6)  
**Date:** Fri, 26 Feb 2021 10:47:01 -0500

(b)(5)

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Friday, February 26, 2021 10:24 AM  
**To:** 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6); Slavitt,  
Andrew M. EOP/WHO (b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Berner, Kate EOP/WHO  
(b)(6) 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) Munoz, Kevin EOP/WHO  
(b)(6) 'Sams, Ian (HHS/ASPA)' <ian.sams@hhs.gov>; Jones, Christopher M.  
(CDC/DDNID/NCIPC/OD) <fjr0@cdc.gov>; Humphrey, Clarke EOP/WHO (b)(6) Sanchez-  
Velasco, Marissa EOP/WHO (b)(6)  
**Subject:** RE: Notes ahead of Briefing

(b)(5)

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Friday, February 26, 2021 9:42 AM  
**To:** 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) Slavitt,  
Andrew M. EOP/WHO (b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Berner, Kate EOP/WHO  
(b)(6) 'Billet, Courtney (NIH/NIAID) [E]' (b)(6) Munoz, Kevin EOP/WHO  
(b)(6) 'Sams, Ian (HHS/ASPA)' <ian.sams@hhs.gov>; Jones, Christopher M.  
(CDC/DDNID/NCIPC/OD) <fjr0@cdc.gov>  
**Subject:** Notes ahead of Briefing

Hi, (b)(5)

(b)(5)

(b)(5)

+++

Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)



## RE: COVID data tracker

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>  
**Cc:** "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Butler, Jay C. (CDC/DDID/OD)" <jcb3@cdc.gov>, "Christie, Athalia (CDC/DDPHSIS/CGH/OD)" <akc9@cdc.gov>  
**Date:** Thu, 10 Jun 2021 14:51:03 -0400

---

Thank you for the update!

(b)(5)

(b)(5)

Much appreciated,  
Cyrus

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>  
**Sent:** Thursday, June 10, 2021 11:44 AM  
**To:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Thursday, June 10, 2021 1:32 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Butler, Jay C. (CDC/DDID/OD) <jcb3@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Wednesday, June 9, 2021 3:26 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Wednesday, June 9, 2021 1:49 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)

**Sent:** Tuesday, June 8, 2021 4:41 PM

**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)

**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>

**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 8, 2021 3:02 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Tuesday, June 8, 2021 1:49 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Monday, June 7, 2021 3:21 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Monday, June 7, 2021 1:26 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** RE: COVID data tracker

Cyrus,

(b)(5)

Best,  
Peggy

**Margaret (Peggy) Honein, PhD, MPH**  
Principal Deputy Incident Manager  
COVID-19 Emergency Response  
U.S. Centers for Disease Control and Prevention  
[mrh7@cdc.gov](mailto:mrh7@cdc.gov)



---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <[mrh7@cdc.gov](mailto:mrh7@cdc.gov)>  
**Sent:** Sunday, June 6, 2021 2:25 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** Re: COVID data tracker

(b)(5)

Get [Outlook for iOS](#)

---

**From:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)  
**Sent:** Sunday, June 6, 2021 1:47:52 PM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Butler, Jay C. (CDC/DDID/OD) <[jcb3@cdc.gov](mailto:jcb3@cdc.gov)>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <[akc9@cdc.gov](mailto:akc9@cdc.gov)>  
**Subject:** COVID data tracker

(b)(5)

Get [Outlook for iOS](#)

## STAT--Vaccinations are plateauing. Don't blame it on 'resistance'

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Thu, 29 Apr 2021 14:29:47 -0400

---

[Vaccinations are plateauing. Don't blame it on 'resistance' - STAT \(statnews.com\)](#)

# Vaccinations are plateauing. Don't blame it on 'resistance'

By Stefanie Friedhoff April 27, 2021

The signs are clear: The U.S. vaccine rollout is plateauing.

A remarkable 230 million shots have been given in a few short months, fully vaccinating [about 95 million Americans](#) as I write this. The next 100 million shots will be harder.

News reports are [chronicling a slowdown](#) in appointments across the nation. The number of daily doses administered is down from the [peak of 4.6 million](#) on April 10 to about 3 million today. By now, this historic effort has captured the vaccine-hungry individuals who are eager, well-resourced, technologically savvy, and excited to get vaccinated. But as fewer people sign up to get their shots, a dominant narrative is emerging: It's because of [hesitancy](#) — too many people [don't want to get the vaccine](#). Some even call this [vaccine resistance](#).

Those are convenient narratives. But they are false, and can have harmful consequences.

Let's start here: If you didn't get your flu shot last year, are you "vaccine hesitant"? If you haven't been vaccinated yet and aren't actively seeking an appointment to do that, are you "resisting"? If you skipped your vaccination appointment because the Food and Drug Administration's [pause of the Johnson & Johnson vaccine](#) raised questions you wanted answered first, are you a "vaccine skeptic"?

Few people would answer any of these questions with "yes," yet experts and commentators are quick to use hesitancy to explain the recent dip in vaccinations.

We have seen this before: When the Johnson & Johnson vaccine was found in January [to be 72% effective](#) in U.S. studies — lower than the Pfizer and Moderna vaccines — many predicted this difference [would make people less likely](#) to get the J&J vaccine. [It did not](#). Instead, this vaccine became the go-to for [hard-to-reach groups](#) that prefer a one-shot deal.

[Related:](#)

[A user's guide: How to talk to those hesitant about the Covid-19 vaccine](#)

After the pause was announced for the J&J vaccine, [many worried](#) about its possible impact [on the intent to vaccinate](#) for *all* vaccines. This, too, was unfounded. [In one new poll](#), 71% of people said the pause didn't matter to them, or that it was a good example of rigorous safety monitoring. In another poll, [88% said](#) the pause was the right call.

As daily vaccination rates settle and the country's progress toward herd immunity slows down, let's not rush to the same misguided conclusion that this is mostly about lack of vaccine confidence.

Individuals who aren't seeking a Covid-19 vaccine right now are not necessarily the same people as those who are truly anti-vaccine. Instead of talking up hesitancy, it's time to talk about [what motivates people](#) to get vaccinated and identify the ongoing barriers to vaccination. Here are three ways to do this.

First, retire the term "vaccine hesitancy." As any crisis communications expert will point out, it's not a good idea to say things you don't want people to be thinking. Repeating the term over and over again unwittingly communicates that there may be something to be hesitant about. The more people [talk about it](#), the [more it becomes](#) a self-fulfilling prophecy. It's the same psychology that puts guardrails around using the word suicide, which news media are urged not to [put in headlines](#) and to apply with utmost caution.

Second, keep in mind that vaccine confidence is not a [fixed mindset](#). Instead, it describes where someone is in his or her vaccination decision-making at a specific time. Are people who aren't ready today to get the Covid-19 vaccine skeptics? Or do they just have important questions about the vaccine? Did they check the "no" box in the poll because they knew enough and truly didn't want the vaccine, or because they [didn't know](#) how and where to get a vaccine, were concerned about health insurance bills, didn't have time to make an appointment, were worried about [missing work](#), or have had negative encounters with the health care system?

Narratives that assume vaccine hesitance or resistance also assume that vaccines are [easily and equally available](#) to all Americans. That [just isn't true](#).

Third, looking past the behavior of individuals can shed light on the more systemic drivers of what prevents people from getting vaccinated against Covid-19, which include a host of systematic health and information inequalities.

I lead a team at Brown University School of Public Health that is undertaking new research in partnership with the Rockefeller Foundation and community organizations across the U.S. to understand people's experiences regarding vaccination, public health, and the health care system more generally, rather than just their intentions about this specific vaccine. What we have learned so far [from this survey](#), fielded by HIT Strategies in communities of color in five U.S. cities, is telling: Even though a majority of Black and Latino Americans want to get vaccinated — 72% in this survey — a surprising 63% said they didn't have enough information about where to get the shot. In addition, more than 20% said they had regularly been treated with disrespect when getting health care in the past, and 20% said they have had trouble finding health care when needed.

Despite these systemic barriers, only 3% of the total sample said that nothing at all would move them to get the Covid-19 vaccine.

Everyone else, even those who said “no” to getting a vaccine now, listed reasons that would motivate them to get a shot, such as “seeing a person I trust get the vaccine” or having “a vaccination site close to my home.”

In fact, “having more information” is the single most important concern expressed by those unsure about the Covid-19 vaccine, according to almost every poll [that asks this question](#). This is true across the political spectrum. Blaming conservative Americans for taking their time or for believing lies, and labeling them as hesitant or resisters [only hardens their viewpoints](#). Instead, the public health community needs to come to grips with [what motivates people](#), and also with the harmful impact of misinformation on Americans who do not have access to quality information.

It’s still a long road to getting most Americans vaccinated against Covid-19. It can be shortened by worrying less about today’s confidence polls and more about persistent barriers to vaccination. The health and public health communities need to continue the hard work of making vaccines ubiquitous and available without complex sign-up procedures — at churches, grocery stores, barber shops, food pantries, and yes, even in [bars and restaurants](#).

People’s questions must be answered and false narratives preempted by flooding online and offline spaces with high-quality information in the languages people speak on the platforms they frequent. Concerted effort is needed to [expose misinformation tactics](#) and how they are unleashed to generate confusion, as well as to regulate the [platforms that empower them](#).

For most Americans — and that [includes conservatives](#) — who are given the chance to discuss vaccination [on their own terms and timelines](#) and for whom vaccination is easy, nearby, and supported by employers, the question shifts from if they will get vaccinated to when and how.

*Stefanie Friedboff is a professor of the practice in health services, policy, and practice as well as strategy director at Brown University School of Public Health.*

## RE: Tough Q&A

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Rowe, Courtney (who.eop.gov)" (b)(6)  
**Date:** Wed, 11 Aug 2021 22:20:08 -0400

---

Great – thank you for this, Ian.

(b)(5)

Best,  
R

---

**From:** Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>  
**Sent:** Wednesday, August 11, 2021 10:14 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Rowe, Courtney (who.eop.gov) (b)(6)  
**Subject:** Tough Q&A

Drs. Fauci and Walensky,

(b)(5)



(b)(5)

--

**Ian Sams**

Deputy Assistant Secretary for Public Affairs (COVID Response)

Office of the Assistant Secretary for Public Affairs

U.S. Department of Health and Human Services

(202) 740-7169

[ian.sams@hhs.gov](mailto:ian.sams@hhs.gov)

## Re: Clinical considerations

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Kessler, David (HHS/IOS)" <david.kessler@hhs.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Wed, 04 Aug 2021 17:58:21 -0400

Many thanks, Tony. (b)(5)  
R

Get [Outlook for iOS](#)

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Wednesday, August 4, 2021 5:57:21 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** RE: Clinical considerations

Rochelle:

(b)(5)

Thanks,  
Tony  
Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b)(6)  
FAX: (b)(6)  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Wednesday, August 4, 2021 3:55 PM  
**To:** Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** RE: Clinical considerations

(b)(5)

**From:** Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>  
**Sent:** Wednesday, August 4, 2021 3:53 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** RE: Clinical considerations

(b)(5)

(b)(5)

d

**From:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>

**Sent:** Wednesday, August 4, 2021 3:45 PM

**To:** Kessler, David (HHS/IOS) <[David.Kessler@hhs.gov](mailto:David.Kessler@hhs.gov)>; Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Zients, Jeffrey D. EOP/WHO <(b)(5)>

**Subject:** FW: Clinical considerations

(b)(5)

# RE: Boosters story leaked

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Folkers, Greg (NIH/NIAID) [E]" (b)(6) "Cheema, Subhan N. EOP/WHO" (b)(6)  
**Date:** Mon, 16 Aug 2021 23:39:44 -0400

(b)(5)

(b)(5)

**From:** Rowe, Courtney M. EOP/WHO  
**Sent:** Monday, August 16, 2021 10:45 PM  
**To:** 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; 'aws8@cdc.gov' <aws8@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Boosters story leaked

Hi all- (b)(5)

(b)(5)

## ***U.S. to Advise Boosters for Most Americans 8 Months After Vaccination***

Nursing home residents and health care workers will most likely be the first to get booster shots, as soon as September, followed by other older people who were vaccinated last winter.

**By Sharon LaFraniere**  
Aug. 16, 2021, 10:22 p.m. ET

WASHINGTON — The Biden administration has decided that most Americans should get a coronavirus booster shot eight months after they completed their initial vaccination, and could begin offering the extra shots as early as mid-September, according to two administration officials familiar with the discussions.

Officials are planning to announce the administration's decision as early as this week. Their goal is to let Americans know now that they will need additional protection against the Delta variant that is causing surging caseloads across the nation.

The first boosters are likely to go to nursing home residents and [health care workers](#), followed by other older people who were near the front of the line when vaccinations began late last year. Officials envision giving people the same vaccine they originally received.

Among other worrisome signals, Biden administration officials are particularly concerned about data from Israel suggesting that the Pfizer-BioNTech's protection against severe disease has fallen significantly for elderly people who were vaccinated in January or February.

Some administration officials have viewed Israel as a kind of template for the United States because it started vaccinating its population sooner. Israel has almost exclusively used the Pfizer-BioNTech vaccine, and it has a nationalized health care system that allows it to systematically track patients.

The latest data from Israel, posted on the government's website on Monday, shows what some experts describe as continued erosion of the efficacy of the Pfizer vaccine over time — both against mild or asymptomatic Covid-19 infections in general and against severe disease among the elderly.

Washington Post story—

The Biden administration is planning to announce that all Americans who have received the coronavirus vaccine will need booster shots to combat waning immunity from the immunizations and the highly transmissible delta variant that is sparking a surge in covid-19 cases throughout the nation, according to four people familiar with the decision.

The administration's health and science experts are coalescing around the view that people will need the boosters eight months after they are fully vaccinated, according to the people who requested anonymity to discuss a decision not yet public. The decision is likely to be announced as soon as this week.

The actual administration of the boosters would not occur until mid- or late September, after Pfizer's application for additional shots for the general public is cleared by the Food and Drug Administration, the individuals said.

The conclusion that boosters will be broadly needed was reached after intense discussions last weekend involving high-ranking officials who scrutinized the latest data from the United States and other countries on the effectiveness of the shots.

The statement is a striking change from public statements by senior officials in recent months who had said it was far too soon to conclude that Americans would need booster shots. In July, the Centers for Disease Control and Prevention and the Food and Drug Administration put out an unusual statement that said: "Americans who have been fully vaccinated do not need a booster shot at this time." Officials have repeatedly said that it wasn't clear whether boosters would be needed.

# Re: The Times of Israel-- 80% of vaccinated COVID carriers didn't infect anyone in public spaces — report

**From:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Quillian, Natalie H. EOP/WHO" (b)(6), "Choucair, Bechara N. EOP/WHO" (b)(6), Marcella Nunez-Smith (b)(6)  
**Date:** Mon, 26 Jul 2021 11:15:29 -0400

(b)(5) thanks Tony

On Jul 26, 2021, at 11:05 AM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

Jeff:

(b)(5)

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b)(6)  
FAX: (b)(6)  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Sent:** Monday, July 26, 2021 8:50 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Quillian, Natalie H. EOP/WHO (b)(6); Choucair, Bechara N. EOP/WHO (b)(6); Marcella Nunez-Smith <marcella.nunez-smith@hhs.gov>  
**Subject:** Fwd: The Times of Israel-- 80% of vaccinated COVID carriers didn't infect anyone in public spaces — report

(b)(5)

Begin forwarded message:

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Date:** July 26, 2021 at 8:47:40 AM EDT  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO"  
(b)(6) "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Cc:** "Wakana, Benjamin L. EOP/WHO" (b)(6) "Hussain, Farhana P. EOP/WHO"  
<(b)(5)>  
**Subject:** The Times of Israel-- 80% of vaccinated COVID carriers didn't infect anyone in public spaces — report

# 80% of vaccinated COVID carriers didn't infect anyone in public spaces — report

Health Ministry data indicates that just 3% of immunized people who contracted breakthrough infections spread it to 2-3 others at concerts, restaurants, gyms

By [TOI STAFF](#) 25 July 2021, 1:01 am

Health Ministry data indicates that 80 percent of vaccinated individuals who recently contracted breakthrough infections of COVID-19 have not infected others in public places, according to a television report on Saturday.

According to the research, the vast majority (80%) of immunized COVID-19 carriers did not spread the virus to anyone else while at concerts, restaurants, gyms or event halls, Channel 12 reported.

Another 10% spread the virus to one other person at these venues, and 3% infected two or three others (for the remaining 7%, it's unclear whether they were responsible for infecting others), according to the network. The report did not offer details on how many were infected by unvaccinated individuals at these sites.

The data was publicized after ministers [approved reinstating the "Green Pass"](#) on Thursday, limiting attendance at large events to those who are vaccinated, have recovered from COVID-19, or who present a valid negative test result.

The renewed restrictions will apply to both indoor and outdoor events with over 100 participants, starting on July 29. The requirement to present proof of vaccination, recovery or a negative test from the past 72 hours will only apply to people 12 and older. Under that age, there will be no restrictions, though rules for those under 12 are expected to be announced in the future.

**Get The Times of Israel's Daily Edition by email and never miss our top stories**

Top of Form

---

Newsletter email address GET IT

---

Bottom of Form

By signing up, you agree to the [terms](#)

A statement from the Prime Minister's Office said the Green Pass will also be reinstated at sporting events, gyms, restaurants, conferences, tourist attractions and houses of worship, while stressing there won't be capacity limitations on gatherings or at these venues.

A technician collects swab samples for COVID-19, at a testing center run by the Tel Aviv municipality in cooperation with Tel haShomer hospital, at Rabin Square in Tel Aviv, on July 20, 2021 (Miriam Alster/Flash90)

On Thursday, Prime Minister Naftali Bennett said the country would start requiring the unvaccinated to pay out of pocket for COVID tests.

“There is no reason that taxpayers and those who fulfill their civic duty to get vaccinated will fund tests for those who refuse to get vaccinated,” he said. It was not immediately clear if this would also apply to school children.

ADVERTISEMENT

Bennett [issued a fresh appeal](#) for all Israelis to get the coronavirus vaccine, accusing those eligible to get vaccinated who have not done so of endangering the rest of the country.

Prime Minister Naftali Bennett speaks at the President's Residence in Jerusalem, on July 21, 2021. (Yonatan Sindel/Flash90)

“One million Israelis are refusing to get vaccinated,” Bennett said. “They are endangering the entire population, they are endangering the other 8 million citizens in the country.”



He warned that the vaccine holdouts could cause the government to impose the fourth national lockdown since the pandemic began.

Government figures show that over 5.7 million Israelis have received at least one shot of the coronavirus vaccine.

Those age 19 and under are responsible for more than 20% of all cases, but just 40% of those between 10 and 19 have gotten at least one shot. Vaccines are offered to those aged 12 and up.

According to new Health Ministry figures released Saturday, 1,430 new cases were confirmed on Friday, with a further 670 cases since midnight, bringing active infections to 11,102. The number of patients in serious condition rose to 89, and one fatality took the death toll to 6,458.

#### ADVERTISEMENT

Public health chief Sharon Alroy-Preis said on Saturday that officials were debating whether to offer a third booster shot to Israelis, or to wait for a vaccine that is specifically tailored for the Delta variant of the coronavirus.

“We are checking if we should give a third dose, or whether we should wait for a vaccine against Delta,” the head of public health at the Health Ministry told Channel 12.

The comment came after a Health Ministry committee on vaccines reportedly voted on Thursday against recommending a third booster shot for the elderly, saying it would be more effective to wait for a vaccine specifically targeting the Delta variant that is being developed by Pfizer.

According to the report by the Kan public broadcaster, the committee members said that even though the [effectiveness of the vaccines](#) appears to be wearing off, it would be more effective to wait for a booster shot tailored to the strain. The final decision will now go to Health Ministry Director-General Nachman Ash.

Last week, Israel began [administering booster doses](#) to those with weakened immune systems, including heart, liver and kidney transplant patients, despite the lack of approval from overseas regulatory agencies.

But Health Ministry officials have indicated that third doses for the general population are not imminent, stressing that the vaccine remains largely effective.

Dr. Sharon Alroy-Preis, head of public health services in the Health Ministry, at a press conference in Jerusalem, on June 23, 2021. (Yonatan Sindel/Flash90)

Alroy-Preis also said on Saturday that the COVID-19 pandemic “is still here, we need to learn to live with it.”

As Israelis increasingly make international trips, Alroy-Preis emphasized the need for quarantine regulations to be obeyed and said that the Health Ministry was working to identify the level of risks in other countries.

“We have to understand that the tests are not 100 percent [as a measure]. We have known this for a while. Tests are not an alternative to quarantine,” she said.

#### ADVERTISEMENT

After COVID morbidity and mortality reached record lows, following a mass vaccination campaign, Israel has seen a jump in infections that has been largely blamed on the Delta variant.

Medical staff conduct tests for coronavirus in Jerusalem, on July 22, 2021. (Olivier Fitoussi/Flash90)

Israel may vaccinate children against COVID-19 in schools, according to a report on Friday, as the country moves toward the start of the school year amid a resurgent wave of coronavirus cases.

The government has been campaigning to get as many children aged 12 and up vaccinated, and could require those who are not to present negative tests before being allowed into school, a report from Channel 12 said.

The report came as the health and education ministries are expected to publish their proposals for the upcoming school year on Sunday. Most schools return at the end of August, but ultra-Orthodox schools start on August 8th.

## WaPo: More than 4 in 10 health-care workers have not been vaccinated, Post-KFF poll finds

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6)  
**Date:** Fri, 19 Mar 2021 10:45:08 -0400

Hi, as you likely saw, there's a new Kaiser/WaPo poll showing vaccine hesitancy among health care workers (b)(5)

(b)(5)

### [More than 4 in 10 health-care workers have not been vaccinated, Post-KFF poll finds](#)

**Washington Post // William Wan, Frances Stead Sellers, Naema Ahmed, Emily Guskin**

Roy Lakes wasn't planning to get a coronavirus shot until he overheard a Zumba instructor urging her attendees to sign up. "You owe it to your kids, to your grandkids, to stay around," the instructor kept saying.

Those words changed his mind. The 46-year-old from Anaheim, Calif., who has worked as a mental health counselor, has now set up an appointment with his doctor to discuss getting vaccinated.

Health-care workers were the first group in the United States to be offered coronavirus vaccinations. But three months into the effort, many remain unconvinced, unreached and unprotected. The lingering obstacles to vaccinating health-care workers foreshadows the challenge the United States will face as it expands the pool of people eligible and attempts to get the vast majority of the U.S. population vaccinated.

According to a Washington Post-Kaiser Family Foundation poll, barely half of front-line health-care workers (52 percent) said they had received at least their first vaccine dose at the time they were surveyed. More than 1 in 3 said they were not confident vaccines were sufficiently tested for safety and effectiveness.

The nationally representative survey of 1,327 front-line health-care workers, conducted Feb. 11 through March 7, illustrates the challenges ahead as vaccine advocates try to persuade a wider population — with less familiarity with medicine — to get vaccinated.

While about 2 in 10 health-care workers said they had scheduled a shot or were planning to, 3 in 10 health-care workers said they were unsure about getting vaccinated or not planning to do so. As many as 1 in 6 health workers said that if employers required them to get vaccinated, they would leave their job.

Vaccination rates are particularly low among health-care workers who are Black, those in lower-paying jobs such as home health aides and those with less education. Partisan politics also play a role, with more Democrats saying they have been vaccinated and Republicans more likely to express uncertainty or concerns about the vaccines.

"Health-care workers are everybody," said Bruce Gellin, president of global immunization at the Sabin Vaccine Institute. Gellin noted that the hesitancy and disparities encompass a range of health workers, from front-line infectious-disease doctors who followed the vaccine science and approval process carefully to home health aides who may have little access to such specialized knowledge — or to the shots — in their work settings.

The Post-KFF survey is the most comprehensive survey of vaccine adoption across the health-care workforce, encompassing those working in hospitals, assisted-living facilities, patient's homes and other health-care delivery settings. Other studies echo the findings. A Centers for Disease Control and Prevention study found that by mid-January, 38 percent of staffers at long-term care facilities in the agency's vaccination program had received a first dose. Becker's Hospital Review found that among eight top-rated hospitals, between 63 percent and 84 percent of employees had received at least one dose by mid-February.

The new vaccines were shipped immediately after receiving emergency use authorization from the federal government. And because health-care workers were the first to be offered vaccinations, some took a wait-and-see approach.

“There was very little time to prepare health-care workers for the vaccines,” said Kelly Moore, deputy director of the Immunization Action Coalition, which promotes vaccine education.

Now that more than 75 million people have been vaccinated, with very few side effects and broad-based national educational campaigns being launched to counter concerns, experts hope vaccine confidence will increase among health-care workers and others.

Swaying those minds toward vaccination will determine how quickly and completely the United States is able to bring the crisis phase of the pandemic to an end.

“Unless we all do it together, we’re not going to be victorious over the virus,” Gellin said.

From ‘shot shopping’ to overrun signup websites, a look into America’s vaccine rollout  
‘I don’t think there is enough research’

The more people are vaccinated in the coming weeks, the closer the country will come to herd immunity, slowing the ability of the virus to transmit. But if large groups of the population never get vaccinated, the virus will continue circulating and mutating.

Even among health-care workers — who have seen the devastation of the virus up close and work in a field rooted in science — 36 percent expressed doubts about the safety and efficacy of the vaccines, a rate that closely mirrors that of the general public.

While individuals’ explanations for that hesitancy vary, they often revolve around three core ideas: safety, efficacy and trust.

About 8 in 10 health-care workers who were not planning to get vaccinated against coronavirus or were on the fence said they were waiting to see how the vaccine affects others and were worried about adverse side effects. About two-thirds of those unvaccinated and without plans to get vaccinated said they did not trust the government to ensure the safety of the coronavirus vaccines.

Rather than considering the critical mass of vaccinated people needed for herd immunity, people are often thinking on an individual level and want an answer to a simple question, Gellin said: “Are people like me taking this vaccine, and how are they doing?”

Shelly Robinson, a long-term care nurse in Upstate New York, said she sees many covid-19 patients but does not want to risk getting a shot, because she feels the vaccines were rushed.

“I don’t think there is enough research,” Robinson said.

Many elderly patients have gotten vaccinated, she said, to be reunited with family members. But for now, she intends to rely on her mask for protection.

“I’m going to wait,” Robinson said. “Me and my family will keep wearing the masks until there are more studies done.”

One of the starkest numbers from the poll shows that 16 percent of health-care workers would rather give up their jobs than get vaccinated. The poll finds 58 percent of health-care workers who are not self-employed support their employer requiring all workers to be vaccinated. Among Americans who are not health workers, 70 percent say people who work with patients should be required to get a coronavirus vaccine.

“I’d quit if work told me I had to take it,” said Sandy Hull, 65, a registered nurse who lives just outside Indianapolis. She works in a prison and in a behavioral health setting for adolescents. “I wouldn’t run the risk of ruining my health to continue working.”

Hull said she believes the coronavirus exists and that she takes general precautions such as washing her hands and wearing a mask, but she said she believes that the virus’s dangers have probably been exaggerated because of political and financial concerns.

“It seems to me if it was as contagious as they say, I would have probably ended up catching it,” Hull said.

[‘We want to be educated, not indoctrinated,’ say Trump voters wary of covid shots]

Even though many health-care employers require influenza vaccines, Moore, of the Immunization Action Coalition, warned against enforcing coronavirus vaccination as a term of employment — at least for now.

“Mandates can be counterproductive” unless they follow extensive confidence-building programs that are designed to address employees’ concerns, she said.

“They come after, not instead of, educational efforts,” she said.

A health-care worker gets a dose of the Pfizer-BioNTech vaccine in Miami in December. (Marco Bello/Reuters)

‘I was so glad to get the shot’

The Post-KFF poll finds sharp income and educational differences in vaccination rates of health-care workers. More than 7 in 10 health-care workers with postgraduate degrees had received at least their first dose, compared with over 6 in 10 of those with bachelor’s degrees and 4 in 10 of those with an associate’s degree or less.

Some health-care workers cannot access the vaccine, even if they want to get it.

Samuel Charles Jr., 67, handles intake of patients at a primary-care doctor’s office in Chicago, taking their temperature and paperwork. Despite the high volume of patients he interacts with, Charles does not know why he was never offered a coronavirus vaccine through his job or his status as a health-care worker.

It was only because he was in the University of Chicago’s hospital’s system as a former patient that he was vaccinated at the end of February. Suffering from chronic obstructive pulmonary disease, he almost died in 2019 and spent two weeks in an intensive care unit. The hospital called and offered him a shot, given his underlying conditions.

“I guess I was lucky in that sense. If I hadn’t almost died, I wouldn’t have been on their list for the vaccine,” Charles said. “I was so glad to get the shot.”

The income disparity among health-care workers is clear. Nearly 7 in 10 health-care workers with household incomes of \$90,000 and above said they had been vaccinated. But that dropped to about half of those with incomes between \$40,000 and \$90,000 and to roughly 3 in 10 of those with incomes even lower than that.

Michael Kauten, 59, has been wanting to get vaccinated for months. Even before the first vaccine was approved in December, he said, he would have been willing to get it. He worked a lower-paying health-care job in a long-term care facility for adults with disabilities, but by the time some health-care workers were starting to get vaccinated at the end of December, cutbacks brought on the pandemic resulted in Kauten getting laid off.

Still, working as a volunteer firefighter in Wisconsin, Kauten should have been able to get a shot as a first responder, but his deeply rural department still has not received a supply.

It wasn’t until a few days ago that he learned he could sign up for the shot at a local drugstore such as Walgreens, he said. No one told him, and he was too busy struggling to find a new job.

“I had no idea,” Kauten said. He recently was hired as a long-term substitute teacher at a local school and is scheduled through the school department to get a shot at the end of the month.

[Tracking the coronavirus vaccine]

Health-care workers wait in line to get vaccinated at the Fairfax County Government Center in Virginia on Jan. 2. (Michael S. Williamson/The Washington Post)

The Post-KFF poll underscores the importance of employers providing vaccinations to health-care workers. Nearly 8 in 10 of those who said they had been vaccinated received doses from their employers. Hospitals have been most effective, with 66 percent of those who work directly with patients in hospitals receiving at least one dose, compared with 50 percent of those working in nursing homes or assisted-care facilities, 39 percent of those who are self-employed and 26 percent of those working in patients’ homes. Just over half of those who work in doctors’ offices said they had been vaccinated (52 percent).

Among health workers who planned to get vaccinated but had yet to make an appointment, just over 6 in 10 said they planned to do so through their employer, though roughly 3 in 10 said their employer had not offered them a shot.

Access is one of the key variables in people’s decision about whether to go through with getting a vaccine, experts say. When people are on the fence, having easy, convenient access can often tip the balance toward vaccination.

“We don’t need every person to be a champion, just comfortable enough to choose to be vaccinated,” Moore said. That means making sure the actual process of vaccination is convenient, considering factors such as work schedules and child-care needs.

‘I was a lot more comfortable’

Partisanship matters when it comes to vaccination, with 48 percent of Republican or Republican-leaning health workers saying they had received at least one dose, compared with 58 percent of Democrats. Over a third of Republican health workers, 36 percent, said they were uncertain or did not plan to get vaccinated, compared with 21 percent of those identifying or leaning Democratic.

Race is one of the strongest predictors of vaccine disparities.

The Post-KFF poll finds that 57 percent of White health-care workers, 39 percent of Black health-care workers and 44 percent of Hispanic health-care workers said they had been vaccinated.

Overall, 53 percent of health-care workers say they have been encouraged by their colleagues to get vaccinated. But only 4 in 10 Black health-care workers say they have been encouraged by their colleagues to get vaccinated, compared with over half of White health-care workers and just over 6 in 10 Hispanic health-care workers.

Robinson, who is Black, said the government's history of mistreatment of minorities — including the infamous "Tuskegee Study of Untreated Syphilis in the Negro Male" in 1972, in which Black men with syphilis were left untreated — is one reason Black Americans remain skeptical of coronavirus vaccines.

[Biden's vaccine push runs into distrust in the Black community]

Lorena Esquivel, 28, a patient access representative at San Ysidro Health in Southern California, worried initially that not enough time had been given to clinical trials. Access to colleagues who were ready to answer questions was key to her decision to get vaccinated.

"All that knowledge. After that, I was a lot more comfortable," said Esquivel, who is Hispanic and has received both doses.

"Even after being vaccinated, there's a possibility I can still get the virus," Esquivel said. "I'm not immune. Patients feel like they are immune and they are not. The vaccine helps prevent them ending up in the hospital."

Health-care workers call a car forward this month at a mass vaccination site set up at Martinsville Speedway in Ridgeway, Va. (Andrew Caballero-Reynolds/AFP/Getty Images)

'It is the only way we will get to the end of this pandemic'

James Conway, 47, knows several co-workers who remain scared of getting the vaccine, and he has wanted to change their minds. Conway works as a respiratory therapist at a hospital in St. Louis and has seen up close for the past year the death and suffering caused by the virus.

"It is the only way we will get to the end of this pandemic," Conway said. But he has been careful not to press too hard or get into debates with co-workers.

"It's like the patients I work with, you can't force the respiratory therapy on them," he said. "Approaching it that way is futile." Instead, he often tells patients about his struggles with asthma and how such therapies have helped him.

Similarly, he has been asking co-workers about their vaccine doubts and trying to listen to them without judgment. And he ends those conversations making sure that they know that he got the vaccine and that he has not had an adverse reaction.

"I think that's more persuasive than getting into argument," Conway said. "For a lot of people, the only thing that will change their mind is time. Once they see others are fine and nothing went wrong, they will be more willing."

For Lakes, at 46-year-old from Anaheim, thinking of his children made him want to get vaccinated. He spent 12 years working as a mental health counselor before the pandemic forced him to stop working.

"I would hate for my kids to be cursing me at my grave for not taking it," he said.

[After months of trauma, vaccinated health-care workers welcome a surprising emotion: Hope]

The Post-KFF poll finds more than 9 in 10 vaccinated health-care workers said they experienced minor side effects (60 percent) or no side effects (34 percent). Among the 6 percent reporting "major side effects," the most common were similar to those found in clinical trials: aches and pain, tiredness, headache, fevers or chills. A separate January study found that across 17.5 million doses given in December and January, just 66 resulted in severe allergic reactions, none of which resulted in death.

A health-care worker in West Chester, Pa., prepares a dose of the Moderna vaccine in December. (Matt Slocum/AP) Mindy Darling, a nurse practitioner in Arizona who works in three nursing homes, said she devoted time to reading up about the research and listening to experts.

Darling, 38, who is White, says she is now passing on that information. She recalled an informal gathering with nurses and patients pulling up in wheelchairs, when she discussed the potential for long-haul covid-19, as opposed to the short-term side effects of a vaccine.

After the conversation, the assistant director of nursing came over. "That's a good point about the effects of the disease," Darling recalled her saying.

Darling was pleased to see that people in leadership positions plastered the walls of one facility with a simple poster listing their names.

"We are taking the covid vaccine," it read. "Ask us why."

Addressing health-care workers' concerns is particularly important, Moore said, because they tend to wield great influence with their families and friends, as well as with their patients.

"Fix this problem and it's going to be better for everyone," Moore said.

Scott Clement contributed to this report.

+++

Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)

# RE: Quantitative Brand Testing Results

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Cc:** "Peck, Joshua (HHS/ASPA)" <joshua.peck@hhs.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>  
**Date:** Sat, 20 Feb 2021 17:54:13 -0500

Dear Courtney and Josh,

(b)(5)

Many thanks,  
Rochelle

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Saturday, February 20, 2021 11:56 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Cc:** Peck, Joshua (HHS/ASPA) <Joshua.Peck@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>  
**Subject:** FW: Quantitative Brand Testing Results

(b)(5)

**From:** Peck, Joshua (HHS/ASPA) <Joshua.Peck@hhs.gov>  
**Sent:** Friday, February 19, 2021 12:38 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) (b)(6) Dunn, Anita B. EOP/WHO (b)(6) (b)(6)  
**Cc:** Berner, Kate EOP/WHO (b)(6) (b)(6) Flaherty, Robert EOP/WHO (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) (b)(6) Webb, Cameron C. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6)  
**Subject:** RE: Quantitative Brand Testing Results

Hi all,

(b)(5)

**From:** Peck, Joshua (HHS/ASPA)  
**Sent:** Thursday, February 18, 2021 9:50 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) (b)(6) Dunn, Anita B. EOP/WHO (b)(6) (b)(6)  
**Cc:** Berner, Kate EOP/WHO (b)(6) (b)(6) Flaherty, Robert EOP/WHO (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) (b)(6) Webb, Cameron C. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6)  
**Subject:** Quantitative Brand Testing Results

Hi all,



(b)(5)

JFAP

# RE: Update for Sunday Morning Press

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Bonds, Michelle E. (CDC/OD/OADC)" <meb0@cdc.gov>, Mariel Saez (b)(6) "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>  
**Cc:** Marissa Padilla (b)(6) "Shahpar, Cyrus (CDC who.eop.gov)" (b)(6)  
"Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Saez, Mariel S. EOP/WHO"  
(b)(6) "Berner, Katherine EOP/WHO" (b)(6) "Tobar, Maria D. EOP/WHO" (b)(6)  
"Gershman, Lynn E. (CDC/OD/OCS)" <veu4@cdc.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>  
**Date:** Fri, 22 Jan 2021 16:24:17 -0500

(b)(5)

**From:** Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>  
**Sent:** Friday, January 22, 2021 2:44 PM  
**To:** Mariel Saez (b)(6) Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Cc:** Marissa Padilla (b)(6) Shahpar, Cyrus EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO (b)(6) Gershman, Lynn E. (CDC/OD/OCS) <veu4@cdc.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>  
**Subject:** RE: Update for Sunday Morning Press

Hi Mariel,

(b)(5)

**From:** Mariel Saez (b)(6)  
**Sent:** Friday, January 22, 2021 2:33 PM  
**To:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Cc:** Marissa Padilla (b)(6) Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6) Berner, Katherine EOP/WHO (b)(6)  
Tobar, Maria D. EOP/WHO (b)(6) Gershman, Lynn E. (CDC/OD/OCS) <veu4@cdc.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Bonds, Michelle E. (CDC/OD/OADC) <meb0@cdc.gov>  
**Subject:** Re: Update for Sunday Morning Press

Hi Sherri,

(b)(5)

Please let me know if you have any other questions. Cell is (b)(6) Thank you!

On Fri, Jan 22, 2021 at 2:21 PM Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov> wrote:

Hi all –

(b)(5)

(b)(5)

Thank you,  
Sherri

**From:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>  
**Sent:** Friday, January 22, 2021 1:22 PM  
**To:** Mariel Saez (b)(6)  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6); Saez, Mariel S. EOP/WHO (b)(6); Berner, Katherine EOP/WHO (b)(6); Tobar, Maria D. EOP/WHO (b)(6); Gershman, Lynn E. (CDC/OD/OCS) <[veu4@cdc.gov](mailto:veu4@cdc.gov)>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <[FJR0@cdc.gov](mailto:FJR0@cdc.gov)>; Bonds, Michelle E. (CDC/OD/OADC) <[meb0@cdc.gov](mailto:meb0@cdc.gov)>  
**Subject:** RE: avail check for Sunday

Got it! Thank you for your patience, as soon as we connect w/ her we will let you know.  
Thank you

**From:** Mariel Saez (b)(6)  
**Sent:** Friday, January 22, 2021 10:40 AM  
**To:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6); Saez, Mariel S. EOP/WHO (b)(6); Berner, Katherine EOP/WHO (b)(6); Tobar, Maria D. EOP/WHO (b)(6); Gershman, Lynn E. (CDC/OD/OCS) <[veu4@cdc.gov](mailto:veu4@cdc.gov)>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <[FJR0@cdc.gov](mailto:FJR0@cdc.gov)>; Bonds, Michelle E. (CDC/OD/OADC) <[meb0@cdc.gov](mailto:meb0@cdc.gov)>  
**Subject:** Re: avail check for Sunday

Thank you (b)(5)  
(b)(5)

On Fri, Jan 22, 2021 at 10:15 AM Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)> wrote:

Good Morning,

(b)(5)  
(b)(5)

Thank you

**From:** Mariel Saez (b)(6)  
**Sent:** Friday, January 22, 2021 10:14 AM  
**To:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Rowe, Courtney M. EOP/WHO (b)(6); Saez, Mariel S. EOP/WHO (b)(6); Berner, Katherine EOP/WHO (b)(6); Tobar, Maria D. EOP/WHO (b)(6)  
**Subject:** avail check for Sunday

Hi there! (b)(5)  
(b)(5)  
(b)(5) Thank you!

# RE: Boosters story leaked

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Cc:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Tue, 17 Aug 2021 07:21:35 -0400

Hi Courtney,  
I can be available at 4. A few reminders. I am speaking today at Governors at 11, Mayors at 2 and our CDC data that my slides will be speaking to were tentatively planned for release tomorrow.  
Thanks,  
R

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Monday, August 16, 2021 10:46 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Boosters story leaked

Hi all- (b)(5)  
(b)(5)

## ***U.S. to Advise Boosters for Most Americans 8 Months After Vaccination***

Nursing home residents and health care workers will most likely be the first to get booster shots, as soon as September, followed by other older people who were vaccinated last winter.

**By Sharon LaFraniere**  
Aug. 16, 2021, 10:22 p.m. ET

WASHINGTON — The Biden administration has decided that most Americans should get a coronavirus booster shot eight months after they completed their initial vaccination, and could begin offering the extra shots as early as mid-September, according to two administration officials familiar with the discussions.

Officials are planning to announce the administration's decision as early as this week. Their goal is to let Americans know now that they will need additional protection against the Delta variant that is causing surging caseloads across the nation.

The first boosters are likely to go to nursing home residents and [health care workers](#), followed by other older people who were near the front of the line when vaccinations began late last year. Officials envision giving people the same

vaccine they originally received.

Among other worrisome signals, Biden administration officials are particularly concerned about data from Israel suggesting that the Pfizer-BioNTech's protection against severe disease has fallen significantly for elderly people who were vaccinated in January or February.

Some administration officials have viewed Israel as a kind of template for the United States because it started vaccinating its population sooner. Israel has almost exclusively used the Pfizer-BioNTech vaccine, and it has a nationalized health care system that allows it to systematically track patients.

The latest data from Israel, posted on the government's website on Monday, shows what some experts describe as continued erosion of the efficacy of the Pfizer vaccine over time — both against mild or asymptomatic Covid-19 infections in general and against severe disease among the elderly.

Washington Post story—

The Biden administration is planning to announce that all Americans who have received the coronavirus vaccine will need booster shots to combat waning immunity from the immunizations and the highly transmissible delta variant that is sparking a surge in covid-19 cases throughout the nation, according to four people familiar with the decision.

The administration's health and science experts are coalescing around the view that people will need the boosters eight months after they are fully vaccinated, according to the people who requested anonymity to discuss a decision not yet public. The decision is likely to be announced as soon as this week.

The actual administration of the boosters would not occur until mid- or late September, after Pfizer's application for additional shots for the general public is cleared by the Food and Drug Administration, the individuals said.

The conclusion that boosters will be broadly needed was reached after intense discussions last weekend involving high-ranking officials who scrutinized the latest data from the United States and other countries on the effectiveness of the shots.

The statement is a striking change from public statements by senior officials in recent months who had said it was far too soon to conclude that Americans would need booster shots. In July, the Centers for Disease Control and Prevention and the Food and Drug Administration put out an unusual statement that said: "Americans who have been fully vaccinated do not need a booster shot at this time." Officials have repeatedly said that it wasn't clear whether boosters would be needed.

# Talking points and tough Q&A on

(b)(5)

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Collins, Francis (NIH/OD) [E]" (b)(6) "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
"Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Wakana, Benjamin L. EOP/WHO"  
(b)(6) "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>,  
"Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Myles, Renate (NIH/OD) [E]"  
(b)(6) "Fine, Amanda (NIH/OD) [E]" (b)(6) "Billet, Courtney (NIH/NIAID)  
[E]" (b)(6)  
**Date:** Mon, 20 Sep 2021 13:00:06 -0400

Hi all- I know some of you are out today, here's some talking points and tough q&a

(b)(5)

(b)(5) t.

(b)(5)

(b)(5)

(b)(5)



(b)(5)



# RE: COVID Tough QA

---

**From:** "Wakana, Benjamin L. EOP/WHO" [redacted] (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b)(6)  
**Date:** Thu, 17 Jun 2021 11:28:06 -0400  
**Attachments:** JZ Tough QA 6.16.21 11pm.docx (49.27 kB)

---

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

(b)(5)

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Thursday, June 17, 2021 8:37 AM

**To:** 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) 'Rochelle Walensky' <aux7@cdc.gov>; 'Vivek Murthy' <vivek.murthy@hhs.gov>; (b)(6) (b)(6)

**Cc:** 'Courtney Rowe' (b)(6) 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'billetc@niaid.nih.gov' (b)(6) 'Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Phillips, Alexandria (HHS/OASH)' <Alexandria.Phillips@hhs.gov>; 'Myles, Renate (NIH/OD) [E]' (b)(6) Sanchez-Velasco, Marissa EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6)

**Subject:** COVID Tough QA

Hi, attached please find the latest Tough QA on COVID. Topics include:

(b)(5)

(b)(5)

Ben

+++

Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)

# RE: Pharmacy update

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6), "Messonnier, Nancy (CDC/DDID/NCIRD/OD)" <nar5@cdc.gov>, "Dawn O'Connell (dawn.oconnell@hhs.gov)" <dawn.oconnell@hhs.gov>  
**Cc:** "Choucair, Bechara EOP/WHO" (b)(6), "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>  
**Date:** Fri, 29 Jan 2021 12:10:34 -0500

I had not seen the full thing- (b)(5)

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Friday, January 29, 2021 12:05 PM  
**To:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6), Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Dawn O'Connell (dawn.oconnell@hhs.gov) <dawn.oconnell@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6), Choucair, Bechara EOP/WHO (b)(6), Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>  
**Subject:** Pharmacy update  
**Importance:** High

Hi Sonya –

(b)(5)

(b)(5)

(b)(5)

Thanks, Sherri

**From:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6)  
**Sent:** Friday, January 29, 2021 11:37 AM  
**To:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Dawn O'Connell (dawn.oconnell@hhs.gov) <dawn.oconnell@hhs.gov>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6), Choucair, Bechara EOP/WHO (b)(6)  
**Subject:** pharmacy

Hi, (b)(5)

Sonya Bernstein  
(b)(6) (cell)

## RE: Of interest...

---

**From:** "Quillian, Natalie H. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Tue, 26 Oct 2021 08:37:51 -0400

---

(b)(5)

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Tuesday, October 26, 2021 7:49 AM  
**To:** Zients, Jeffrey D. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** Of interest...

(b)(5)

# RE: DC and the pharmacy program

**From:** "Cisneros, Eduardo EOP/WHO" (b)(6)  
**To:** "Choucair, Bechara EOP/WHO" (b)(6) "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6) "Messonnier, Nancy (CDC/DDID/NCIRD/OD)" <nar5@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Lubar, Debra (CDC/DDID/NCEZID/OD)" <dpl9@cdc.gov>  
**Date:** Tue, 02 Feb 2021 15:56:42 -0500

Just pinged them

**From:** Choucair, Bechara EOP/WHO  
**Sent:** Tuesday, February 2, 2021 3:39 PM  
**To:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6) Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Cisneros, Eduardo EOP/WHO (b)(6)  
**Cc:** Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>  
**Subject:** RE: DC and the pharmacy program

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

**From:** Sackner-Bernstein, Sonya E. EOP/WHO  
**Sent:** Tuesday, February 2, 2021 9:52 AM  
**To:** Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Choucair, Bechara EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Cisneros, Eduardo EOP/WHO (b)(6)  
**Cc:** Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>  
**Subject:** RE: DC and the pharmacy program

(b)(5)

**From:** Sackner-Bernstein, Sonya E. EOP/WHO  
**Sent:** Tuesday, February 2, 2021 9:37 AM  
**To:** 'Messonnier, Nancy (CDC/DDID/NCIRD/OD)' <nar5@cdc.gov>; Choucair, Bechara EOP/WHO (b)(6) 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>  
**Cc:** 'Lubar, Debra (CDC/DDID/NCEZID/OD)' <dpl9@cdc.gov>  
**Subject:** RE: DC and the pharmacy program

(b)(5)

Thank you as always!

**From:** Sackner-Bernstein, Sonya E. EOP/WHO  
**Sent:** Tuesday, February 2, 2021 9:20 AM  
**To:** 'Messonnier, Nancy (CDC/DDID/NCIRD/OD)' <nar5@cdc.gov>; Choucair, Bechara EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Cc:** Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>  
**Subject:** RE: DC and the pharmacy program

(b)(5)

(b)(5)

**From:** Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>

**Sent:** Tuesday, February 2, 2021 9:06 AM

**To:** Choucair, Bechara EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

**Cc:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6) Lubar, Debra  
(CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>

**Subject:** DC and the pharmacy program

(b)(5)

(b)(5)

Nancy

**From:** Burris, Heather (DOH) <[Heather.Burris@dc.gov](mailto:Heather.Burris@dc.gov)>

**Sent:** Sunday, January 24, 2021 11:02 PM

**To:** Zimmerman, Laura (CDC/DDPHSIS/CGH/GID) <[laz5@cdc.gov](mailto:laz5@cdc.gov)>

**Subject:** Retail Pharmacy Program

Hi Laura,

At this time, the District of Columbia declines participation in the CDC Retail Pharmacy Program partnership. We may reconsider our participation if enrollment is available to jurisdictions after the program launch.

Kind regards,  
Heather

**Heather Burris, MPH**

Pronouns: She/Her/Hers

COVID-19 Vaccine Planning Team Lead

Community Health Administration/Health Care Access Bureau

[Heather.burris@dc.gov](mailto:Heather.burris@dc.gov)

Main: 202-576-9319

Direct: 202-576-1142

Cell: 202-380-6934

899 North Capitol Street NE, 3rd Fl, Washington, DC 20002

[dchealth.dc.gov](http://dchealth.dc.gov)

# RE: COVID Deputies Meeting Agenda | Mon, 08/23/21

**From:** "Kwak, Grace J. EOP/WHO" (b)(6)  
**To:** "Kwak, Grace J. EOP/WHO" (b)(6)  
**Cc:** "Quillian, Natalie H. EOP/WHO" (b)(6) "Rowe, Courtney M. EOP/WHO"  
(b)(6)  
**Date:** Mon, 23 Aug 2021 13:11:31 -0400

Good afternoon everyone,

(b)(5)

Thank you,  
Grace

###

(b)(5)

## [FDA Approves First COVID-19 Vaccine](#) *Approval Signifies Key Achievement for Public Health*

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir'-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

**“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,”** said Acting FDA Commissioner Janet Woodcock, M.D. **“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”**

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.

FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval.

Comirnaty contains messenger RNA (mRNA), a kind of genetic material. The mRNA is used by the body to make a mimic of one of the proteins in the virus that causes COVID-19. The result of a person receiving this vaccine is that their immune system will ultimately react defensively to the virus that causes COVID-19. The mRNA in Comirnaty is only present in the

body for a short time and is not incorporated into - nor does it alter - an individual's genetic material. Comirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart.

**“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,”** said Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research. **“We have not lost sight that the COVID-19 public health crisis continues in the U.S. and that the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S.”**

### **FDA Evaluation of Safety and Effectiveness Data for Approval for 16 Years of Age and Older**

The first [EUA](#), issued Dec. 11, for the Pfizer-BioNTech COVID-19 Vaccine for individuals 16 years of age and older was [based on safety and effectiveness data](#) from a randomized, controlled, blinded ongoing clinical trial of thousands of individuals.

To support the FDA’s approval decision today, the FDA reviewed updated data from the clinical trial which supported the EUA and included a longer duration of follow-up in a larger clinical trial population.

Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.

Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.

### **Ongoing Safety Monitoring**

The FDA and Centers for Disease Control and Prevention have monitoring systems in place to ensure that any safety concerns continue to be identified and evaluated in a timely manner. In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.

The FDA granted this application [Priority Review](#). The approval was granted to BioNTech Manufacturing GmbH.

---

**From:** Kwak, Grace J. EOP/WHO  
**Sent:** Sunday, August 22, 2021 5:45 PM  
**To:** Grace Kwak (b)(6)  
**Cc:** Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** COVID Deputies Meeting Agenda | Mon, 08/23/21

Good evening everyone,

Please find attached the agenda for tomorrow’s meeting. As always, please do not hesitate to reach out with any questions and/or concerns.

Thank you,  
Grace



# RE: [EXTERNAL] STC-EPO/WHO-CDC-Daily Situation Report-June 7, 2021

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Shahpar, Cyrus EOP/WHO" (b)(6) Tiffany Dent <tiffany\_dent@stchome.com>, "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Cc:** "Fitzpatrick, Kelsey V. EOP/WHO" (b)(6) Mike Popovich <michael\_popovich@stchome.com>, Todd Watkins <todd\_watkins@stchome.com>  
**Date:** Mon, 07 Jun 2021 21:38:14 -0400

(b)(5)

Many thanks,  
Rochelle

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Monday, June 7, 2021 9:30 PM  
**To:** Tiffany Dent <tiffany\_dent@stchome.com>; Slavitt, Andrew M. EOP/WHO (b)(6)  
**Cc:** Fitzpatrick, Kelsey V. EOP/WHO (b)(6) Mike Popovich <michael\_popovich@stchome.com>; Todd Watkins <todd\_watkins@stchome.com>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** RE: [EXTERNAL] STC-EPO/WHO-CDC-Daily Situation Report-June 7, 2021

Hi Tiffany,

(b)(5)

much appreciated,  
Cyrus

**From:** Tiffany Dent <tiffany\_dent@stchome.com>  
**Sent:** Monday, June 7, 2021 6:26 PM  
**To:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Cc:** Fitzpatrick, Kelsey V. EOP/WHO (b)(6) Mike Popovich <michael\_popovich@stchome.com>; Todd Watkins <todd\_watkins@stchome.com>; Shahpar, Cyrus EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** RE: [EXTERNAL] STC-EPO/WHO-CDC-Daily Situation Report-June 7, 2021

Andv-

(b)(5)

Thanks,  
Tiffany



**Tiffany Dent, MPH**  
Vice President, Customer Experience at STChalth

A 411 S 1st Street, Phoenix AZ 85004  
P 480-745-8500 M 480-522-0228 E [tiffany\\_dent@stchome.com](mailto:tiffany_dent@stchome.com) W [www.stchealth.com](http://www.stchealth.com)



Intelligent Solutions for a Healthier Future



CONFIDENTIALITY NOTICE - The information enclosed in this transmission is the private, confidential property of the sender, and the material is privileged communication intended solely for the individual indicated. If you are not the intended recipient, you are notified that any review, disclosure, copying, distribution, or taking any other action relevant to the contents of this transmission is strictly prohibited. If you have received this transmission in error, please notify STC immediately at [security@stchome.com](mailto:security@stchome.com)

**From:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Sent:** Monday, June 7, 2021 6:08 PM  
**To:** Tiffany Dent <[tiffany\\_dent@stchome.com](mailto:tiffany_dent@stchome.com)>  
**Cc:** Fitzpatrick, Kelsey V. EOP/WHO (b)(6) Mike Popovich <[michael\\_popovich@stchome.com](mailto:michael_popovich@stchome.com)>; Todd Watkins <[todd\\_watkins@stchome.com](mailto:todd_watkins@stchome.com)>; Shahpar, Cyrus EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>  
**Subject:** Re: [EXTERNAL] STC-EPO/WHO-CDC-Daily Situation Report-June 7, 2021

(b)(5)

Sent from my iPhone

On Jun 7, 2021, at 4:26 PM, Tiffany Dent <[tiffany\\_dent@stchome.com](mailto:tiffany_dent@stchome.com)> wrote:

All-

(b)(5)

Thanks,  
Tiffany

<image001.png>

## **Tiffany Dent, MPH**

Vice President, Customer Experience at STChealth

A 411 S 1st Street, Phoenix AZ 85004

P [480-745-8500](tel:480-745-8500) M [480-522-0228](tel:480-522-0228) E [tiffany\\_dent@stchome.com](mailto:tiffany_dent@stchome.com) W [>>www.stchealth.com<<](http://www.stchealth.com);

[<image002.png>](#)

[<image003.png>](#)

[Intelligent Solutions for a Healthier Future](#)

[<image004.jpg>](#)

CONFIDENTIALITY NOTICE - The information enclosed in this transmission is the private, confidential property of the sender, and the material is privileged communication intended solely for the individual indicated. If you are not the intended recipient, you are notified that any review, disclosure, copying, distribution, or taking any other action relevant to the contents of this transmission is strictly prohibited. If you have received this transmission in error, please notify STC immediately at [security@stchome.com](mailto:security@stchome.com)

<STC-WH-CDC-Daily Situation Report-COVID Vaccine Data-June 7 2021.pdf>

# WSJ: Pfizer Vaccine Is Highly Effective After One Dose and Can Be Stored in Normal Freezers, Data Shows

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6), "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Date:** Fri, 19 Feb 2021 09:57:41 -0500

Hi, (b)(5)  
(b)(5)

(b)(5)

## **WSJ: Pfizer Vaccine Is Highly Effective After One Dose and Can Be Stored in Normal Freezers, Data Shows**

Peer-reviewed study comes as some governments debate whether to delay second vaccine doses

By Bojan Pancevski and Dov Lieber

Updated Feb. 19, 2021 7:53 am ET

The Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE generates robust immunity after one dose and can be stored in ordinary freezers instead of at ultracold temperatures, according to new research and data released by the companies.

The findings provide strong arguments in favor of delaying the second dose of the two-shot vaccine, as the U.K. has done. They could also have substantial implications on vaccine policy and distribution around the world, simplifying the logistics of distributing the vaccine.

A single shot of the vaccine is 85% effective in preventing symptomatic disease 15 to 28 days after being administered, according to a peer-reviewed study conducted by the Israeli government-owned Sheba Medical Center and published in the Lancet medical journal. Pfizer and BioNTech recommend that a second dose is administered 21 days after the first.

The finding is a vindication of the approach taken by the U.K. government to delay a second dose by up to 12 weeks so it could use limited supplies to deliver a single dose to more people, and could encourage others to follow suit. Almost one-third of the U.K.'s adult population has now received at least one vaccine shot. Other authorities in parts of Canada and Europe have prioritized an initial shot, hoping they will have enough doses for a booster when needed.

Preliminary data also suggest that the other widely used vaccine in the U.K. developed by AstraZeneca PLC and the University of Oxford could have a substantial effect after a first dose.

The Israeli findings came from the first real-world data about the effect of the vaccine gathered outside of clinical trials in one of the leading nations in immunization against the coronavirus. Israel has given the first shot to 4.2 million people—more than two-thirds of eligible citizens over 16 years old—and a second shot to 2.8 million, according to its health ministry. The country has around 9.3 million citizens.

The study, which involved about 9,000 people, also found a 75% reduction in both symptomatic and asymptomatic infections after the first shot. The study was published as a correspondence, meaning it represents the views of the authors and not the Lancet.

“This is the first study assessing effectiveness of a single vaccine dose in real-life conditions and shows early effectiveness, even before the second dose was administered,” said Eyal Leshem, director of Sheba’s Center for Travel Medicine and Tropical Diseases and one of the authors of the study.

Separately, the vaccine, which has been authorized in the U.S., the U.K., the EU and elsewhere, can be stored and transported at between minus 25 and minus 15 degrees Celsius, or minus 13 and 5 degrees Fahrenheit—similar to a consumer freezer—Pfizer and BioNTech said. Currently, the vaccine’s labels say it must be stored at between minus 80 and minus 60 degrees Celsius, requiring sophisticated equipment.

The companies said they were seeking approval from the U.S. Food and Drug Administration to change the vaccine’s storage rules, a move that would make it much easier to handle and potentially accessible to poorer countries with no access to ultracold distribution and storage equipment.

Ugur Sahin, the co-founder of BioNTech, said the temperature data would enable the vaccine to be handled by ordinary pharmacies.

Pfizer’s original clinical study showed 52.4% effectiveness after one shot, but didn’t differentiate between before and after two weeks. That focused on a two-dose regime and found 95% efficacy a week after the second shot. The Sheba study shows just one dose could reach close to that level of efficacy.

During the period when the data was gathered, a coronavirus variant that was first detected in the U.K. and is considered more contagious than the original pathogen made up over 81% of confirmed infections. The data amount to strong evidence that the vaccine is highly effective against a mutation that has forced European governments to prolong their lockdowns.

An annex to the Sheba study showed the vaccine had 94% effectiveness in preventing symptomatic Covid-19 as many as 22 to 28 days after the first shot. This result was similar to those from two previous analyses of the vaccine that used clinical data submitted to the FDA.

Britain is the only Western country mandating a delay of three months between first and second dose instead of the initially recommended three weeks. The U.S. Centers for Disease Control and Prevention has updated its guidance to say that doses can be administered 42 days apart, though the agency still advises individuals to stick to the initial schedule.

The policy has enabled the U.K. to accelerate its vaccination program, but also stirred controversy in the scientific community. The need to set aside half of doses delivered for second injections is one reason why vaccination in the European Union has proceeded much more slowly.

Dr. Sahin told The Wall Street Journal in December that next-generation Covid-19 shots would probably consist of one dose.

“This groundbreaking research supports the British government’s decision to begin inoculating its citizens with a single dose of the vaccine,” said Arnon Afek, Sheba’s deputy director general.

The results might differ from others because the subjects were largely younger and healthier, said Gili Regev-Yochay, another of the authors. She also said the study couldn’t confirm how long protection from one shot would last, as most of the subjects received a second shot.

## RE: Board endorses 75% goal

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Cc:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "O'Connell, Dawn (HHS/IOS)" <dawn.oconnell@hhs.gov>  
**Date:** Wed, 24 Feb 2021 11:55:49 -0500

Hi Andy,

(b)(5)

Many thanks,  
Rochelle

**From:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Sent:** Monday, February 22, 2021 11:48 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Fwd: Board endorses 75% goal

(b)(5)

Sent from my iPhone

Begin forwarded message:

**From:** "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6)  
**Date:** February 22, 2021 at 11:30:12 PM EST  
**To:** "Slavitt, Andrew M. EOP/WHO" (b)(6) "Rowe, Courtney M. EOP/WHO" (b)(6) "Choucair, Bechara EOP/WHO" (b)(6) "Wakana, Benjamin L. EOP/WHO" (b)(6) "Butterworth, Zach Z. EOP/WHO" (b)(5)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6)  
**Subject:** RE: Board endorses 75% goal

Hi, my apologies for the delay. Thoughts below—let me know how I can help from here.

**From:** Slavitt, Andrew M. EOP/WHO  
**Sent:** Friday, February 19, 2021 2:30 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Butterworth, Zach Z. EOP/WHO (b)(5) Sackner-Bernstein, Sonya E. EOP/WHO (b)(5)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** FW: Board endorses 75% goal

(b)(5)

**From:** Mark Parkinson <mparkinson@AHCA.org>  
**Sent:** Friday, February 19, 2021 2:24 PM  
**To:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Cc:** David Gifford <dgifford@AHCA.org>; Courtney Bishnoi <cbishnoi@ahca.org>; Urvi Patel <upatel@AHCA.org>  
**Subject:** [EXTERNAL] Board endorses 75% goal

Andy: I'm pleased to report that we were able to pull our Board together today and it endorsed a plan to work with the Administration to increase staff uptake of the Covid vaccine to 75% and achieve that by June 30 of this year. We are excited to partner with you and the Biden Administration on this critical effort. AHCA would like to make a joint announcement, or an announcement that someone from the Administration supports, with a quote in the press release, and we would like to do it ASAP.

To achieve this goal, AHCA will do the following:

1. Identify a set of core practices to increase uptake and encourage providers to adopt, such as
  - Developing peer-level vaccine "ambassadors"
  - Frequent town halls led by medical director or other clinical staff
  - One-on-one conversations between leadership and staff
  - Celebrating staff for taking the vaccine and creating opportunities for peer-to-peer dialog on the vaccine
  - Emphasizing the value of taking the vaccine to protect others (e.g. residents and family) and return to normal activities
  - Providing incentives to staff to take the vaccine, including paid time off for both getting the vaccine and recovery if there are adverse events
  - Providing resources to explain vaccine safety
2. Encourage providers to report their staff vaccination uptake through the vaccine module in NHSN on a weekly basis.
3. Launch a social media campaign to address vaccine hesitancy; this is underway imminently with the support of CDC. The CDC has already approved our effort on this and the campaign launches in the next 7 to 14 days.
4. Recognize any provider that achieves the goal. We will develop an award program, with public recognition, for facilities that achieve these levels.

We ask that the Administration take the following actions to support attainment of the goal:

1. Jointly launch the initiative with full White House support of the goal. If the White House is not comfortable with a joint initiative, we need a quote from yourself, or someone else at CDC, HHS, or CMS that acknowledges the effort, supports the goal, and agrees to provide the resources needed to achieve it.

(b)(5)

2. HHS clarify that provider relief funds can be utilized to increase vaccine uptake, such as:
  - a. Providing financial incentives to staff
  - b. Time off for receiving the vaccination
  - c. Sick time for any adverse event or severe side effects.

(b)(5)

3. CDC provide update guidance about activities that can be allowed or resumed if vaccine targets are achieved; specifically permit facilities that achieve the goal be allowed to open to visitors.

(b)(5)

4. CMS promote vaccine reporting to NHSN in non-punitive manner.

(b)(5)

5. Provide a federal allocation of vaccine available for LTC workers. This last point may be the most important. The third clinic will be complete in most facilities soon. We need to make sure that the long term care pharmacies, and CVS and Walgreens buy into having vaccine set aside for employees that will be visiting them for the shots.

(b)(5)

Andy---I really appreciate you coming up with this idea and I personally commit to you that we will have a laser like focus on the effort. I don't know if we can get the whole sector to 75%, but we know that individual buildings have done it, and there is no doubt in my mind that we can increase the overall number.

Let me know if you'd like to discuss this tonight, or anytime this weekend. I'm presenting at a Healthcare symposium from 3:00 to 5:30 pm today, but other than that, I'm free all evening and weekend.

Mark Parkinson

(b)(5)

### Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd.**



## RE: Board endorses 75% goal

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Date:** Tue, 23 Feb 2021 22:31:11 -0500

Hi Andy,

(b)(5)

Best,  
Rochelle

**From:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Sent:** Monday, February 22, 2021 11:48 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Fwd: Board endorses 75% goal

(b)(5)

Sent from my iPhone

Begin forwarded message:

**From:** "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6)  
**Date:** February 22, 2021 at 11:30:12 PM EST  
**To:** "Slavitt, Andrew M. EOP/WHO" (b)(6) "Rowe, Courtney M. EOP/WHO"  
(b)(6) "Choucair, Bechara EOP/WHO" (b)(6) "Wakana,  
Benjamin L. EOP/WHO" (b)(6) "Butterworth, Zach Z. EOP/WHO"  
(b)(5)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO"  
(b)(6)  
**Subject:** RE: Board endorses 75% goal

Hi, my apologies for the delay. Thoughts below—let me know how I can help from here.

**From:** Slavitt, Andrew M. EOP/WHO  
**Sent:** Friday, February 19, 2021 2:30 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO  
(b)(6) Wakana, Benjamin L. EOP/WHO (b)(6)  
Butterworth, Zach Z. EOP/WHO (b)(5) Sackner-Bernstein, Sonya E. EOP/WHO  
(b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO  
(b)(6)  
**Subject:** FW: Board endorses 75% goal

(b)(5)

**From:** Mark Parkinson <[mparkinson@AHCA.org](mailto:mparkinson@AHCA.org)>  
**Sent:** Friday, February 19, 2021 2:24 PM  
**To:** Slavitt, Andrew M. EOP/WHO (b)(6)  
**Cc:** David Gifford <[dgifford@AHCA.org](mailto:dgifford@AHCA.org)>; Courtney Bishnoi <[bishnoi@ahca.org](mailto:bishnoi@ahca.org)>; Urvi Patel <[upatel@AHCA.org](mailto:upatel@AHCA.org)>  
**Subject:** [EXTERNAL] Board endorses 75% goal

Andy: I'm pleased to report that we were able to pull our Board together today and it endorsed a plan to work with the Administration to increase staff uptake of the Covid vaccine to 75% and achieve that by June 30 of this year. We are excited to partner with you and the Biden Administration on this critical effort. AHCA would like to make a joint announcement, or an announcement that someone from the Administration supports, with a quote in the press release, and we would like to do it ASAP.

To achieve this goal, AHCA will do the following:

1. Identify a set of core practices to increase uptake and encourage providers to adopt, such as
  - Developing peer-level vaccine "ambassadors"
  - Frequent town halls led by medical director or other clinical staff
  - One-on-one conversations between leadership and staff
  - Celebrating staff for taking the vaccine and creating opportunities for peer-to-peer dialog on the vaccine
  - Emphasizing the value of taking the vaccine to protect others (e.g. residents and family) and return to normal activities
  - Providing incentives to staff to take the vaccine, including paid time off for both getting the vaccine and recovery if there are adverse events
  - Providing resources to explain vaccine safety
2. Encourage providers to report their staff vaccination uptake through the vaccine module in NHSN on a weekly basis.
3. Launch a social media campaign to address vaccine hesitancy; this is underway imminently with the support of CDC. The CDC has already approved our effort on this and the campaign launches in the next 7 to 14 days.
4. Recognize any provider that achieves the goal. We will develop an award program, with public recognition, for facilities that achieve these levels.

We ask that the Administration take the following actions to support attainment of the goal:

1. Jointly launch the initiative with full White House support of the goal. If the White House is not comfortable with a joint initiative, we need a quote from yourself, or someone else at CDC, HHS, or CMS that acknowledges the effort, supports the goal, and agrees to provide the resources needed to achieve it.

(b)(5)

2. HHS clarify that provider relief funds can be utilized to increase vaccine uptake, such as:
  - a. Providing financial incentives to staff
  - b. Time off for receiving the vaccination
  - c. Sick time for any adverse event or severe side effects.

(b)(5)

3. CDC provide update guidance about activities that can be allowed or resumed if vaccine targets are achieved; specifically permit facilities that achieve the goal be allowed to open to visitors.

(b)(5)

4. CMS promote vaccine reporting to NHSN in non-punitive manner.

(b)(5)

5. Provide a federal allocation of vaccine available for LTC workers. This last point may be the most important. The third clinic will be complete in most facilities soon. We need to make

sure that the long term care pharmacies, and CVS and Walgreens buy into having vaccine set aside for employees that will be visiting them for the shots.

(b)(5)

Andy---I really appreciate you coming up with this idea and I personally commit to you that we will have a laser like focus on the effort. I don't know if we can get the whole sector to 75%, but we know that individual buildings have done it, and there is no doubt in my mind that we can increase the overall number.

Let me know if you'd like to discuss this tonight, or anytime this weekend. I'm presenting at a Healthcare symposium from 3:00 to 5:30 pm today, but other than that, I'm free all evening and weekend.

Mark Parkinson

(b)(6)

#### **Disclaimer**

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd.**

# RE: (U//FOUO) For Review by: COB Wed 7/28 -- UNGA + Targets

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Cameron, Beth E. EOP/NSC" (b)(6) "Smith, Gayle E" <smithge@state.gov>, "Kahan, Alexandra L" <kahanal@state.gov>, Jeremy Konyndyk <jkonyndyk@usaid.gov>, Natasha Bilimoria <nbilimoria@usaid.gov>, "Wolfe, Mitchell (CDC/OD)" <maw6@cdc.gov>, "Prescott, Jeffrey" <prescottj@state.gov>, Jasmine Wyatt <wyattj1@state.gov>, "Marchick, David (PO)" <david.marchick@dfc.gov>, "Jiwani, Nafisa (PO)" <nafisa.jiwani@dfc.gov>, "Pace, Loyce (HHS/OS/OGA)" <loyce.pace@hhs.gov>  
**Cc:** "Finer, Jon J. EOP/WHO" (b)(6) "Singh, Daleep EOP/NSC" (b)(6) "Etim, Linda EOP/NSC" (b)(6) "Lipin, Ella J. EOP/NSC" (b)(6) "Parikh, Viraj K. EOP/NSC" (b)(6) "Bartee, Maureen S. EOP/NSC" (b)(6) "McBroom, Jessica A. EOP/NSC" (b)(6) "Bouri, Nidhi EOP/NSC" (b)(6) "Cormier, Justin P. EOP/NSC" (b)(6)  
**Date:** Wed, 28 Jul 2021 09:01:48 -0400

---

Dear all,

(b)(5)

(b)(5)

(b)(5)

We appreciate your consideration.  
Best,  
Rochelle

**From:** Cameron, Beth E. EOP/NSC (b)(6)  
**Sent:** Monday, July 26, 2021 6:40 PM  
**To:** Smith, Gayle E <SmithGE@state.gov>; Kahan, Alexandra L <KahanAL@state.gov>; Jeremy Konyndyk <jkonyndyk@usaid.gov>; 'Natasha Bilimoria' <nbilimoria@usaid.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Wolfe, Mitchell (CDC/OD) <msw6@cdc.gov>; Prescott, Jeffrey <PrescottJ@state.gov>; 'Jasmine Wyatt' <wyattj1@state.gov>; Marchick, David (PO) <David.Marchick@dfc.gov>; Jiwani, Nafisa (PO) <Nafisa.Jiwani@dfc.gov>  
**Cc:** Finer, Jon J. EOP/WHO (b)(6) Singh, Daleep EOP/NSC (b)(6) Etim, Linda EOP/NSC (b)(6) Lipin, Ella J. EOP/NSC (b)(6) Parikh, Viraj K. EOP/NSC (b)(6) Bartee, Maureen S. EOP/NSC (b)(6) McBroom, Jessica A. EOP/NSC (b)(6) Bouri, Nidhi EOP/NSC (b)(6) Cormier, Justin P. EOP/NSC (b)(6)  
**Subject:** (U//FOUO) For Review by: COB Wed 7/28 -- UNGA + Targets  
**Importance:** High

**UNCLASSIFIED//FOR OFFICIAL USE ONLY – NOT FOR DISTRIBUTION**

Hi all,

(b)(5)

Thanks,  
Beth & Linda, on behalf of our teams

-----  
Elizabeth (Beth) E. Cameron, PhD  
Special Assistant to the President and  
Senior Director for Global Health Security & Biodefense  
National Security Council staff  
The White House

(b)(6)

(b)(6)

# Re: Pharmacy update

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>  
**Cc:** "Choucair, Bechara EOP/WHO" (b)(6) "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6) "Messonnier, Nancy (CDC/DDID/NCIRD/OD)" <nar5@cdc.gov>, "Dawn O'Connell (dawn.oconnell@hhs.gov)" <dawn.oconnell@hhs.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Quillian, Natalie H. EOP/WHO" (b)(6)  
**Date:** Fri, 29 Jan 2021 12:53:47 -0500

(b)(5)

(b)(6)

(b)(5)

Sent from my iPhone

On Jan 29, 2021, at 12:47 PM, Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov> wrote:

(b)(5)

**From:** Choucair, Bechara EOP/WHO (b)(6)  
**Sent:** Friday, January 29, 2021 12:38 PM  
**To:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>; Dawn O'Connell (dawn.oconnell@hhs.gov) <dawn.oconnell@hhs.gov>; Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <FJR0@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** RE: Pharmacy update

(b)(5)

Bechara

Bechara Choucair, MD

Vaccinations Coordinator

White House COVID Response Team

(b)(6)

**From:** Sackner-Bernstein, Sonya E. EOP/WHO

**Sent:** Friday, January 29, 2021 12:20 PM

**To:** Rowe, Courtney M. EOP/WHO (b)(6)

**Cc:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <[nar5@cdc.gov](mailto:nar5@cdc.gov)>; Dawn O'Connell ([dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)) <[dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)>; Choucair, Bechara EOP/WHO (b)(6)

Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <[FJR0@cdc.gov](mailto:FJR0@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Quillian, Natalie H. EOP/WHO (b)(6)

**Subject:** Re: Pharmacy update

(b)(5)

Thanks so much.

Sent from my iPhone

On Jan 29, 2021, at 12:11 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

(b)(5)

**From:** Sackner-Bernstein, Sonya E. EOP/WHO

**Sent:** Friday, January 29, 2021 12:11 PM

**To:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <[nar5@cdc.gov](mailto:nar5@cdc.gov)>; Dawn O'Connell ([dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)) <[dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)>

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO (b)(6)

Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <[FJR0@cdc.gov](mailto:FJR0@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>; Rowe, Courtney M. EOP/WHO (b)(6)

Quillian, Natalie H. EOP/WHO (b)(6)

**Subject:** RE: Pharmacy update

Thanks – (b)(5)

**From:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>

**Sent:** Friday, January 29, 2021 12:05 PM

**To:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6) Messonnier, Nancy (CDC/DDID/NCIRD/OD) <[nar5@cdc.gov](mailto:nar5@cdc.gov)>; Dawn O'Connell ([dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)) <[dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)>

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO (b)(6)

Jones, Christopher M. (CDC/DDNID/NCIPC/OD) <[FJR0@cdc.gov](mailto:FJR0@cdc.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Schuchat, Anne MD (CDC/OD) <[acs1@cdc.gov](mailto:acs1@cdc.gov)>

**Subject:** Pharmacy update

**Importance:** High

Hi Sonya –

(b)(5)

(b)(5)

*COVID-19 Vaccine Task Force*

Thanks, Sherri

---

**From:** Sackner-Bernstein, Sonya E. EOP/WHO (b)(6)  
**Sent:** Friday, January 29, 2021 11:37 AM  
**To:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>; Messonnier, Nancy (CDC/DDID/NCIRD/OD) <[nar5@cdc.gov](mailto:nar5@cdc.gov)>; Dawn O'Connell ([dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)) <[dawn.oconnell@hhs.gov](mailto:dawn.oconnell@hhs.gov)>  
**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Choucair, Bechara EOP/WHO (b)(6)  
**Subject:** pharmacy

Hi, (b)(5)

Sonya Bernstein

(b)(6) (cell)



## RE: Material for 7pm prep

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Woodcock, Janet (FDA/OC)" <janet.woodcock@fda.hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "O'Connell, Dawn (OS/ASPR/IO)" <dawn.oconnell@hhs.gov>  
**Cc:** "Anderson, Charlie D. EOP/WHO" (b)(6) "Rowe, Courtney M. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Fitzpatrick, Kelsey V. EOP/WHO" (b)(6)  
**Date:** Wed, 03 Nov 2021 19:30:57 -0400

---

Thanks again (b)(5)  
(b)(5) -Ben

(b)(5)



(b)(5)

**From:** Wakana, Benjamin L. EOP/WHO

**Sent:** Wednesday, November 3, 2021 6:34 PM

**To:** janet.woodcock@fda.hhs.gov; 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) Rochelle Walensky <aux7@cdc.gov>; O'Connell, Dawn (OS/ASPR/IO) <Dawn.Oconnell@hhs.gov>

**Cc:** Anderson, Charlie D. EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Fitzpatrick, Kelsey V. EOP/WHO (b)(6)

**Subject:** Material for 7pm prep

Hi, (b)(5)

(b)(5)

(b)(5)

Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

## RE: NEA Follow up items

---

**From:** "Johnson, Carole A. EOP/WHO" (b)(6)  
**To:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "O'Connell, Dawn (HHS/IOS)" <dawn.oconnell@hhs.gov>  
**Date:** Wed, 03 Feb 2021 12:54:33 -0500

---

(b)(5)  
(b)(5) Thanks

---

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Wednesday, February 3, 2021 12:41 PM  
**To:** Johnson, Carole A. EOP/WHO (b)(6); Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>  
**Subject:** RE: NEA Follow up items

Thanks Carole, I will share the feedback with the CDC team. Do we have a few more meetings to schedule this week for you/Rochelle? I sent you a separate note, re: 6PM. Thanks again, Sherri

---

**From:** Johnson, Carole A. EOP/WHO (b)(5)  
**Sent:** Wednesday, February 3, 2021 12:09 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; O'Connell, Dawn (HHS/IOS) <Dawn.Oconnell@hhs.gov>  
**Subject:** FW: NEA Follow up items

Rochelle – Below is the follow-up email from our NEA call. Txs, Carole

---

**From:** Bilal-Threats, Daaiyah [NEA] <DBilal@nea.org>  
**Sent:** Tuesday, February 2, 2021 7:57 PM  
**To:** Sharma, Vidur K. EOP/WHO (b)(6)  
**Cc:** Pugh, Carrie [NEA-CAO-CE] <CPugh@nea.org>; Bilal-Threats, Daaiyah [NEA] <DBilal@nea.org>; Johnson, Carole A. EOP/WHO (b)(6); Tracey-Mooney, Maureen EOP/WHO (b)(6)  
**Subject:** [EXTERNAL] FW: NEA Follow up items

Thank you all again for the invitation to meet and exchange ideas yesterday.

As promised we are following up with a brief summary of the priority items and questions Becky laid out on the call along with a list of a few places where labor management collaboration has helped lay an important foundation for the union and district leaders to solve problems together.

- A timeline for, and a set of clear, prescriptive guidance that includes criteria for in-person learning and other school engagements and factors in both community transmission rates and school-based transmission;
- Transparency about COVID-19 vaccine production, distribution, and timelines for availability, and a strong call to prioritize educations for vaccines as part of any plan for in-person instruction;
- Continuing to protect high-risk educators, students, and family members by encouraging the provision of reasonable accommodations and paid leave;
- Collection and public availability of information on COVID-19 cases in schools and on school-based compliance with mitigation guidelines;
- Recognition that widespread, rapid, free, and equitably distributed COVID-19 testing is a crucial component of plans for in-person instruction and that, in order to be effective and to build trust among educators, students, and parents, it must be accompanied by policies that emphasize transparency, confidentiality, and clear procedures for responding to positive cases, clusters, and increased positivity rates in schools;
- Attention to racial and socioeconomic equity and rural/urban differences at every stage of COVID-19 policy development and action;
- In addition to detail on all necessary mitigation strategies for all routes of transmission (airborne, aerosol, droplet, and contact), more detail on ventilation-related mitigation strategies, including but not limited to specific situations like special education and high-risk areas like COVID-19 isolation rooms, nurses' offices, and bathrooms;
- As part of information on necessary mitigation strategies, clear directives for universal mask-wearing for all staff and, for those who are developmentally able to wear them, all students; clear guidance that any period of time in which

students or staff are not masked poses risks of COVID-19 transmission; and clear directives that distancing of students and staff throughout the day are necessary to protect the safety of both;

- Inclusion of all educators—teachers, education support professionals, and specialized instructional support personnel, and their unions—in the planning, execution, and follow-up to COVID-19 plans, including collective bargaining when available.

We look forward to future conversations and opportunities to work together. We would welcome a staff level discussion on hot spots and we would also like to follow up on Becky's offer for Dr Walensky to do a future teletownhall with our members.

Please feel free to contact me (Daaiyah) or Carrie Pugh if you have questions, or to follow up on any of the items we covered.

-Daaiyah

Daaiyah Bilal-Threats  
Safe and Just School Reopening Lead

# RE: COVID Tough QA

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Collins, Francis (NIH/OD) [E]" (b)(6), "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6), "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6), "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6), "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6), "Sanchez-Velasco, Marissa EOP/WHO" (b)(6), "Cheema, Subhan N. EOP/WHO" (b)(6), "Munoz, Kevin A. EOP/WHO" (b)(6), "Berner, Kate K. EOP/WHO" (b)(6), "Saez, Mariel S. EOP/WHO" (b)(6), "Folkers, Greg (NIH/NIAID) [E]" (b)(6)  
**Date:** Mon, 02 Aug 2021 07:00:57 -0400

(b)(5)

(b)(5)

**From:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>

**Sent:** Monday, August 2, 2021 5:38 AM

**To:** Collins, Francis (NIH/OD) [E] (b)(6), Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Wakana, Benjamin L. EOP/WHO (b)(6), Fauci, Anthony (NIH/NIAID) [E] (b)(6), Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6), Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Billet, Courtney (NIH/NIAID) [E] (b)(6), Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Myles, Renate (NIH/OD) [E] (b)(6), Sanchez-Velasco, Marissa EOP/WHO (b)(6)

(b)(6), Cheema, Subhan N. EOP/WHO (b)(6), Munoz, Kevin A. EOP/WHO (b)(6), Berner, Kate K. EOP/WHO (b)(6), Saez, Mariel S. EOP/WHO (b)(6), Folkers, Greg (NIH/NIAID) [E] (b)(6)

**Subject:** Re: COVID Tough QA

Hi all,

(b)(5)

Regards

Abbigail

**From:** Collins, Francis (NIH/OD) [E] (b)(6)

**Sent:** Monday, August 2, 2021 5:33 AM

**To:** Murthy, Vivek (HHS/OASH); Wakana, Benjamin (who.eop.gov); Fauci, Anthony (NIH/NIAID) [E]; Walensky, Rochelle (CDC/OD)

**Cc:** Rowe, Courtney (who.eop.gov); Sams, Ian (HHS/ASPA); Billet, Courtney (NIH/NIAID) [E]; Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD); Phillips, Alexandria (HHS/OASH); Myles, Renate (NIH/OD) [E]; Sanchez-Velasco, Marissa EOP/WHO; Cheema, Subhan N. EOP/WHO; Kevin.Munoz; Berner, Kate K. EOP/WHO; Saez, Mariel S. EOP/WHO; Folkers, Greg (NIH/NIAID) [E]

**Subject:** RE: COVID Tough QA

(b)(6)

Francis

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>

**Sent:** Monday, August 2, 2021 12:36 AM

**To:** Wakana, Benjamin (who.eop.gov) (b)(6) Fauci, Anthony (NIH/NIAID) [E]

(b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Collins, Francis (NIH/OD) [E]

(b)(6)

**Cc:** Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;

Billet, Courtney (NIH/NIAID) [E] (b)(6) Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@CDC.GOV>;

Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Myles, Renate (NIH/OD) [E] (b)(6)

Sanchez-Velasco, Marissa EOP/WHO (b)(6) Cheema, Subhan N. EOP/WHO

(b)(6) Kevin.Munoz (b)(6) Berner, Kate K. EOP/WHO

(b)(6) Saez, Mariel S. EOP/WHO (b)(6) Folkers, Greg (NIH/NIAID)

[E] (b)(6)  
**Subject:** Re: COVID Tough QA

Thanks Ben (b)(6)

(b)(6)

(b)(6)

**From:** Wakana, Benjamin L. EOP/WHO (b)(6)

**Sent:** Sunday, August 1, 2021 11:16 PM

**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy,

Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Collins, Francis (NIH/OD) [E] (b)(6)

**Cc:** Rowe, Courtney (who.eop.gov) (b)(6) Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>;

Billet, Courtney (NIH/NIAID) [E] (b)(6) Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)

<aws8@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>; Myles, Renate (NIH/OD) [E]

(b)(6) Sanchez-Velasco, Marissa EOP/WHO (b)(6) Cheema,

Subhan N. EOP/WHO (b)(6) Kevin.Munoz (b)(6) Berner, Kate

K. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6) Folkers,

Greg (NIH/NIAID) [E] (b)(6)  
**Subject:** COVID Tough QA

Hi all, (b)(6)

(b)(6)

Many thanks,  
Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)

# RE: CLIPS I J&J Announcement and Morning News

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Munoz, Kevin EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Rowe, Courtney M. EOP/WHO" (b)(6) "Sanchez-Velasco, Marissa EOP/WHO" (b)(6)  
**Date:** Wed, 24 Feb 2021 10:22:26 -0500

(b)(5)

**From:** Sanchez-Velasco, Marissa EOP/WHO  
**Sent:** Wednesday, February 24, 2021 9:53 AM  
**To:** DL EOP COVID All Staff <DL.EOP.COVIDAllStaff@eop.gov>  
**Cc:** Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** CLIPS I J&J Announcement and Morning News

(b)(5)

## J&J

[Jeremy Diamond/CNN](#): The most important topline from the FDA's review of the Johnson & Johnson vaccine are this: The vaccine was shown to be 86% effective in preventing severe Covid-19 disease in the United States.

[Eric Strauss/ABC News health](#): NEW: J&J single-dose safe & effective at preventing severe illness & death according to FDA analysis. Public hearing Friday - authorization likely this weekend. 4M doses ready. 20M end of March. 100m in June via

[Sara Willna Ernst/TX local](#): The Johnson & Johnson vaccine could get authorized as early as Saturday reports @nytimes this morning. This is a big deal. It's only one-dose and no thawing needed. There won't be anymore stories of pulling random people off the street to prevent wasted doses with this one.

[Zain Chagla/professor](#): FDA Data set around J+J Vaccine Released. This is the hopeful vaccine that will change the world - knowing that a) storage requirements are amazing (2-8 degrees) and b) single dose regimen, which in LMIC is going to be great for mass vaccination. Some highlights

[Isaac Stanley-Becker/WaPo](#): J&J single-shot vaccine found to be safe and effective, completely preventing hospitalizations and deaths in large clinical trial. Supplies are sharply limited, with just 2 million doses going out to states next week.

[Dr. Nicole Saphier](#): TODAY: FDA review confirms safety and efficacy of single-shot J&J vaccine. Data is encouraging showing 85% efficacy 28 days after vaccination for severe disease & no deaths. In a smaller cohort it also appears to have high efficacy (87.8%) with blocking asymptomatic infection.

[Peter Baker/NYT](#): The one-shot Johnson & Johnson covid vaccine provides strong protection against severe disease and death and may reduce the spread of the virus by vaccinated people, according to new analyses posted online by the FDA.

[David Gelles/CNN](#): The FDA says the Johnson & Johnson Covid-19 vaccine meets the requirements for emergency use authorization This is a big deal because...IT'S A SINGLE DOSE VACCINE

[Thomas Bossert/ABC contributor](#): The FDA found the Johnson & Johnson Covid-19 vaccine "was 66.1% effective in preventing moderate to severe virus disease" in trials. That supports J&J's earlier claims. Good news. The more, the better. We are racing against variants gaining a foothold.



[Lisa Mirando/CNN](#): HUGE NEWS: FDA says the Johnson & Johnson Covid-19 vaccine has met the requirements for emergency use authorization. The efficacy of the J&J vaccine against moderate to severe/critical Covid-19 across all geographic areas was 66.9% at least 14 days after the (1/3)

NYT: [New analyses show Johnson & Johnson's one-dose vaccine works well.](#)

Washington Post: [FDA review confirms safety and efficacy of single-shot Johnson & Johnson coronavirus vaccine, especially against severe cases](#)

CNN: [Questions remain on J&J Covid-19 vaccine rollout as authorization decision approaches](#)

CNN: [FDA says Johnson & Johnson Covid-19 vaccine meets requirements for emergency use authorization](#)

Politico: [FDA says J&J single-dose shot prevents Covid](#)

ABC News: [Single-dose Johnson & Johnson vaccine effective against COVID-19 variants: Data](#)

CBS News: [Johnson & Johnson's single-dose vaccine is effective against COVID-19, FDA says](#)

NBC News: [Johnson & Johnson vaccine deemed safe and effective in documents released by FDA](#)

USA Today: [One-dose J&J COVID-19 vaccine meets criteria as safe and effective, FDA report finds](#)

Axios: [FDA analysis finds Johnson & Johnson COVID vaccine is safe and effective](#)

#### **Other News:**

Washington Post: [Becerra falls in line with Biden health policies at Senate confirmation hearing](#)

Reuters: [COVID-19 vaccine makers tell Congress U.S. supply will surge soon](#)

Bloomberg: [Biden Shelves Mass Mask Shipments In Favor of Targeted Push](#)

CNN: [New coronavirus variant spotted in California raises alarm](#)

Washington Post: [Coronavirus deaths fell by 20% last week, WHO says](#)

Newsweek: [Biden Administration Has Achieved Nearly 50% of COVID Vaccination Goal, Data Shows](#)

CBS News: [Biden targets diverse groups with vaccine hesitancy for COVID-19 funds](#)

Bloomberg: [Covid Death Outlook Improves as Drop in U.S. Exceeds Forecasts](#)

Washington Times: [U.S. leads in rolling out COVID-19 vaccine with 1 in 20 fully protected](#)

**RE: Prep for Meeting** (b)(5)

**From:** "Choucair, Bechara EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Smith, Marcella N. EOP/OSTP" (b)(6), "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Sun, 28 Feb 2021 11:47:52 -0500

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Sunday, February 28, 2021 11:32 AM  
**To:** Choucair, Bechara EOP/WHO (b)(6), Smith, Marcella N. EOP/OSTP (b)(6), Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** RE: Prep for Meeting (b)(5)

Thanks, Bechara,

(b)(5)

R

**From:** Choucair, Bechara EOP/WHO (b)(6)  
**Sent:** Sunday, February 28, 2021 11:28 AM  
**To:** Smith, Marcella N. EOP/OSTP (b)(6), Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** Prep for Meeting (b)(5)

Rochelle/Tony/Marcella- (b)(5)

(b)(5)

(b)(5)

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

# Vaccine Inequity

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6)  
**Date:** Fri, 05 Mar 2021 10:22:54 -0500

---

Hi, (b)(5)  
(b)(5)  
(b)(5)

(b)(5)

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

# RE: April 19th presser

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Slavitt, Andrew M. EOP/WHO" (b)(6) "Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Cheema, Subhan N. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Zients, Jeffrey D. EOP/WHO" (b)(6) "Wakana, Benjamin L. EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Munoz, Kevin EOP/WHO" (b)(6)  
**Date:** Sun, 18 Apr 2021 23:20:01 -0400

(b)(5)

(b)(5)

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Sunday, April 18, 2021 3:42 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Slavitt, Andrew M. EOP/WHO (b)(6) Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@CDC.GOV>; Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Billet, Courtney (NIH/NIAID) [E] (b)(6)  
**Cc:** Cheema, Subhan N. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Berner, Kate EOP/WHO (b)(6) Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** RE: April 19th presser

Courtney:

Thanks

(b)(5)

(b)(5)

Thanks,  
Tony

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Sunday, April 18, 2021 3:31 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) Tumpey, Abigail (CDC/DDPHSS/CSELS/OD) <aws8@CDC.GOV>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Billet, Courtney (NIH/NIAID) [E] (b)(6)  
**Cc:** Cheema, Subhan N. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Berner, Kate EOP/WHO (b)(6) Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** RE: April 19th presser

(b)(5)

**From:** Rowe, Courtney M. EOP/WHO  
**Sent:** Sunday, April 18, 2021 3:28 PM  
**To:** 'Walensky, Rochelle (CDC/OD)' <aux7@cdc.gov>; 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) 'aws8@cdc.gov' <aws8@cdc.gov>; 'Sams, Ian (HHS/ASPA)' <Ian.Sams@hhs.gov>; 'Billet, Courtney (NIH/NIAID) [E]' (b)(6)  
**Cc:** Cheema, Subhan N. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Berner, Kate EOP/WHO (b)(6) Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** RE: April 19th presser

(b)(5)

**From:** Rowe, Courtney M. EOP/WHO  
**Sent:** Saturday, April 17, 2021 4:10 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) 'aws8@cdc.gov' <aws8@cdc.gov>; Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Billet, Courtney (NIH/NIAID) [E] (b)(6)  
**Cc:** Cheema, Subhan N. EOP/WHO (b)(6) Quillian, Natalie H. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6) Berner, Kate EOP/WHO (b)(6) Munoz, Kevin EOP/WHO (b)(6)  
**Subject:** April 19th presser

Hi all- (b)(5)

(b)(5)

Thanks,  
Courtney

**RE: Prep for Meeting** (b)(5)

**From:** "Choucair, Bechara EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Sun, 28 Feb 2021 14:12:18 -0500

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Sunday, February 28, 2021 11:32 AM  
**To:** Choucair, Bechara EOP/WHO (b)(6) Smith, Marcella N. EOP/OSTP (b)(6)  
(b)(6) Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** RE: Prep for Meeting (b)(5)

Thanks, Bechara,

(b)(5)

R

**From:** Choucair, Bechara EOP/WHO (b)(6)  
**Sent:** Sunday, February 28, 2021 11:28 AM  
**To:** Smith, Marcella N. EOP/OSTP (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>;  
Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Cc:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Subject:** Prep for Meeting (b)(5)

Rochelle/Tony/Marcella- (b)(5)  
(b)(5)

(b)(5)

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)



## RE: Great job team

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Cc:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6); "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>  
**Date:** Wed, 18 Aug 2021 16:30:19 -0400

(b)(5)

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Wednesday, August 18, 2021 2:04 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6); Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Re: Great job team

I'll call you

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:34 PM  
**To:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** RE: Great job team

(b)(5)



**Céline Gounder, MD, ScM, FIDSA**

@celinegounder

· 57m

1/ A pleasure speaking with @nytimes's @apoorva\_nyc. [nytimes.com/2021/08/18/hea](https://nytimes.com/2021/08/18/hea) ... with @BillHanage & @EpiEllie I do not understand the urgency of giving the general population additional doses of COVID vaccine at this time. They remain highly protective vs hospitalization & death.

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Wednesday, August 18, 2021 1:27 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Re: Great job team

Excellent

On Aug 18, 2021, at 1:22 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Thanks Dr. Fauci

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:16 PM  
**To:** Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Rowe, Courtney M. EOP/WHO (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6) Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** RE: Great job team

(b)(5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)

National Institutes of Health  
Bethesda, MD 20892-2520

Phone: (b)(6)

FAX: (b)(6)

E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Sams, Ian (HHS/ASPA) <Ian.Sams@hhs.gov>

**Sent:** Wednesday, August 18, 2021 12:23 PM

**To:** Rowe, Courtney (who.eop.gov) (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6) Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>

**Subject:** Re: Great job team

Dr. Fauci (b)(5)

(b)(5)

On Aug 18, 2021, at 12:10 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Hi all- (b)(5)

(b)(5)

Thank you for everything!  
Courtney

# RE: Heartfelt congratulations on NAM!

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Hotez, Peter Jay" <hotez@bcm.edu>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6); "Collins, Francis (NIH/OD) [E]" (b)(6)  
"Choucair, Bechara N. EOP/WHO" (b)(6); "Awwad, David (NIH/NIAID) [C]" (b)(6)  
mto@umn.edu, "Offit, Paul" <offit@chop.edu>  
**Date:** Mon, 18 Oct 2021 14:28:51 -0400

Many thanks, Peter and all, for all of your collective wisdom and support in what we are doing every day...together.  
My best,  
Rochelle

**From:** Hotez, Peter Jay <hotez@bcm.edu>  
**Sent:** Monday, October 18, 2021 11:17 AM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Collins, Francis (NIH/OD) [E] (b)(6); Choucair, Bechara N. EOP/WHO (b)(6); Awwad, David (NIH/NIAID) [C] (b)(6); mto@umn.edu; Offit, Paul <OFFIT@chop.edu>  
**Subject:** Heartfelt congratulations on NAM!

Well deserved congratulations to Drs Murthy and Walensky! Warmest regards Peter

<https://nam.edu/national-academy-of-medicine-elects-100-new-members-2021/>

## **Peter Hotez, MD, PhD, DSc (hon), FASTMH, FAAP**

Dean, [National School of Tropical Medicine](#)  
Professor, Departments of Pediatrics, Molecular Virology & Microbiology  
Health Policy Scholar  
Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics  
Co-Director, [Texas Children's Hospital Center for Vaccine Development](#)

University Professor, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study  
Senior Fellow, Scowcroft Institute of International Affairs  
Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University  
Adjunct Professor, University of Texas, School of Public Health

**Donate** to our [COVID-19 Vaccine Development](#)

E-mail: [hotez@bcm.edu](mailto:hotez@bcm.edu)  
Twitter: [@peterhotez](#)  
Skype: **p.hotez**  
LinkedIn [Peter Hotez](#)

Amazon Author Center: <https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48>  
Daily Beast Contributor <https://www.thedailybeast.com/author/peter-j-hotez>  
Like us on Facebook <https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/>

Senior Coordinator / Executive Support: [Douglas Soriano](#)  
[Douglas.SorianoOsejo@bcm.edu](mailto:Douglas.SorianoOsejo@bcm.edu)  
Phone: [713-798-1199](tel:713-798-1199)  
Fax: 713-798-2299



iPhone

On Oct 12, 2021, at 2:19 PM, Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)> wrote:

\*\*\*CAUTION:\*\*\* This email is not from a BCM Source. Only click links or open attachments you know are safe.

Topic: Vivek Murthy's Personal Meeting Room

Join ZoomGov Meeting

(b)(6)

Meeting ID: (b)(6)

One tap mobile

(b)(6) US (San Jose)  
(b)(6) US (New York)

Dial by your location

(b)(6)

Meeting ID: (b)(6)

Find your local number: (b)(5)

(b)(6)

Join by SIP

(b)(6)

Join by H.323

161.199.138.10 (US West)

161.199.136.10 (US East)

Meeting ID: (b)(6)

Vivek Murthy is inviting you to a scheduled ZoomGov meeting.

<meeting.ics>

## RE: Messaging guidance on J&J unpause

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>  
**Cc:** "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Wakana, Benjamin (who.eop.gov)"  
(b)(6)  
**Date:** Sat, 24 Apr 2021 11:02:15 -0400

---

Ian,

(b)(5)

Appreciated,  
Rochelle

---

**From:** Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>  
**Sent:** Saturday, April 24, 2021 10:57 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>  
**Cc:** Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD) <aws8@cdc.gov>; Wakana, Benjamin (who.eop.gov)  
(b)(6)  
**Subject:** Messaging guidance on J&J unpause

Hey Drs. Walensky and Schuchat –

(b)(5)

Thank you

Ian

--

**Ian Sams**  
Deputy Assistant Secretary for Public Affairs (COVID Response)  
Office of the Assistant Secretary for Public Affairs  
U.S. Department of Health and Human Services  
(202) 740-7169  
[ian.sams@hhs.gov](mailto:ian.sams@hhs.gov)

## Re: Great job team

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Zients, Jeffrey D. EOP/WHO" (b)(6), "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>  
**Date:** Wed, 18 Aug 2021 18:12:35 -0400

---

Thank you!!

Sent from my iPhone

On Aug 18, 2021, at 6:11 PM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

(b)(5)

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Wednesday, August 18, 2021 4:30 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** RE: Great job team

(b)(5)

---

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Wednesday, August 18, 2021 2:04 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6); Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Re: Great job team

I'll call you

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:34 PM  
**To:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** RE: Great job team

(b)(5)

<image001.jpg>

**Céline Gounder, MD, ScM, FIDSA**

@celinegounder

· 57m

1/ A pleasure speaking with @nytimes's @apoorva\_nyc. <https://nytimes.com/2021/08/18/health/cdc-boosters.html> with @BillHanage & @EpiEllie I do not understand the urgency of giving the general population additional doses of COVID vaccine at this time. They remain highly protective vs hospitalization & death.

---

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Wednesday, August 18, 2021 1:27 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** Re: Great job team

Excellent

On Aug 18, 2021, at 1:22 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Thanks Dr. Fauci

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:16 PM  
**To:** Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>; Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Zients, Jeffrey D. EOP/WHO (b)(6); Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** RE: Great job team

(b)(5)

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)

National Institutes of Health  
Bethesda, MD 20892-2520



Phone: (b)(6)  
FAX: (b)(6)  
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Sams, Ian (HHS/ASPA) <[lan.Sams@hhs.gov](mailto:lan.Sams@hhs.gov)>  
**Sent:** Wednesday, August 18, 2021 12:23 PM  
**To:** Rowe, Courtney (who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Zients, Jeffrey D. EOP/WHO (b)(6)  
(b)(6) Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** Re: Great job team

Dr. Fauci, (b)(5)  
(b)(5)

On Aug 18, 2021, at 12:10 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Hi all (b)(5)

(b)(5)

Thank you for everything!  
Courtney



# Re: Great job team

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>  
**Date:** Wed, 18 Aug 2021 20:04:36 -0400

Thank you!!

Sent from my iPhone

On Aug 18, 2021, at 7:44 PM, Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov> wrote:

(b)(5)

Sent from my iPhone

On Aug 18, 2021, at 6:13 PM, Zients, Jeffrey D. EOP/WHO (b)(6) wrote:

Thanks Dr F! Well done. JZ

On Aug 18, 2021, at 6:11 PM, Fauci, Anthony (NIH/NIAID) [E] (b)(6)

(b)(5)

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Wednesday, August 18, 2021 4:30 PM  
**To:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** RE: Great job team

(b)(5)

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Wednesday, August 18, 2021 2:04 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Sams, Ian (HHS/ASPA) <ian.sams@hhs.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Phillips, Alexandria (HHS/OASH) <Alexandria.Phillips@hhs.gov>  
**Subject:** Re: Great job team

I'll call you

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:34 PM  
**To:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** RE: Great job team

(b)(5)

<image001.jpg>

**Céline Gounder, MD, ScM, FIDSA**

@celinegounder

57m

1/ A pleasure speaking with @nytimes's @apoorva\_nyc. <https://nytimes.com/2021/08/18/health/cdc-boostershots.html> with @BillHanage & @EpiEllie I do not understand the urgency of giving the general population additional doses of COVID vaccine at this time. They remain highly protective vs hospitalization & death.

---

**From:** Zients, Jeffrey D. EOP/WHO  
**Sent:** Wednesday, August 18, 2021 1:27 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Fauci, Anthony (NIH/NIAID) [E] (b)(6); Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>; Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** Re: Great job team

Excellent

On Aug 18, 2021, at 1:22 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Thanks Dr. Fauci

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Wednesday, August 18, 2021 1:16 PM  
**To:** Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>; Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Zients, Jeffrey D. EOP/WHO (b)(6); Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>  
**Subject:** RE: Great job team

(b)(5)

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases

(b)(6)

National Institutes of Health  
Bethesda, MD 20892-2520

Phone: (b)(6)

FAX: (b)(6)

E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Sams, Ian (HHS/ASPA) <[lan.Sams@hhs.gov](mailto:lan.Sams@hhs.gov)>

**Sent:** Wednesday, August 18, 2021 12:23 PM

**To:** Rowe, Courtney (who.eop.gov) (b)(6)

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6)

Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>; Zients, Jeffrey D. EOP/WHO

(b)(6) Phillips, Alexandria (HHS/OASH) <[Alexandria.Phillips@hhs.gov](mailto:Alexandria.Phillips@hhs.gov)>

**Subject:** Re: Great job team

Dr. Fauci (b)(5)

(b)(5)

On Aug 18, 2021, at 12:10 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Hi all (b)(5)

(b)(5)

Thank you for everything!  
Courtney

## RE: CDC Weekly Data Check in

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Berger, Sherri (CDC/OD/OCS)" <sob8@cdc.gov>, "Goldstein, Robert (CDC/OD/OADPS)" <qyd2@cdc.gov>, "Mahon, Barbara (CDC/DDID/NCIRD/OD)" <bdm3@cdc.gov>, "Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>, "Masseti, Greta M. (CDC/DDNID/NCIPC/DVP)" <ghz6@cdc.gov>, "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Remley, Karen (CDC/DDNID/NCBDDD/OD)" <uxz0@cdc.gov>  
**Cc:** "Corley, Ronald D. (CDC/OCOO/OCIO/CEO) (CTR)" <hhj5@cdc.gov>, "Howe, Kristin (CDC/OCOO/OCIO/CEO) (CTR)" <lzu3@cdc.gov>  
**Date:** Sun, 02 Jan 2022 09:49:13 -0500

Hi all,

(b)(5)

Thank you,  
Cyrus

-----Original Appointment-----

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

**Sent:** Wednesday, November 10, 2021 9:51 AM

**To:** Walensky, Rochelle (CDC/OD); Shahpar, Cyrus G. EOP/WHO; Berger, Sherri (CDC/OD/OCS); Goldstein, Robert (CDC/OD/OADPS); Mahon, Barbara (CDC/DDID/NCIRD/OD); Salcido, Dorinda (Dori) (CDC/OD); Massetti, Greta M. (CDC/DDNID/NCIPC/DVP); Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD); Remley, Karen (CDC/DDNID/NCBDDD/OD)  
**Cc:** Corley, Ronald D. (CDC/OCOO/OCIO/CEO) (CTR); Howe, Kristin (CDC/OCOO/OCIO/CEO) (CTR)

**Subject:** CDC Weekly Data Check in

**When:** Monday, January 3, 2022 10:30 AM-11:00 AM (UTC-05:00) Eastern Time (US & Canada).

**Where:** (b)(6)

Hi there,

Lynn Gershman is inviting you to a scheduled Zoom meeting.

[Join Zoom Meeting](#)

One tap mobile: [redacted] (b)(6)

Meeting URL: [redacted] (b)(6)

Meeting ID: [redacted] (b)(6)  
Passcode: [redacted]

**Join by Telephone**

For higher quality, dial a number based on your current location.

Dial: [redacted] (b)(6)

Meeting ID: [redacted] (b)(6)

Passcode: [redacted] (b)(6) [redacted] (b)(5)

International numbers

**Join from an H.323/SIP room system**

H.323: [redacted]  
Meeting ID: [redacted]  
Passcode: [redacted] (b)(6)  
SIP: [redacted]  
Passcode: [redacted]

**Skype for Business (Lync)**

[redacted] (b)(6)

# RE: Potential Unreported Doses-STC/CDC next steps - Updated to Zoom

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**To:** "Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP)" <yzq5@cdc.gov>, Tiffany Dent <tiffany\_dent@stchome.com>, "Gibbs-Scharf, Lynn (CDC/DDID/NCIRD/ISD)" <lig1@cdc.gov>, "Sackner-Bernstein, Sonya E. EOP/WHO" (b)(6) "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Gershman, Lynn E. (CDC/OD/OCS)" <veu4@cdc.gov>, "Chang, Amy X. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Jarman-Miller, Hannah L. EOP/WHO" (b)(6) "Fitter, David L. (CDC/DDPHSS/CGH/GID)" <vid3@cdc.gov>, "Layden, Jennifer (CDC/DDPHSS/OS/OD)" <qbg5@cdc.gov>  
**Cc:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Srinivasan, Arunkumar (CDC/DDID/NCIRD/OD)" <fos2@cdc.gov>, "Martin, Tonya D. (CDC/DDID/OD)" <tdm4@cdc.gov>  
**Date:** Fri, 25 Jun 2021 17:52:55 -0400

Hi all,

(b)(5)

Thank you,  
Cyrus

-----Original Appointment-----

**From:** akn1@cdc.gov <akn1@cdc.gov> **On Behalf Of** Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP)  
**Sent:** Friday, June 25, 2021 6:09 AM  
**To:** Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP); Tiffany Dent; Gibbs-Scharf, Lynn (CDC/DDID/NCIRD/ISD); Sackner-Bernstein, Sonya E. EOP/WHO; Berger, Sherri (CDC/OCOO/OD); Gershman, Lynn E. (CDC/OD/OCS); Chang, Amy X. EOP/WHO; Quillian, Natalie H. EOP/WHO; Shahpar, Cyrus G. EOP/WHO; Fitter, David L. (CDC/DDPHSS/CGH/GID); Layden, Jennifer (CDC/DDPHSS/OS/OD); Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP)  
**Cc:** Walensky, Rochelle (CDC/OD); Srinivasan, Arunkumar (CDC/DDID/NCIRD/OD); Martin, Tonya D. (CDC/DDID/OD)  
**Subject:** Potential Unreported Doses-STC/CDC next steps - Updated to Zoom  
**When:** Friday, June 25, 2021 10:30 AM-11:00 AM (UTC-05:00) Eastern Time (US & Canada).  
**Where:** Microsoft Teams Meeting; >[## Updating to make this a Zoom Meeting](https://cdc.zoomgov.com/j/>(b)(6)</a><br/>pwd=cUoyVXVabIVBS2RGNktmeGNLIRDZz09&from=addon<</p></div><div data-bbox=)

(b)(5)

Demetre

**Special Assistant to the COVID-19 Deputy Incident Manager Vaccine Task Force**  
CDR Jemekia Thornton | Phone: (404) 718-8151 | Email: [akn1@cdc.gov](mailto:akn1@cdc.gov)



Hi there,

Jemekia Morris Thornton is inviting you to a scheduled Zoom meeting.


## [Join Zoom Meeting](#)

One tap mobile:

Meeting URL:

Meeting ID:

Passcode:




### **Join by Telephone**

For higher quality, dial a number based on your current location.

Dial:

Meeting ID:

Passcode:



[International numbers](#)

### **Join from an H.323/SIP room system**


H.323:

Meeting ID:

Passcode:

SIP:

Passcode:





## Re: Boosters story leaked

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>  
**Date:** Tue, 17 Aug 2021 08:56:11 -0400

---

Hi all- (b)(5)

Sent from my iPhone

On Aug 16, 2021, at 10:45 PM, Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Hi all- (b)(5)

(b)(5)

### ***U.S. to Advise Boosters for Most Americans 8 Months After Vaccination***

Nursing home residents and health care workers will most likely be the first to get booster shots, as soon as September, followed by other older people who were vaccinated last winter.

By [Sharon LaFraniere](#)

Aug. 16, 2021, 10:22 p.m. ET

WASHINGTON — The Biden administration has decided that most Americans should get a coronavirus booster shot eight months after they completed their initial vaccination, and could begin offering the extra shots as early as mid-September, according to two administration officials familiar with the discussions.

Officials are planning to announce the administration's decision as early as this week. Their goal is to let Americans know now that they will need additional protection against the Delta variant that is causing surging caseloads across the nation.

The first boosters are likely to go to nursing home residents and [health care workers](#), followed by other older people who were near the front of the line when vaccinations began late last year. Officials envision giving people the same

vaccine they originally received.

Among other worrisome signals, Biden administration officials are particularly concerned about data from Israel suggesting that the Pfizer-BioNTech's protection against severe disease has fallen significantly for elderly people who were vaccinated in January or February.

Some administration officials have viewed Israel as a kind of template for the United States because it started vaccinating its population sooner. Israel has almost exclusively used the Pfizer-BioNTech vaccine, and it has a nationalized health care system that allows it to systematically track patients.

The latest data from Israel, posted on the government's website on Monday, shows what some experts describe as continued erosion of the efficacy of the Pfizer vaccine over time — both against mild or asymptomatic Covid-19 infections in general and against severe disease among the elderly.

Washington Post story—

The Biden administration is planning to announce that all Americans who have received the coronavirus vaccine will need booster shots to combat waning immunity from the immunizations and the highly transmissible delta variant that is sparking a surge in covid-19 cases throughout the nation, according to four people familiar with the decision.

The administration's health and science experts are coalescing around the view that people will need the boosters eight months after they are fully vaccinated, according to the people who requested anonymity to discuss a decision not yet public. The decision is likely to be announced as soon as this week.

The actual administration of the boosters would not occur until mid- or late September, after Pfizer's application for additional shots for the general public is cleared by the Food and Drug Administration, the individuals said.

The conclusion that boosters will be broadly needed was reached after intense discussions last weekend involving high-ranking officials who scrutinized the latest data from the United States and other countries on the effectiveness of the shots.

The statement is a striking change from public statements by senior officials in recent months who had said it was far too soon to conclude that Americans would need booster shots. In July, the Centers for Disease Control and Prevention and the Food and Drug Administration put out an unusual statement that said: "Americans who have been fully vaccinated do not need a booster shot at this time." Officials have repeatedly said that it wasn't clear whether boosters would be needed.

# Pfizer talkers

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Collins, Francis (NIH/OD) [E]" (b)(6)  
"Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO"  
(b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Munoz, Kevin A.  
EOP/WHO" (b)(6) "Wakana, Benjamin L. EOP/WHO"  
(b)(6) "Cheema, Subhan N. EOP/WHO" (b)(6)  
"Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]"  
(b)(6) "Myles, Renate (NIH/OD) [E]" (b)(6)  
**Date:** Fri, 17 Dec 2021 14:08:10 -0500

---

Hi all- (b)(5)

(b)(5)

## FW: Package of materials

---

**From:** "Choucair, Bechara N. EOP/WHO" [REDACTED]  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED]  
**Date:** Wed, 21 Jul 2021 18:33:09 -0400  
**Attachments:** AHAAAdvisoryandStatementMandatoryCOVID-19Vaccination07-21-21final.pdf (712.53 kB); Proposed AHA Policy Statement on Mandatory COVID\_2021-07-14.pdf (742.68 kB)

---

Here's the AHA statement from earlier today. Adopted unanimously by their board, in favor of hospitals and health systems mandating the vaccine to health care workers.

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

[REDACTED]

---

**From:** Hood, Michelle <mhood@aha.org>  
**Sent:** Wednesday, July 21, 2021 4:36 PM  
**To:** Choucair, Bechara N. EOP/WHO [REDACTED]  
**Cc:** Siegel, Jared P. EOP/OMB [REDACTED] Bash, Robyn <rbash@aha.org>  
**Subject:** [EXTERNAL] Package of materials

As I mentioned earlier in the week, our Board is meeting this week and we took up the issue of our vaccination position statement. The attached was passed unanimously and a communication cascade has begun, with the press release scheduled sometime after 4 P ET today. Wanted you to have a heads up.

*M. Michelle Hood, FACHE  
Executive Vice President and Chief Operating Officer  
American Hospital Association  
mhood@aha.org*

## RE: a few tough qs

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Cc:** "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Mon, 16 Aug 2021 18:41:50 -0400

---

(b)(5)

Rochelle

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
**Sent:** Monday, August 16, 2021 6:34 PM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Rowe, Courtney M. EOP/WHO (b)(6)  
Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Cc:** Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>  
**Subject:** RE: a few tough qs

Rochelle:

(b)(5)

Tony

---

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Monday, August 16, 2021 11:14 AM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Fauci, Anthony (NIH/NIAID) [E] (b)(6)  
Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Cc:** Sams, Ian (HHS/ASPA) <ian.Sams@hhs.gov>  
**Subject:** RE: a few tough qs

Some thoughts:

(b)(5)

R

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6)  
**Sent:** Monday, August 16, 2021 9:29 AM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>; Fauci, Anthony (NIH/NIAID) [E] <(b)(6)>; Murthy, Vivek (HHS/OASH) <[Vivek.Murthy@hhs.gov](mailto:Vivek.Murthy@hhs.gov)>  
**Cc:** Sams, Ian (HHS/ASPA) <[Ian.Sams@hhs.gov](mailto:Ian.Sams@hhs.gov)>  
**Subject:** a few tough qs

(b)(5)

## Fwd: [EXTERNAL] thank you

**From:** "Choucair, Bechara N. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
Vivek Murthy <vivek.murthy@hhs.gov>, Marcella Nunez-Smith (b)(6)  
**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Fri, 06 Aug 2021 16:57:17 -0400

Marc is the CEO at Houston Methodist and the chair of the board of Texas Hospital Association. (b)(5)

(b)(5)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

Sent from my iPhone

Begin forwarded message:

**From:** "Boom, Marc L., M.D." <MBOOM@houstonmethodist.org>

**Date:** August 6, 2021 at 12:40:54 PM CDT

**To:** "Choucair, Bechara N. EOP/WHO" (b)(6)

**Subject:** [EXTERNAL] thank you

Dr. Choucair,

Thank you so much for coming to the THA to discuss vaccines. It was great to hear of your BCM connection for your residency and consequently your connection to Houston Methodist. I (once upon a time) got my MD from BCM.

I really appreciate your willingness to discuss openly and frankly the challenges regarding vaccination campaigns and the issues facing hospitals today.

Thanks for your mention of Houston Methodist's leadership position in mandating vaccines. I wish many more hospitals had followed our lead months ago, but it is gratifying to see so many move quickly now.

Any time Houston Methodist physicians/scientists and/or I can be helpful, please let me know. We have worked hard to be leaders in the community and across the country in COVID-19 response. We were first in the country to use convalescent plasma, the first hospital system in the country to mandate vaccine for employees, we have given more vaccines than anywhere else in the state of Texas (843K and counting), we have provided more monoclonal antibody infusions than anywhere else in Texas (and published in NEJM Catalyst as well as serving as one of three national institutions the Biden administration looked to as best practices for mAb), and we do essentially all of the sequencing of COVID-19 in the greater Houston community (over 50,000 sequences and counting). We have cared for over 19,000 inpatients with COVID-19 so far.

Finally, I'd like to reiterate a couple of my suggestions/requests:

1. I would encourage the federal government to get really creative with a combination of incentives, disincentives (meaning things that require vaccination to access), and mandates to get more of the population vaccinated. I speak from experience that the combination works. I also speak from experience that it takes firm resolve and a willingness to take some criticism. But, in the end, saving lives is the most important responsibility for everyone in a leadership position.
2. I know there is a firewall with the FDA, but nonetheless, we would love the message to get conveyed that the front lines are incredibly frustrated with the FDA's slow pace. Almost 200M doses of Pfizer have been administered. We are seeing many of our most vulnerable patients (transplant, cancer, etc) with inadequate antibody responses. Our hands are tied in terms of our ability to do what we know is right, which is to give a booster. To me, it is inexplicable that the FDA has not at least expanded the EUA for booster shots for the highest risk individuals. This should have happened weeks ago.

3. At Houston Methodist, we have been looking very closely at the data of who is admitted. 82.5% are unvaccinated with an average age of 51. 17.5% are vaccinated with an average age of 69. The older the age band, the higher the proportion of vaccinated individuals. That is from some combination of three factors: i) in the older groups, the denominator of vaccinated individuals is much larger, ii) we know that older individuals mount a smaller immune response, and iii) immunity wanes over time. We are without a doubt seeing front line, real world evidence of waning immunity. Just as the countries of Israel, Germany, and France have done, the time to begin authorizing (either through EUA specifically or with full approval which would allow off-label usage) boosters is NOW!! We have the sad situation where the most vulnerable rushed to do the right thing and got vaccinated earlier, which worked well for previous variants. Now we have a mostly-avoidable (there would have been some surge from delta, but not like this had more people been vaccinated) surge that is largely the result of the unvaccinated, and we are seeing the most vulnerable with waning immunity at exactly the wrong time against this more infectious variant. I fully recognize we don't have full data, but we're in a pandemic, and this is the time for common sense.
4. People are taking matters into their own hands because they have the common sense to do so. They go to different sites and fib about whether or not they've had previous vaccines. Clinicians are put in an impossible position when asked about this by patients. We can't collect the data and the most educated, wealthiest individuals do this while less-educated, underserved citizens likely do not at the same rate, so we face yet another potential exacerbation of inequities. An EUA expansion to allow boosters or full FDA approval would help mitigate the inequities and would allow all of us to track the necessary data to understand who has received boosters, etc. Most importantly, we can ensure optimal protection of the most vulnerable.

Thanks for hearing me out. I know my recommendations are pretty direct, but they're intended in a collaborative manner to do the best thing for our country. I'm always happy to discuss with anyone you'd like to connect me with. I can be reached at this email or my office phone below. My cell is (b)(6) and please feel free to call me 24/7/365 if I can be helpful.

Again, thank you for your hard work and leadership in helping our country through this pandemic. It is really great to see someone with strong Houston, BCM, and Houston Methodist ties be so successful and make such a meaningful difference.

## Marc

Marc L. Boom, M.D.  
President and Chief Executive Officer  
Ella Fondren and Josie Roberts Presidential Distinguished Centennial Chair  
Houston Methodist  
[mboom@houstonmethodist.org](mailto:mboom@houstonmethodist.org)  
713.441.2671

Houston Methodist. Leading Medicine.

*U.S. News & World Report* has named Houston Methodist Hospital the Best Hospital in Texas for 10 years in a row. Houston Methodist is the No. 1 hospital in Texas and No. 16 in the nation. For more than 100 years, Houston Methodist has provided the best — and safest — clinical care, advanced technology and patient experience. That is our promise of leading medicine.

[houstonmethodist.org](http://houstonmethodist.org)  
[twitter.com/MethodistHosp](https://twitter.com/MethodistHosp)  
[facebook.com/HoustonMethodist](https://facebook.com/HoustonMethodist)

\*\*\*CONFIDENTIALITY NOTICE\*\*\* This e-mail is the property of Houston Methodist and/or its relevant affiliates and may contain restricted and privileged material for the sole use of the intended recipient(s). Any review, use, distribution or disclosure by others is strictly prohibited. If you are not the intended recipient (or authorized to receive for the recipient), please contact the sender and delete all copies of the message. Thank you.



## Business Insider-- Some experts who had Johnson & Johnson's single-dose vaccine are now getting extra shots of Pfizer or Moderna to try to protect against the Delta variant

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Choucair, Bechara N. EOP/WHO" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" <marcella.nunez-smith@hhs.gov>, "Zients, Jeffrey D. EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6)  
**Cc:** "Hussain, Farhana P. EOP/WHO" (b)(6)  
**Date:** Mon, 28 Jun 2021 17:39:33 -0400

---

(b)(5)

## Some experts who had Johnson & Johnson's single-dose vaccine are now getting extra shots of Pfizer or Moderna to try to protect against the Delta variant

### Dr. Catherine Schuster-Bruce

Some experts who got Johnson & Johnson's one-dose vaccine are trying an extra shot of Moderna's or Pfizer's vaccine to try to protect against the [fast-spreading](#) Delta coronavirus variant.

Officials have not recommended getting a booster shot after J&J's vaccine or any other vaccine, and two experts said everyone should wait for more data.

Angela Rasmussen, a virologist at the University of Saskatchewan, [tweeted on Tuesday](#) that she got the Pfizer vaccine to "top off" the J&J vaccine she received in April.

Rasmussen said that the rise of the [Delta variant in the UK](#) — where more than 95% of new infections are caused by Delta — showed the "crucial importance" of getting as many people vaccinated as possible.

Rasmussen said that we don't know whether an extra vaccine dose after a J&J shot boosts protection against variants, and neither the Food and Drug Administration nor the Centers for Disease Control and Prevention has made any recommendations. But it was likely to work, she said, given that boosters work for nearly every other vaccine in use.

"We shouldn't wait to make recommendations about this," she said.

Rasmussen encouraged people who'd had J&J's shot, especially those living in communities with low vaccination rates, to speak with healthcare providers about getting an extra dose.

Dr. Anthony Fauci, President Joe Biden's chief medical adviser, [said on Wednesday](#) that the Delta variant accounted for more than 20% of new infections in the US and was the "greatest threat" to the nation's efforts to eradicate COVID-19.

There's no data on how well J&J's vaccine works against the Delta variant. More than 9 million Americans have been given the single-dose vaccine, the [CDC said](#).

Jason Gallagher, a clinical professor in infectious diseases at Temple University's School of Pharmacy, [told Reuters on Monday](#) that he got J&J's vaccine in a trial in November, and recently had a dose of Pfizer-BioNTech's COVID-19 vaccine.

Gallagher said he was concerned [about data that suggested](#) that a single shot of either Pfizer's or AstraZeneca's vaccine was only 33% effective against symptomatic COVID-19 caused by the Delta variant. "So I took the plunge," he said.

Professor Peter Hotez, the dean of the National School of Tropical Medicine at Baylor College of Medicine, [tweeted on Thursday](#) that adding a second J&J dose, or an extra shot of Pfizer's or Moderna's vaccine, could provide broader protection against variants, "but we need data and CDC-FDA guidance."

Dr. John Beigel, an associate director for clinical research at the National Institute of Allergy and Infectious Disease, [told Reuters on Monday](#) that J&J recipients should wait for more data.

Due Outs from (b)(5) Discussion - Monday (12/13)

**From:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**To:** "Rice, Susan E. EOP/WHO" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, miguel.cardona@ed.gov, xb78@hhs.gov, "Martin, Carmel M. EOP/WHO" (b)(6) "Tracey-Mooney, Maureen EOP/WHO" (b)(6) "Quillian, Natalie H. EOP/WHO" (b)(6) "Masseti, Greta M. (CDC/DDNID/NCIPC/DVP)" <ghz6@cdc.gov>, "Meadvin, Hayley" <hayley.meadvin@ed.gov>, "O'Connell, Dawn (OS/ASPR/IO)" <dawn.oconnell@hhs.gov>, "Wall, Mary C. EOP/WHO" (b)(6)  
**Cc:** "Hussain, Farhana P. EOP/WHO" (b)(6) "Berger, Sherri (CDC/OD/OCS)" <sob8@cdc.gov>, "Berger, Sherri (CDC/OD/OCS)" <sob8@cdc.gov>, "Gershman, Lynn E. (CDC/OD/OCS)" <veu4@cdc.gov>, "Murphy, Sarah (Maggie)" <maggie.murphy@ed.gov>, "Flores, Cristina" <crystina.flores@ed.gov>, "Williams, Bridget" <bridget.williams@ed.gov>, "Kwak, Grace J. EOP/WHO" (b)(6) "Orozco, Esmeralda (HHS/IOS)" <esmeralda.orozco@hhs.gov>, "Palafox, Cynthia (HHS/IOS)" <cynthia.palafox@hhs.gov>, "Czerwinski, William (OS/IOS)" <william.czerwinski@hhs.gov>, "Hart, Rio I. EOP/WHO" (b)(6) "Bousbar, Sabrina (OS/ASPR/IO)" <sabrina.bousbar@hhs.gov>  
**Date:** Tue, 14 Dec 2021 10:09:10 -0500

Team – thanks again (b)(5)  
(b)(5) Thanks, JZ

(b)(5)

-----Original Appointment-----

**From:** Hussain, Farhana P. EOP/WHO **On Behalf Of** Zients, Jeffrey D. EOP/WHO  
**Sent:** Sunday, December 5, 2021 1:42 PM  
**To:** Zients, Jeffrey D. EOP/WHO; Quillian, Natalie H. EOP/WHO; aux7@cdc.gov; Miguel.Cardona@ed.gov; Meadvin, Hayley; Rice, Susan E. EOP/WHO; Dawn.Oconnell@hhs.gov; Martin, Carmel M. EOP/WHO; ghz6@cdc.gov; Wall, Mary C. EOP/WHO  
**Cc:** sberger@cdc.gov; sob8@cdc.gov; Lynn Gershman (veu4@cdc.gov); Murphy, Sarah (Maggie); Flores, Cristina; Williams, Bridget; Kwak, Grace J. EOP/WHO; Hussain, Farhana P. EOP/WHO; Orozco, Esmeralda (HHS/IOS); Palafox, Cynthia (HHS/IOS); Czerwinski, William (OS/IOS); Hart, Rio I. EOP/WHO; Sabrina.Bousbar@hhs.gov; Maureen EOP/WHO Tracey-Mooney (b)(5)  
**Subject:** 11:30am VC (b)(5) Discussion  
**When:** Monday, December 13, 2021 11:30 AM-12:15 PM (UTC-05:00) Eastern Time (US & Canada).  
**Where:** [\(b\)\(6\)](https://pitc.zoomgov.com/j/(b)(6))

(b)(5)

(b)(5)

**MANIFEST**

Xavier Becerra

Dawn O'Connell

Miguel Cardona

Hayley Meadvin

Susan Rice

Carmel Martin

Rochelle Walensky

Greta Massetti

Jeffrey Zients

Natalie Quillian

Mary Wall

---

## COVAX/Global supply answers

---

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Slavitt, Andrew M. EOP/WHO" (b)(6) "Wakana, Benjamin L. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>  
**Date:** Mon, 22 Mar 2021 10:40:13 -0400

---

(b)(5)

(b)(5)

(b)(5)

(b)(5)

## CDC COVID-related MMWR Early Releases for Oct 29

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Thu, 28 Oct 2021 12:58:38 -0400  
**Attachments:** CDC COVID-related MMWR Early Releases for Oct 29, 2021.docx (50.22 kB)

---

Jeff,

(b)(5)

# RE: Today?

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Sat, 25 Dec 2021 08:54:57 -0500

---

(b)(5)

(b)(5)

(b)(5)

(b)(5)

---

**From:** Zients, Jeffrey D. EOP/WHO (b)(6)  
**Sent:** Saturday, December 25, 2021 8:04 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Today?

(b)(5)

**South Africa ends quarantines and contact tracing, and authorizes booster shots.** The South African health ministry said that asymptomatic individuals who had been in contact with a case of COVID-19 no longer had to isolate but should monitor for symptoms for 5-7 days and avoid attending large gatherings. Only those people who developed symptoms needed to get tested, the statement continued, adding that those with mild symptoms should isolate for eight days and severe cases for 10 days. All quarantine in facilities outside the home would be stopped, it continued, while contact tracing efforts would also be scrapped aside from in specific scenarios such as cluster outbreaks. Additionally, a booster shot of the Pfizer-BioNTech vaccine will be available starting on Tuesday for people who received their first dose at least six months ago or who are at higher risk for becoming severely ill. The South African authorities also authorized a booster shot for J&J.



# CDC COVID-related MMWR Early Release for Jan. 19

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Tue, 18 Jan 2022 17:24:18 -0500  
**Attachments:** CDC COVID-related MMWR Early Release for Jan 19 2022.docx (51.14 kB)

---

Jeff,

(b)(5)

Happy to chat further if you'd like.  
Best,  
Rochelle

## CDC Weekly Data Check in

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Berger, Sherri (CDC/OD/OCS)" <sob8@cdc.gov>, "Goldstein, Robert (CDC/OD)" <qyd2@cdc.gov>, "Mahon, Barbara (CDC/DDID/NCIRD/OD)" <bdm3@cdc.gov>, "Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>, "Masseti, Greta M. (CDC/DDNID/NCIPC/DVP)" <ghz6@cdc.gov>, "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Remley, Karen (CDC/DDNID/NCBDDD/OD)" <uxz0@cdc.gov>, "Lubar, Debra (CDC/DDID/NCEZID/OD)" <dpl9@cdc.gov>  
**Cc:** "Corley, Ronald D. (CDC/OCOO/OCIO/CEO) (CTR)" <hhj5@cdc.gov>, "Howe, Kristin (CDC/OCOO/OCIO/CEO) (CTR)" <lzu3@cdc.gov>  
**Date:** Mon, 17 Jan 2022 22:43:19 -0500

---

Hi all,

(b)(5)

Thank you,  
Cyrus

## RE: Your visit

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Mon, 15 Mar 2021 08:58:40 -0400

---

Great thank you. (b)(5)  
Cyrus

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Monday, March 15, 2021 5:38 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Shahpar, Cyrus EOP/WHO (b)(6)  
**Subject:** RE: Your visit

(b)(5)

Thanks

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Monday, March 15, 2021 7:57 AM  
**To:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Subject:** RE: Your visit

(b)(5)

R

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Monday, March 15, 2021 7:53 AM  
**To:** Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** RE: Your visit

Great!

(b)(5)

Thanks

**From:** Shahpar, Cyrus EOP/WHO (b)(6)  
**Sent:** Sunday, March 14, 2021 10:40 PM  
**To:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Subject:** RE: Your visit

(b)(5)

Thanks again,  
Cyrus

---

**From:** Berger, Sherri (CDC/OCOO/OD) <[sob8@cdc.gov](mailto:sob8@cdc.gov)>

**Sent:** Sunday, March 14, 2021 6:53 PM

**To:** Shahpar, Cyrus EOP/WHO (b)(5)

**Cc:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>

**Subject:** Your visit

Hi Cyrus – (b)(5)

(b)(5)

(b)(5)

? Thanks, Sherri

## FYI: Two COVID-19 science related docs

---

**From:** "Shahpar, Cyrus EOP/WHO" (b)(6)  
**To:** "Quillian, Natalie H. EOP/WHO" (b)(6) david.kessler@hhs.gov, "Schuchat, Anne MD (CDC/OD)" <acs1@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Choucair, Bechara EOP/WHO" (b)(6)  
**Date:** Sat, 13 Feb 2021 13:58:04 -0500

---

Hi all,  
FYI  
Cyrus

(b)(5)

(b)(5)

Cyrus

## Re: COVID Tough QA for Wednesday

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
"Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Smith, Marcella N. EOP/OSTP"  
(b)(6)  
**Date:** Wed, 10 Mar 2021 08:00:07 -0500

---

(b)(5)

<https://www.nytimes.com/live/2021/03/10/world/covid-19-coronavirus/biden-will-announce-he-intends-to-secure-another-100-million-doses-of-johnson-johnsons-vaccine>

### **Biden will announce he intends to secure another 100 million doses of Johnson & Johnson's vaccine.**

President Biden will announce on Wednesday that he intends to secure an additional 100 million doses of Johnson & Johnson's Covid-19 single-shot vaccine by the end of this year, with the goal of having enough on hand to vaccinate children and, if necessary, administer booster doses or reformulate the vaccine to combat emerging variants of the virus.

Mr. Biden will make the announcement during an afternoon meeting with executives from Johnson & Johnson and the pharmaceutical giant Merck, according to two senior administration officials. The rival companies are partnering to ramp up production of the Johnson & Johnson vaccine, in a deal brokered by the White House.

In announcing that agreement last week, [Mr. Biden said](#) that the United States would now have enough vaccine available by the end of May to vaccinate every American adult — roughly 260 million people. But the senior officials, who spoke on condition of anonymity to preview the president's announcement, said the administration was trying to prepare for unpredictable challenges, from the emergence of dangerous virus variants to manufacturing breakdowns that could disrupt vaccine production.

The officials said that they expected the doses to be delivered sometime in the second half of this year, but could not be more specific. They said Mr. Biden would direct officials at the Department of Health and Human Services to negotiate the details with Johnson & Johnson, and that Wednesday's announcement would be a first step.

The White House had initially intended to hold Wednesday's event at the Baltimore manufacturing facility of Emergent BioSolutions, another company that

partners with Johnson & Johnson to make coronavirus vaccine. But [Mr. Biden canceled his trip](#) after The New York Times published [an investigation](#) into how Emergent used its Washington connections to gain outsized influence over the Strategic National Stockpile, the nation's emergency repository of drugs and medical supplies.

The White House press secretary, Jen Psaki, has since said that the administration will conduct a comprehensive audit of the stockpile.

Emergent officials will not attend Wednesday's session. In explaining the change in plans, Ms. Psaki said that the administration thought the White House was a "more appropriate place to have the meeting," which it is billing as a celebration of what Mr. Biden has called the "historic" partnership between Johnson & Johnson and Merck.

The [administration says](#) the collaboration will increase manufacture of the vaccine itself, and will also bolster Johnson & Johnson's packaging capacity, known in the vaccine industry as "fill-finish" — two big bottlenecks that have put the company behind schedule.

Wednesday's announcement is in keeping with Mr. Biden's aggressive efforts to acquire as much vaccine supply as possible, as quickly as possible. Before Mr. Biden took office, he pledged to get ["100 million shots into the arms"](#) of the American people by his 100th day in office — a timetable that seemed aggressive at the time, but more recently has looked tame. He has been trying to speed it up ever since.

At the time, two vaccines — one made by Moderna and the other by Pfizer-BioNTech — had been authorized by the Food and Drug Administration for emergency use. [In January, Mr. Biden said](#) the administration would have enough vaccine to cover every American by the end of summer. Last month, the president announced his administration had secured enough doses from those two companies to have enough to cover every American [by the end of July](#).

The recent addition of the Johnson & Johnson vaccine, which received emergency authorization in late February, opened a path for the administration to move up the timetable yet again. But Johnson & Johnson and its other partners, including Emergent, were behind schedule, which prompted the administration to reach out to Merck

Hi, [redacted] (b)(5)  
[redacted] (b)(5)

[redacted] (b)(5)

[redacted] (b)(5)

Ben

+++

Ben Wakana

Deputy Director for Strategic Communications and Engagement

White House COVID Response Team

[redacted] (b)(6)

<Tough QA for COVID 3.9.21 11PM.docx>



**RE: Re:**

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Kessler, David (HHS/IOS)" <david.kessler@hhs.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Choucair, Bechara N. EOP/WHO" (b)(6) "Zients, Jeffrey D. EOP/WHO" (b)(6) natalie.h.quillian (eop.gov) (b)(6) "Shahpar, Cyrus (CDC who.eop.gov)" (b)(6)  
**Date:** Tue, 23 Nov 2021 15:44:45 -0500

Adding my gratitude for sending, David.  
R

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Tuesday, November 23, 2021 2:41 PM  
**To:** Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] <AFAUCI@niaid.nih.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara N. EOP/WHO (b)(6) (b)(6); Zients, Jeffrey D. EOP/WHO (b)(6) natalie.h.quillian (eop.gov) (b)(6) Shahpar, Cyrus (CDC who.eop.gov) (b)(6)  
**Subject:** Re: Re:

(b)(5)

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Tuesday, November 23, 2021 2:36 PM  
**To:** Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>; Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Choucair, Bechara N. EOP/WHO (b)(6) (b)(6); Zients, Jeffrey D. EOP/WHO (b)(6) natalie.h.quillian (eop.gov) (b)(6) Shahpar, Cyrus G. EOP/WHO (b)(6)  
**Subject:** Re:

very helpful, thanks David

**From:** Kessler, David (HHS/IOS) <David.Kessler@hhs.gov>  
**Sent:** Tuesday, November 23, 2021 10:31 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b)(6) Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>; Choucair, Bechara N. EOP/WHO (b)(6) (b)(6); Zients, Jeffrey D. EOP/WHO (b)(6) natalie.h.quillian (eop.gov) (b)(6) Shahpar, Cyrus G. EOP/WHO (b)(6)  
**Subject:**

(b)(5)

(b)(5)

# FW: Quantitative Brand Testing Results

**From:** "Rowe, Courtney M. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Peck, Joshua (HHS/ASPA)" <joshua.peck@hhs.gov>, "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>  
**Date:** Sat, 20 Feb 2021 11:53:35 -0500  
**Attachments:** HHS COVID-19 Brand Testing Findings 18 FEB 2021.pdf (2.63 MB)

Hi Dr. Walensky- (b)(5)

(b)(5)

Thanks and happy Saturday!  
Courtney

**From:** Peck, Joshua (HHS/ASPA) <Joshua.Peck@hhs.gov>  
**Sent:** Thursday, February 18, 2021 9:50 PM  
**To:** Rowe, Courtney M. EOP/WHO (b)(6) Dunn, Anita B. EOP/WHO (b)(6)  
**Cc:** Berner, Kate EOP/WHO (b)(6) Flaherty, Robert EOP/WHO (b)(6) Slavitt, Andrew M. EOP/WHO (b)(6) Webb, Cameron C. EOP/WHO (b)(6) Wakana, Benjamin L. EOP/WHO (b)(6)  
**Subject:** Quantitative Brand Testing Results

Hi all,

(b)(5)

JFAP

## CDC Weekly Data Check in

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Berger, Sherri (CDC/OD/OCS)" <sob8@cdc.gov>, "Goldstein, Robert (CDC/OD/OADPS)" <qyd2@cdc.gov>, "Mahon, Barbara (CDC/DDID/NCIRD/OD)" <bdm3@cdc.gov>, "Cohn, Amanda (CDC/DDNID/NCBDDD/DBDID)" <anc0@cdc.gov>, "Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>, "Braden, Chris (CDC/DDID/NCEZID/OD)" <crb5@cdc.gov>, "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Jarman-Miller, Hannah (CDC who.eop.gov)" (b)(6)  
**Cc:** "Corley, Ronald D. (CDC/OCOO/OCIO/CEO) (CTR)" <hhj5@cdc.gov>, "Howe, Kristin (CDC/OCOO/OCIO/CEO) (CTR)" <lzu3@cdc.gov>  
**Date:** Sun, 12 Dec 2021 18:07:07 -0500

---

Hi all,

(b)(5)

Thank you,  
Cyrus

# RE: Flagging

---

**From:** "Johnson, Carole A. EOP/WHO" (b)(6)  
**To:** "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "O'Connell, Dawn (OS/ASPR/IO)" <dawn.oconnell@hhs.gov>  
**Cc:** "Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI)" <mrh7@cdc.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Thu, 15 Jul 2021 08:54:19 -0400

---

Yes Thank you

---

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Thursday, July 15, 2021 8:52 AM  
**To:** Johnson, Carole A. EOP/WHO (b)(6) O'Connell, Dawn (OS/ASPR/IO) <Dawn.Oconnell@hhs.gov>  
**Cc:** Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Flagging

Good morning –

(b)(5)

Thanks,  
Sherri



~~~~~  
**Call for Cases: COVID-19 Cluster Associated with Travel to Provincetown, Massachusetts -- July 2021**

The Massachusetts DPH, in collaboration with CDC, is investigating a cluster of COVID-19 associated with travel to Provincetown, MA during the week beginning July 3. Over 20 cases from 7 jurisdictions have been identified to date; case characteristics include symptomatic, vaccine breakthrough disease. Please report cases with a travel history to Provincetown, MA since July 1 to the Massachusetts DPH at 617-983-6800 or by completing the attached spreadsheet and reporting through Epi-X.

><https://epix2.cdc.gov/v2/reports/display.aspx?id=380478><

~~~~~

# RE: COVID Tough QA

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6), "Slavitt, Andrew M. EOP/WHO" (b)(6), "Collins, Francis (NIH/OD) [E]" (b)(6), "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Smith, Marcella N. EOP/OSTP" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6), "Berner, Kate EOP/WHO" (b)(6), "Billet, Courtney (NIH/NIAID) [E]" (b)(6), "Munoz, Kevin EOP/WHO" (b)(6), "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Hall, Bill (HHS/ASPA)" <bill.hall@hhs.gov>, "Burklow, John (NIH/OD) [E]" <burklowj@od.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6), "Lesko, Max (HHS/OASH)" <max.lesko@hhs.gov>, "Cheema, Subhan N. EOP/WHO" (b)(6), "Saez, Mariel S. EOP/WHO" (b)(6), "Webb, Cameron C. EOP/WHO" (b)(6)  
**Date:** Fri, 23 Apr 2021 11:37:58 -0400  
**Attachments:** JZ Tough QA 04.23.21 1030AM.docx (54.8 kB)

Hi, (b)(5)  
(b)(5)  
Ben

**From:** Wakana, Benjamin L. EOP/WHO  
**Sent:** Thursday, April 22, 2021 9:12 PM  
**To:** 'Rochelle Walensky' <aux7@cdc.gov>; 'Fauci, Anthony (NIH/NIAID) [E]' (b)(6), Slavitt, Andrew M. EOP/WHO (b)(6), (b)(6), (b)(6), 'Murthy, Vivek (HHS/OASH)' <Vivek.Murthy@hhs.gov>; Smith, Marcella N. EOP/OSTP (b)(6)  
**Cc:** 'Courtney Rowe' (b)(6), Berner, Kate EOP/WHO (b)(6), (b)(6), Munoz, Kevin EOP/WHO (b)(6), 'Sams, Ian (HHS/ASPA)' <ian.sams@hhs.gov>; 'Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)' <aws8@cdc.gov>; 'Hall, Bill (HHS/ASPA)' <bill.hall@hhs.gov>; 'Burklow, John (NIH/OD) [E]' (b)(6), 'Myles, Renate (NIH/OD) [E]' (b)(6), 'Lesko, Max (HHS/OASH)' <Max.Lesko@hhs.gov>; Cheema, Subhan N. EOP/WHO (b)(6), Saez, Mariel S. EOP/WHO (b)(6), Webb, Cameron C. EOP/WHO (b)(6)  
**Subject:** COVID Tough QA

Hi (b)(5)  
(b)(5)  
(b)(5)  
Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

# Talking Points on COVID: January 20

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**Date:** Thu, 20 Jan 2022 06:39:33 -0500

---

Hi (b)(5)  
(b)(5)

(b)(5)

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

## Re: I found this interesting

---

**From:** "Quillian, Natalie H. EOP/WHO" [REDACTED] (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Cc:** "Zients, Jeffrey D. EOP/WHO" [REDACTED] (b)(6)  
**Date:** Tue, 21 Dec 2021 17:47:15 -0500

---

[REDACTED] (b)(5)

Sent from my iPhone

On Dec 21, 2021, at 10:09 AM, Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> wrote:

[REDACTED] (b)(5)

# RE: Global Vaccination

---

**From:** "Quillian, Natalie H. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Sun, 13 Jun 2021 19:51:25 -0400

---

Thanks. (b)(5)

(b)(5)

Thanks!  
N

---

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Sent:** Saturday, June 12, 2021 9:48 AM  
**To:** Quillian, Natalie H. EOP/WHO (b)(6)  
**Subject:** FW: Global Vaccination

Hi Natalie,

(b)(5)

Best,  
Rochelle

---

**From:** (b)(6)  
**Sent:** Monday, June 7, 2021 4:44 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Global Vaccination

Dear Dr Walensky,

I hope all is well at your end.

I am writing to you to share with you my high interest in working with you in any capacity that you deem suitable for vaccine allocation & distribution across the low income countries to secure equity and minimize disparities.

As a public health servant in a low income country, I have gained experience in leading the vaccination campaign in a resource depleted country by ensuring prioritization and equity. and ability to control the spread among the underprivileged and underserved communities.

Despite the minimal resources available in Lebanon, we have managed to vaccinate the most vulnerable and our covid hospitalization rates are lowest since pandemic.

I have been following the US news and the initiatives of the Biden administration and US house chamber on foreign affairs in relation to this topic. I have also been dealing with covax and unicef and WHO...unfortunately they haven't been up to the needed standard probably mainly related to the limited vaccine supply.

I am a US citizen and I believe that US can lead in saving many lives especially in low income countries and countries that are facing major outbreaks. Vaccine disparities have been something that is difficult to watch around the world especially when we can do something to decrease it.

If there is any available opportunity, I am interested in working with you in any capacity that you deem appropriate on this topic. I believe my experience in leading the covid response plan in a third world country that suffers from bankruptcy, major poverty, and financial collapse on top of the pandemic has provided me with unique expertise that might be beneficial when building a global vaccine management strategy.

Thanks for reading thru my email given how much you have on your plate.

Best Regards,

(b)(6)



## RE: Pre-decisional, deliberative budget information

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Mon, 07 Jun 2021 10:38:05 -0400

---

Hi Jeff,

(b)(5)

Thanks,  
Rochelle

---

**From:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>  
**Sent:** Monday, June 7, 2021 9:58 AM  
**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
**Subject:** Pre-decisional, deliberative budget information

Hi Rochelle – (b)(5)  
(b)(5) on. Thanks, Sherri

(b)(5)

# COVID-19 Daily Update: November 15

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Date:** Sun, 14 Nov 2021 21:03:20 -0500  
**Attachments:** COVID Daily Update 20211115 vf.pdf (7.46 MB)

---

Dear all,

(b)(5)

(b)(5)

Thanks,  
Cyrus

# COVID Tough QA

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Collins, Francis (NIH/OD) [E]" (b)(6) "Smith, Marcella N. EOP/OSTP" (b)(6) "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**Cc:** "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Rowe, Courtney M. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6) "Burklow, John (NIH/OD) [E]" <burklowj@od.nih.gov>, "Hall, Bill (HHS/ASPA)" <bill.hall@hhs.gov>, "Munoz, Kevin EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6)  
**Date:** Fri, 26 Mar 2021 00:09:19 -0400  
**Attachments:** Tough QA for COVID 3.25.21 11PM.docx (34.58 kB)

H (b)(5)  
(b)(5)

(b)(5)

(b)(5)  
Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

## RE: CDC Weekly Data Check in

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Berger, Sherri (CDC/OCOO/OD)" <sob8@cdc.gov>, "Goldstein, Robert (CDC/OD/OADPS)" <qyd2@cdc.gov>, "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>, "Williams, Ian (CDC/DDPHSIS/CPR/OD)" <iaw3@cdc.gov>, "Mahon, Barbara (CDC/DDID/NCIRD/OD)" <bdm3@cdc.gov>, "Daskalakis, Demetre (CDC/DDID/NCHHSTP/DHP)" <yzq5@cdc.gov>, "Cohn, Amanda (CDC/DDNID/NCBDDD/DBDID)" <anc0@cdc.gov>  
**Cc:** "Corley, Ronald D. (CDC/OCOO/OCIO/CEO) (CTR)" <hhj5@cdc.gov>, "Howe, Kristin (CDC/OCOO/OCIO/CEO) (CTR)" <lzu3@cdc.gov>, "Jarman-Miller, Hannah (CDC who.eop.gov)" (b)(6)  
**Date:** Fri, 24 Sep 2021 15:11:55 -0400

---

Hello all,

(b)(5)

Thank you!  
Cyrus

(b)(5)

# COVID Tough QA

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Collins, Francis (NIH/OD) [E]" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6) "Sanchez-Velasco, Marissa EOP/WHO" (b)(6) "Cheema, Subhan N. EOP/WHO" (b)(6) "Munoz, Kevin A. EOP/WHO" (b)(6) "Berner, Kate K. EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6) "Folkers, Greg (NIH/NIAID) [E]" (b)(6) "Perry, Sherice (OS/IEA)" <sherice.perry@hhs.gov>  
**Date:** Wed, 25 Aug 2021 23:19:44 -0400  
**Attachments:** JZ Tough QA 8.25.21 8PM.docx (47.13 kB)

---

Hi all, attached (b)(5)  
(b)(5)

(b)(5)  
Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

# COVID Tough QA

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Slavitt, Andrew M. EOP/WHO" (b)(6) "Collins, Francis (NIH/OD) [E]" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Smith, Marcella N. EOP/OSTP" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Munoz, Kevin EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Hall, Bill (HHS/ASPA)" <bill.hall@hhs.gov>, "Burklow, John (NIH/OD) [E]" <burklowj@od.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6) "Lesko, Max (HHS/OASH)" <max.lesko@hhs.gov>, "Cheema, Subhan N. EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6) "Webb, Cameron C. EOP/WHO" (b)(6) "Beckman, Adam (HHS/OASH)" <adam.beckman@hhs.gov>  
**Date:** Sat, 24 Apr 2021 13:43:36 -0400  
**Attachments:** Tough QA 4.24.21 1PM.docx (35.02 kB)

Hi (b)(5)

(b)(5)

(b)(5)

(b)(5)

Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)

# Tough QA on COVID

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Collins, Francis (NIH/OD) [E]" (b)(6) "Kessler, David (HHS/IOS)" <david.kessler@hhs.gov>, "Webb, Cameron C. EOP/WHO" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Cheema, Subhan N. EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Phillips, Alexandria (HHS/OASH)" <alexandria.phillips@hhs.gov>, "Sanchez-Velasco, Marissa EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6) "Berner, Kate K. EOP/WHO" (b)(6) "Munoz, Kevin A. EOP/WHO" (b)(6) "Salcido, Dorinda (Dori) (CDC/OD)" <spe9@cdc.gov>, "Cheema, Subhan N. EOP/WHO" (b)(6) "Fine, Amanda (NIH/OD) [E]" (b)(6) "Myles, Renate (NIH/OD) [E]" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6)  
**Date:** Mon, 06 Dec 2021 22:18:09 -0500  
**Attachments:** Tough QA 12.6.21 11PM.docx (46.1 kB)

---

Hi, (b)(5)  
(b)(5)  
(b)(5)  
(b)(5)  
Ben

## Re: NY Times article now live

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, Jeffrey D. Zients (b)(6),  
natalie.h.quillian (eop.gov) (b)(6), "Fauci, Anthony (NIH/NIAID) [E]"  
(b)(6) Bechara Choucair (b)(6)  
**Date:** Sat, 22 May 2021 18:50:57 -0400

---

Yup. Just received. Thabjs

Get [Outlook for iOS](#)

---

**From:** Murthy, Vivek (HHS/OASH) <Vivek.Murthy@hhs.gov>  
**Sent:** Saturday, May 22, 2021 6:50:14 PM  
**To:** Jeffrey D. Zients (b)(6), natalie.h.quillian (eop.gov)  
(b)(6), Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Fauci, Anthony  
(NIH/NIAID) [E] (b)(6); Bechara Choucair (b)(6)  
**Subject:** NY Times article now live

<https://www.nytimes.com/live/2021/05/22/world/covid-vaccine-coronavirus-mask#the-cdc-is-investigating-a-heart-problem-in-a-few-young-vaccine-recipients>

(b)(5)

Vivek

--

**Vivek Murthy**  
U.S. Surgeon General  
Vice Admiral, U.S. Public Health Service

The information in this e-mail and its attachments are confidential, pre-decisional and deliberative. Contents may include sensitive information and are for official use only. If you are not the original intended recipient, please delete the content and notify the sender.



# COVID Tough QA

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6), "Slavitt, Andrew M. EOP/WHO" (b)(6), "Collins, Francis (NIH/OD) [E]" (b)(6), "Smith, Marcella N. EOP/OSTP" (b)(6)  
**Cc:** "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Billet, Courtney (NIH/NIAID) [E]" (b)(6), "Berner, Kate EOP/WHO" (b)(6), "Rowe, Courtney M. EOP/WHO" (b)(6), "Munoz, Kevin EOP/WHO" (b)(6), "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Webb, Cameron C. EOP/WHO" (b)(6), "Sanchez-Velasco, Marissa EOP/WHO" (b)(6)  
**Date:** Fri, 19 Mar 2021 22:29:25 -0400  
**Attachments:** Tough QA for COVID 3.19.21 11PM.docx (66.33 kB)

---

Hi, (b)(5)

(b)(5)

(b)(5)

Ben

+++

Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team

(b)(6)

# COVID Tough QA

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Slavitt, Andrew M. EOP/WHO" (b)(6) "Collins, Francis (NIH/OD) [E]" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Munoz, Kevin EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Tumpey, Abbigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Jones, Christopher M. (CDC/DDNID/NCIPC/OD)" <fjr0@cdc.gov>, "Hall, Bill (HHS/ASPA)" <bill.hall@hhs.gov>, "Burklow, John (NIH/OD) [E]" <burklowj@od.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6) "Lesko, Max (HHS/OASH)" <max.lesko@hhs.gov>  
**Date:** Wed, 31 Mar 2021 23:52:36 -0400  
**Attachments:** Tough QA for COVID 3.31.21 11PM.docx (39.22 kB)

---

Hi, (b)(5)

(b)(5)

(b)(5)

-Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

# COVID Tough QA

---

**From:** "Wakana, Benjamin L. EOP/WHO" (b)(6)  
**To:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Slavitt, Andrew M. EOP/WHO" (b)(6) "Collins, Francis (NIH/OD) [E]" (b)(6) "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Smith, Marcella N. EOP/OSTP" (b)(6)  
**Cc:** "Rowe, Courtney M. EOP/WHO" (b)(6) "Berner, Kate EOP/WHO" (b)(6) "Billet, Courtney (NIH/NIAID) [E]" (b)(6) "Munoz, Kevin EOP/WHO" (b)(6) "Sams, Ian (HHS/ASPA)" <ian.sams@hhs.gov>, "Tumpey, Abigail (CDC/DDPHSS/CSELS/OD)" <aws8@cdc.gov>, "Hall, Bill (HHS/ASPA)" <bill.hall@hhs.gov>, "Burklow, John (NIH/OD) [E]" <burklowj@od.nih.gov>, "Myles, Renate (NIH/OD) [E]" (b)(6) "Lesko, Max (HHS/OASH)" <max.lesko@hhs.gov>, "Cheema, Subhan N. EOP/WHO" (b)(6) "Saez, Mariel S. EOP/WHO" (b)(6) "Webb, Cameron C. EOP/WHO" (b)(6)  
**Date:** Sun, 18 Apr 2021 23:37:55 -0400  
**Attachments:** Tough QA 04.18.21 11PM.docx (40.22 kB)

---

Hi, (b)(5)  
(b)(5)  
(b)(5)  
(b)(5)  
Ben

+++  
Ben Wakana  
Deputy Director for Strategic Communications and Engagement  
White House COVID Response Team  
(b)(6)

## Just went live -- data through end of October (bottom)

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>

**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)

**Cc:** "Zients, Jeffrey D. EOP/WHO" (b)(6)

**Date:** Fri, 17 Dec 2021 16:37:47 -0500

---

(b)(5)

R

# COVID-19 Daily Update: November 24

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Date:** Tue, 23 Nov 2021 23:56:06 -0500  
**Attachments:** COVID Daily Update 20211124 vf.pdf (2.92 MB)

---

Dear all,

(b)(5)

Thanks,  
Cyrus

# Executive Order - Covid Supply Chain

---

**From:** "Ryan, Evan M. EOP/WHO" (b)(6)  
**Cc:** "Alex, Cristobal J. EOP/WHO" (b)(6) "Isen, Thomas EOP/WHO"  
(b)(6)  
**Date:** Thu, 21 Jan 2021 17:57:07 -0500

---

Good afternoon –

(b)(5)

(b)(5)

Thank you,

Evan Ryan  
Cabinet Secretary  
The White House

[Emails](#)

# COVID-19 Daily Update: December 6

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Date:** Sun, 05 Dec 2021 23:49:53 -0500  
**Attachments:** COVID Daily Update 20211206 vf.pdf (2.97 MB)

---

Dear all,

(b)(5)

Thank you,  
Cyrus

# COVID-19 Daily Update: November 22

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Date:** Sun, 21 Nov 2021 23:37:02 -0500  
**Attachments:** COVID Daily Update 20211122 vf.pdf (7.44 MB)

---

Dear all,

(b)(5)

Thanks,  
Cyrus



# COVID-19 Daily Update: December 13

---

**From:** "Shahpar, Cyrus G. EOP/WHO" (b)(6)  
**Date:** Sun, 12 Dec 2021 23:41:21 -0500  
**Attachments:** COVID Daily Update 20211213 vf.pdf (2.98 MB)

---

Dear all,

(b)(5)

Thank you,  
Cyrus

# CDC COVID-related MMWR Early Release for Aug 10

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** "Zients, Jeffrey D. EOP/WHO" (b)(6)  
**Date:** Mon, 09 Aug 2021 11:54:41 -0400  
**Attachments:** CDC COVID-related MMWR Early Release for Aug 10, 2021.docx (49.13 kB)

---

Hi Jeff,

(b)(5)

(b)(5)

Thanks,  
Rochelle

# Fwd: [EXTERNAL] EMBARGOED Vaccine Monitor Report - for use 3 AM ET Friday Feb. 26

**From:** "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**To:** Joshua Peck <joshua.peck@hhs.gov>, "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6), "Zients, Jeffrey D. EOP/WHO" (b)(6), "Quillian, Natalie H. EOP/WHO" (b)(6), "Rowe, Courtney M. EOP/WHO" (b)(6)  
**Date:** Thu, 25 Feb 2021 00:11:35 -0500  
**Attachments:** EMBARGOED KFF February VM News Release - for use 3 AM ET Friday Feb. 26.pdf (994.06 kB); EMBARGOED KFF Vaccine Monitor Report - for use 3 AM ET Friday Feb. 26.pdf (2.69 MB); EMBARGOED KFF VM Toplines - for use 3 AM ET Friday Feb. 26.pdf (1.02 MB)

FYSA

Sent from my iPhone

Begin forwarded message:

**From:** Drew Altman <DrewA@kff.org>  
**Date:** February 24, 2021 at 10:24:29 PM EST  
**To:** "Smith, Marcella" (b)(6), Slavitt, Andrew M. EOP/WHO", "David A. Kessler", "Vivek Murthy" (b)(6), (b)(6), (b)(6)  
**Subject:** [EXTERNAL] EMBARGOED Vaccine Monitor Report - for use 3 AM ET Friday Feb. 26

Here is our next Vaccine Monitor release, which will be public Friday. It shows vaccine confidence continuing to grow. The groups I remain most concerned about are Black, Latino and rural Americans but overall it's an improving picture. You can find all our Monitor products on the Dashboard here: >[https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-monitor-dashboard/?utm\\_source=web&utm\\_medium=trending&utm\\_campaign=COVID-19-vaccine-monitor](https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-monitor-dashboard/?utm_source=web&utm_medium=trending&utm_campaign=COVID-19-vaccine-monitor)<

Of note, a share (25%) of the wait and see group says a single shot will make them more likely to get the vaccine, but it does not appear to be a game changer on confidence/hesitancy (obviously it has other advantages).

We will be launching Greater Than Covid soon with the Black Coalition Against Covid, W Kamau Bell and Google/YouTube. It has really come together well. More on that soon.

Best to you all,

Drew

P.S. I apologize I don't have all of your official emails and I don't have Rochelle Walensky's email. If one of you would send this on I would appreciate it. I promised her I would send her these findings as we have them.

Drew Altman, Ph.D.  
President and CEO, Kaiser Family Foundation  
Founding Publisher, KHN

San Francisco, CA  
DAltman@kff.org<mailto:DAltman@kff.org> / @DrewAltman<><https://twitter.com/DrewAltman><> / 650 854 9400

[cid:image003.png@01D70AE1.894B45D0]

See my latest columns: [kff.org/from-drew-altman/](https://www.kff.org/from-drew-altman/)<><https://www.kff.org/from-drew-altman/><>

Stay connected with:

[kff.org](http://kff.org/)<><http://kff.org/><> / [email](http://kff.org/email/)<><http://kff.org/email/><> / [twitter](https://twitter.com/KaiserFamFound)<><https://twitter.com/KaiserFamFound><> / [facebook](https://www.facebook.com/KaiserFamilyFoundation)<><https://www.facebook.com/KaiserFamilyFoundation><>  
[khn.org](http://www.khn.org/)<><http://www.khn.org/><> / [email](http://khn.org/email-signup/)<><http://khn.org/email-signup/><> / [twitter](https://twitter.com/KHNNews)<><https://twitter.com/KHNNews><> / [facebook](https://www.facebook.com/KaiserHealthNews)<><https://www.facebook.com/KaiserHealthNews><>

## Re: brief on USVI

---

**From:** "Johnson, Carole A. EOP/WHO" (b)(6)  
**To:** "Walke, Henry (CDC/DDID/NCEZID/DPEI)" <hfw3@cdc.gov>  
**Cc:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Wed, 11 Aug 2021 20:34:05 -0400

---

Thank you Henry

On Aug 11, 2021, at 8:32 PM, Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov> wrote:

Follow-up on USVI question from (b)(5) today. Best, Henry

---

**From:** Villanueva, Julie M. (CDC/DDID/NCEZID/DPEI) <jfv3@cdc.gov>  
**Sent:** Wednesday, August 11, 2021 1:01 PM  
**To:** Walke, Henry (CDC/DDID/NCEZID/DPEI) <hfw3@cdc.gov>  
**Cc:** Rose, Dale A. (CDC/DDID/NCEZID/DPEI) <ido8@cdc.gov>; Anderson, Mark (CDC/DDPHSIS/CGH/DGHP) <mea6@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>  
**Subject:** RE: brief on USVI

### USVI Post Deployment Summary

CDC provided a multidisciplinary surge deployment team to join the USVI Department of Health (DOH) to join a DOH Health Brigade from July 26 – August 6, 2021 to encourage vaccination and address hesitancy issues. The territory continues to experience an increase of cases and hospitalizations, amplified by low vaccination coverage and vaccine hesitancy amongst the local population and high transmission in the neighboring British Virgin Islands. The team implemented a Rapid Community Assessment (RCA); preliminary results suggest reasons for hesitation include misinformation, knowing that vaccinated people still get COVID-19, and the rapid development of the vaccine. Efforts are planned for education, first-hand testimonials, public forums and social media to address the concerns. Community outreach by the team included an event organized by the Department of Education to about 160 instructional, administrative and janitorial staff, a religious service for close to 100 Haitian people, and several radio interviews in both English and Spanish.

---

**From:** Villanueva, Julie M. (CDC/DDID/NCEZID/DPEI)  
**Sent:** Wednesday, August 11, 2021 10:38 AM  
**To:** Walke, Henry (CDC/DDID/NCEZID/DPEI) ([hfw3@cdc.gov](mailto:hfw3@cdc.gov)) <[hfw3@cdc.gov](mailto:hfw3@cdc.gov)>  
**Cc:** Rose, Dale A. (CDC/DDID/NCEZID/DPEI) <[ido8@cdc.gov](mailto:ido8@cdc.gov)>; Anderson, Mark (CDC/DDPHSIS/CGH/DGHP) <[mea6@cdc.gov](mailto:mea6@cdc.gov)>  
**Subject:** brief on USVI

#### 1. USVI

- a. CDC's USVI 4 person deployment team returned Saturday, August 7. They collaborated with DOH to evaluate vaccine hesitancy in the islands and recommend strategies for targeting messages to different populations.
- b. The USVI team also partnered with the Department of Education to present COVID-19 information to K-12 teachers and school workers. The DOE has recommended virtual education for public schools due to the recent surge of cases.

We'll work on finding out more.

# Re: [EXTERNAL] EMBARGOED Vaccine Monitor materials - for use at 5 AM ET Wednesday August 4

---

**From:** "Choucair, Bechara N. EOP/WHO" (b)(6)  
**To:** Drew Altman <drewa@kff.org>  
**Cc:** david kessler (b)(6) "Smith, Marcella" <(b)(6)>, Vivek Murthy (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, (b)(6)@nih.hhs.gov  
**Date:** Mon, 02 Aug 2021 21:54:53 -0400

---

Thanks Drew. As always, very helpful.

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

Sent from my iPhone

> On Aug 2, 2021, at 9:27 PM, Drew Altman <DrewA@kff.org> wrote:

>  
>

> Hi everyone. Here is our next Monitor Report. We were out of the field July 27th. It will be followed by a larger report in about a week on kids and "back to school" (we are just getting out of the field on that one).

>  
>

> This report reflects the realities you are familiar with. One ray of light:

>  
>

> A quarter of unvaccinated adults (8% of all adults) say it is likely they will get a COVID-19 vaccine by the end of the year. This includes nearly half (45%) of those in the "wait and see" group.

> My comment: "A quarter of those who were unvaccinated say they likely will get a shot by the end of the year," KFF President and CEO Drew Altman said. "Seeing their friends get sick and local hospitals fill up again with COVID patients may speed them along and add to their ranks."

>  
>

> Also, 1/3 of unvaccinated people say that getting the virus is a bigger risk to their health than getting the vaccine. I think there is something to be learned by understanding who they are and why they haven't gotten vaccinated yet. We will get on that.

>  
>

> I continue to believe that FDA approval will provide an opportunity to refresh basic messages and a boost for a significant subset of the unvaccinated.

>  
>

> Best to all of you.

>  
>

> Drew

>  
>

## [Weekly] COVID-19 Clinicians Check-In

**From:** "Choucair, Bechara N. EOP/WHO" (b)(6)  
**To:** "Collins, Francis (NIH/OD) [E]" (b)(6) "Nunez-Smith, Marcella (OS/ASPR/IO) (CTR)" (b)(6) "Lander, Eric S. EOP/OSTP" (b)(6) "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>, "Fauci, Anthony (NIH/NIAID) [E]" (b)(6) "Woodcock, Janet (FDA/OC)" <janet.woodcock@fda.hhs.gov>, "Murthy, Vivek (HHS/OASH)" <vivek.murthy@hhs.gov>, "Kessler, David (HHS/IOS)" <david.kessler@hhs.gov>  
**Date:** Wed, 06 Oct 2021 18:09:38 -0400

(b)(5)

(b)(5)

### [Weekly] COVID-19 Clinicians Check-In

Scheduled: Oct 6, 2021 at 5:00 PM to 5:45 PM, EDT

Location: Zoom Details Below

Invitees: Barasch, Kimberly (NIH/NIAID) [E], Williams, Teresa (CDC/OD/OCS), Cure, Kelly (OS/OASH) (CTR), Mcqueen, BG Anthony (HHS/IOS), Gonzalez, Noe EOP/WHO, LaBovick, Hannah EOP/OSTP, Collins, Francis (NIH/OD) [E], Waterstraat, Tamiaka (OS/ASPR/IO) (CTR), Nunez-Smith, Marcella (OS/ASPR/IO) (CTR), Gershman, Lynn E. (CDC/OD/OCS), Beckman, Adam (HHS/OASH), Levine, Rachel (HHS/OASH), Conrad, Patricia (NIH/NIAID) [E], Rizzo, Tara, Lander, Eric S. EOP/OSTP, McManus, Ayanna (NIH/OD) [E], Walensky, Rochelle (CDC/OD), Fauci, Anthony (NIH/NIAID) [E], Woodcock, Janet (FDA/OC), Murthy, Vivek (HHS/OASH), Perry, Sherice (OS/IEA), Kessler, David (HHS/IOS)

Bechara

Bechara Choucair, MD  
Vaccinations Coordinator  
White House COVID Response Team

(b)(6)

Sent from my iPhone

# Re: Study shows vaccines carry much lower risk of blood clots than COVID-19 - CBS News

**From:** "Slavitt, Andrew M. EOP/WHO" (b)(6)  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)  
**Cc:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**Date:** Thu, 15 Apr 2021 09:24:41 -0400

(b)(5)

Sent from my iPhone

> On Apr 15, 2021, at 8:56 AM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

> Thanks, Anndy. (b)(5)

> -----Original Message-----

> From: Slavitt, Andrew M. EOP/WHO (b)(6)  
> Sent: Thursday, April 15, 2021 6:55 AM  
> To: Fauci, Anthony (NIH/NIAID) [E] (b)(6); Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>  
> Subject: Study shows vaccines carry much lower risk of blood clots than COVID-19 - CBS News

> (b)(5)

> Sent from my iPhone

# FW: teacher prioritization for vaccination

---

**From:** "Walensky, Rochelle (CDC/OD)" <aux7@cdc.gov>  
**To:** (b)(6)  
**Date:** Sun, 31 Jan 2021 19:06:10 -0500

---

Hi Jeff,

(b)(5)

Best,

R

(b)(5)

(b)(5)

(b)(5)

(b)(5)



**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

**Sent:** Thursday, January 21, 2021 8:06 AM

**To:** Mariel Saez (b)(6) Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO

(b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

Pleasure (b)(5) Get [Outlook for iOS](#)

---

**From:** Mariel Saez (b)(6)

**Sent:** Thursday, January 21, 2021 8:02:13 AM

**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO

(b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

(b)(5) ! On Thu, Jan 21, 2021 at 12:22 AM Mariel Saez

(b)(6) wrote: (b)(5) On Wed, Jan 20, 2021 at 9:55 PM Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> wrote:Great — I think I'm in pretty

(b)(5)

(b)(5) [Outlook for iOS](#)

---

**From:** Mariel Saez (b)(6)

**Sent:** Wednesday, January 20, 2021 9:54:20 PM

**To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>**Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO

(b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

On Wed, Jan 20, 2021 at 9:32 PM Mariel Saez (b)(6) wrote: (b)(5)

(b)(5) Thanks

(b)(5) On Wed, Jan 20, 2021 at 9:29 PM Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>

wrote:Great — thanks — (b)(5)  
(b)(5) .RGet [Outlook for iOS](#)

---

**From:** Mariel Saez (b)(6)  
**Sent:** Wednesday, January 20, 2021 9:27:09 PM  
**To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>**Cc:** Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6)  
**Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)  
Thank you so much! On Wed, Jan 20, 2021 at 9:17 PM Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)> wrote (b)(5)  
(b)(5) ? Thanks!Get [Outlook for iOS](#)

---

**From:** Rochelle Walensky (b)(6)  
**Sent:** Wednesday, January 20, 2021 9:12:34 PM  
**To:** Mariel Saez (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Courtney Rowe (b)(6) Saez, Mariel S. EOP/WHO (b)(6) Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)>

**Subject:** Re: FW: [EXTERNAL] TV Tomorrow  
(b)(5) Thank you!RochelleOn Wed, Jan 20, 2021 at 9:11 PM Mariel Saez (b)(6) wrote: (b)(5)  
(b)(5) ok? On Wed, Jan 20, 2021 at 9:07 PM Rowe, Courtney M. EOP/WHO (b)(6) wrote:+ (b)(5)

---

**From:** Rochelle Walensky (b)(6)  
**Sent:** Wednesday, January 20, 2021 9:07 PM  
**To:** Courtney Rowe (b)(6) **Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Mariel Saez (b)(6)

**Subject:** Re: FW: [EXTERNAL] TV Tomorrow  
Good evening, Courtney, (b)(5)  
(b)(5) Thanks,R On Wed, Jan 20, 2021 at 7:35 PM Courtney Rowe (b)(6) wrote:Rochelle- (b)(5)  
(b)(5) ----- Forwarded message -----

---

**From:** Rowe, Courtney M. EOP/WHO (b)(6) Wed, Jan 20, 2021 at 7:34 PM  
**Subject:** FW: [EXTERNAL] TV Tomorrow

**To:** (b)(6) (b)(6)

---

**From:** Mariel Saez (b)(6)  
**Sent:** Wednesday, January 20, 2021 7:30 PM

**To:** Rowe, Courtney M. EOP/WHO (b)(6) (b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO

**Subject:** Re: [EXTERNAL] TV Tomorrow

Thank you! (b)(5)  
(b)(5) On Wed, Jan 20, 2021 at 7:28 PM Rowe, Courtney M.

EOP/WHO (b)(6) wrote: (b)(5)  
(b)(5)

**From:** Mariel Saez (b)(6)

**Sent:** Wednesday, January 20, 2021 7:26 PM

**To:** Rowe, Courtney M. EOP/WHO (b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

Thanks (b)(5)  
(b)(5)

On Wed, Jan 20, 2021 at 7:12 PM Rowe, Courtney M. EOP/WHO (b)(6) wrote: Adding Marissa

**From:** Berner, Katherine EOP/WHO

**Sent:** Wednesday, January 20, 2021 7:01 PM

**To:** Tobar, Maria D. EOP/WHO (b)(6) Mariel Saez (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)

**Subject:** RE: [EXTERNAL] TV Tomorrow

(b)(5)

**From:** Tobar, Maria D. EOP/WHO

**Sent:** Wednesday, January 20, 2021 7:00 PM

**To:** Mariel Saez (b)(6) Berner, Katherine EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)  
(b)(5) sent from my iPhone On Jan 20, 2021, at 6:54 PM, Mariel Saez (b)(6) wrote: Thank you (b)(5)  
(b)(5) NBC Today Show (7AM) - (b)(5)

(b)(5)

(b)(5) On Wed, Jan 20, 2021 at 6:21 PM Berner,  
Katherine EOP/WHO (b)(6) wrote: (b)(5)  
(b)(5)  
(b)(5) Thanks

From: Mariel Saez (b)(6)  
**Sent:** Wednesday, January 20, 2021 6:20 PM  
**To:** (b)(5) Berner, Katherine EOP/WHO (b)(6)  
**Subject:** [EXTERNAL] TV Tomorrow

(b)(5)

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> **Sent:** Wednesday, January 20, 2021 10:46 PM **To:** Ben Wakana (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)  
**Cc:** Wakana, Benjamin L. EOP/WHO (b)(6) **Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

R

Get [Outlook for iOS](#)

---

**From:** Ben Wakana (b)(6) **Sent:** Wednesday, January 20, 2021 10:26:55 PM **To:** Rowe, Courtney M. EOP/WHO (b)(6) **Cc:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov>; Wakana, Benjamin L. EOP/WHO (b)(6) **Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

(b)(5)

Ben

On Wed, Jan 20, 2021 at 10:21 PM Rowe, Courtney M. EOP/WHO (b)(6) wrote:

Ben- (b)(5) ?

**From:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> **Sent:** Wednesday, January 20, 2021 9:56 PM **To:** Mariel Saez (b)(6) **Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6) **Subject:** Re: [EXTERNAL] TV Tomorrow

Great — (b)(5)  
(b)(5)

Get Outlook for iOS

---

**From:** Mariel Saez (b)(6) **Sent:** Wednesday, January 20, 2021 9:54:20 PM **To:** Walensky, Rochelle (CDC/OD) <aux7@cdc.gov> **Cc:** Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>;

Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M.  
EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO  
(b)(6) **Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

(b)(5)

(b)(5)

Thank you again!

On Wed, Jan 20, 2021 at 9:32 PM Mariel Saez (b)(6) wrote:

(b)(5)

(b)(5)

Thanks for your patience!

On Wed, Jan 20, 2021 at 9:29 PM Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)> wrote:

Great — thanks — did they give you the questions or leave it vague as above?

(b)(5)

R

Get Outlook for iOS

---

**From:** Mariel Saez (b)(6) **Sent:** Wednesday, January 20, 2021 9:27:09 PM **To:** Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)> **Cc:** Courtney Rowe (b)(6) Rochelle Walensky (b)(6) Rowe, Courtney M. EOP/WHO (b)(6) Saez, Mariel S. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

We're confirmed for 7:30 at videolink, cleared well before 7:50. Would you like a car to pick you up? And yes same topics as before. Where do we go from here and how do we right the ship on COVID. Thank you so much!

On Wed, Jan 20, 2021 at 9:17 PM Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)> wrote:

(b)(5)  
(b)(5) ? Thanks!

Get Outlook for iOS

---

**From:** Rochelle Walensky (b)(6)  
PM **To:** Mariel Saez (b)(6)  
(b)(6) Courtney Rowe (b)(6) Saez, Mariel S. EOP/WHO  
(b)(6) Walensky, Rochelle (CDC/OD) <[aux7@cdc.gov](mailto:aux7@cdc.gov)> **Sent:** Wednesday, January 20, 2021 9:12:34  
**Cc:** Rowe, Courtney M. EOP/WHO

**Subject:** Re: FW: [EXTERNAL] TV Tomorrow

(b)(5) Thank you! Rochelle

On Wed, Jan 20, 2021 at 9:11 PM Mariel Saez (b)(6) wrote:  
(b)(5)

On Wed, Jan 20, 2021 at 9:07 PM Rowe, Courtney M. EOP/WHO  
(b)(6) wrote:



(b)(5)

**From:** Rochelle Walensky (b)(6)

**Sent:** Wednesday, January 20, 2021 9:07 PM

**To:** Courtney Rowe (b)(6)

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6) Mariel Saez  
(b)(6) [aux7@cdc.gov](mailto:aux7@cdc.gov)

**Subject:** Re: FW: [EXTERNAL] TV Tomorrow

Good evening, Courtney,

(b)(5)

(b)(5)

Thanks,

R

On Wed, Jan 20, 2021 at 7:35 PM Courtney Rowe (b)(6) wrote:

Rochelle- we've reached out to the CDC press team, but flagging this for you directly

----- Forwarded message -----

From: Rowe, Courtney M. EOP/WHO (b)(6)

Date: Wed, Jan 20, 2021 at 7:34 PM

Subject: FW: [EXTERNAL] TV Tomorrow

To: (b)(6) (b)(6)

From: Mariel Saez (b)(6)

Sent: Wednesday, January 20, 2021 7:30 PM

To: Rowe, Courtney M. EOP/WHO (b)(6)

Cc: (b)(6) Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D.  
EOP/WHO (b)(6) [jyc5@cdc.gov](mailto:jyc5@cdc.gov)

Subject: Re: [EXTERNAL] TV Tomorrow

Thank you! (b)(5)  
(b)(5)

On Wed, Jan 20, 2021 at 7:28 PM Rowe, Courtney M. EOP/WHO  
(b)(6) wrote:

Actually, just realized its not Marissa anymore. She's rolled off. Adding Janine from CDC to help here!

**From:** Mariel Saez (b)(6)

**Sent:** Wednesday, January 20, 2021 7:26 PM

**To:** Rowe, Courtney M. EOP/WHO (b)(6)

**Cc:** Berner, Katherine EOP/WHO (b)(6) Tobar, Maria D. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

Thanks! (b)(5)

(b)(5)

Jen

(b)(5)

Kate

•  
(b)(5)

On Wed, Jan 20, 2021 at 7:12 PM Rowe, Courtney M. EOP/WHO

(b)(6) wrote:

Adding Marissa

**From:** Berner, Katherine EOP/WHO

**Sent:** Wednesday, January 20, 2021 7:01 PM

**To:** Tobar, Maria D. EOP/WHO (b)(6) Mariel Saez (b)(6)

**Cc:** Rowe, Courtney M. EOP/WHO (b)(6)

**Subject:** RE: [EXTERNAL] TV Tomorrow

(b)(5)

(b)(5)

Courtney – (b)(5)

Thanks

**From:** Tobar, Maria D. EOP/WHO

**Sent:** Wednesday, January 20, 2021 7:00 PM

**To:** Mariel Saez (b)(6)

**Cc:** Berner, Katherine EOP/WHO (b)(6) Rowe, Courtney M. EOP/WHO (b)(6)

**Subject:** Re: [EXTERNAL] TV Tomorrow

(b)(5)

Sent from my iPhone

On Jan 20, 2021, at 6:54 PM, Mariel Saez (b)(6) wrote:

(b)(5)

(b)(5)

(b)(5)

(b)(5)

Fox America Reports (1PM) - Rouse

MSNBC All In with Chris Hayes - Cedric or Jen

(b)(5)

(b)(5)

On Wed, Jan 20, 2021 at 6:21 PM Berner, Katherine EOP/WHO

(b)(6) wrote:

(b)(5)

(b)(5) they are

(b)(5)

Thanks

**From:** Mariel Saez (b)(6)

**Sent:** Wednesday, January 20, 2021 6:20 PM

**To:** (b)(6) Berner, Katherine EOP/WHO (b)(6)

**Subject:** [EXTERNAL] TV Tomorrow

(b)(5)

(b)(5)